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ABSTRACT 
Breast cancer is the second leading cause of cancer mortality among women. Many 
risk factors for breast cancer are related to estrogen exposure and high serum estrogen 
levels. Studies have demonstrated the critical role of estrogen in breast carcinogenesis, but 
less clear how estrogen acts as an initiator of carcinogenesis. Several mechanisms have 
been implicated the pathogenic actions of estrogens. 1) Estrogens cause increased 
proliferation to indirectly introduce mutations that promote breast tumorigenesis. 2) 
Estrogens can form DNA adducts which may directly promote mutagenesis. 3) Estrogens 
induce DNA double strand breaks in the breast epithelial cells to promote transcription of 
estrogen target genes but also replication stress and genomic instability. 4) Estrogen also 
induces co-transcriptional products, called R-loops, that can lead to DNA damage.  
Recent studies have suggested associations between exposures to environmental 
chemicals may also increase risk of breast cancer. Environmental chemicals such as 
endocrine disrupting chemicals or xenoestrogens can mimic the effects of estrogen by 
binding with the receptors and alter the endocrine system. However, there is a lack of 
vii 
detailed mechanistic understanding. The focus of our first study is to investigate the effects 
of two xenoestrogens – Benophenone-3 (BP-3) and Propyl Paraben (PP) in the breast 
epithelial cells at concentrations relevant to human exposures and are commonly found in 
cosmetics, personal care products and sunscreens. With luciferase reporter assays, our lab 
confirmed that these two xenoestrogens are able to bind with the estrogen receptor 
complexes. We showed that 17-estradiol (E2), BP-3 and PP are able to induce DNA 
damage via estrogen receptor manner in vitro but BP-3 and PP were weakly estrogenic in 
terms of transcriptional and proliferation responses. The DNA damage response from E2, 
BP-3 and PP is strongly associated with levels of ERα-mediated DNA: RNA hybrids 
triplex structures called R-loops. We also showed the induction of DNA damage and R 
loops from these compounds in mice without inducing transcription of estrogen target 
genes or proliferation in the mammary epithelial cells. These studies demonstrated that 
xenoestrogens possess the potential for genotoxic activity mediated by ERα through the 
formation of R-loops and DNA double-strand breaks. 
 While all women are exposed to endogenous and exogenous estrogens, only 1 in 8 
women are expected to develop breast cancer suggesting that the cancer-promoting effects 
of estrogen exposure vary among individuals. Our second study demonstrated that E2-
induced DNA damage is most pronounced in rodents that are genetically susceptible to 
mammary tumors and among women who are at high risk of breast cancer. Rodents which 
are susceptible to hormone-induced mammary tumors, such as BALB/c mice and ACI rats, 
showed significantly increased levels of DNA damage in the mammary epithelial cells with 
E2 treatment. E2 induced DNA damage in BALB/c mice was mainly found in ERα positive 
cells. Strains that are resistant to mammary tumors such as C57BL/6 mice and BN rats 
viii 
showed little damage with E2. We also found increased E2-induced DNA damage in 
human breast tissues from women with inherited breast cancer risk alleles affecting DNA 
double-strand break repair. In contrast, only 1 in 5 of average risk donors exhibited a 
significant increase in E2 induced DNA damage. Together, these data demonstrate genetic 
differences in sensitivity to E2-stimulated DNA damage in rodents and that similar 
variation is observed in normal breast tissues from women.   
Lastly, we investigated the mechanism by which E2 and BP-3 induce DNA damage 
in breast cancer cell lines. We showed that treatment with E2 and BP-3 promotes another 
non-canonical DNA secondary structure called G quadruplexes (G4s) in ER+ breast cancer 
cells. Most of the G4s induced by E2 and BP-3 colocalized with R-loops indicating G-loop 
formation. The induction of G4 formation and DNA damage with E2 and BP-3 in breast 
cancer cells is mediated by reactive oxygen species (ROS). Therefore, our data suggest a 
mechanism in which E2 and BP3 induce R loop stabilization is dependent on ROS which 
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Breast cancer and Estrogen Exposure 
Breast cancer is the most prevalent cancer type among women worldwide and the 
second leading cause of cancer related death in women (Siegel et al., 2021). It is a spectrum 
of many subtypes related to biological characteristics, such as tumor size, lymph node 
involvement, histological grade, patient’s age, estrogen receptors (ERs), progesterone 
receptor (PRs) and human epidermal growth factor receptor 2 (HER2 or c-erbB2) or triple 
negative status (lack ER, PR and HER2) (Yersal and Barutca, 2014). The risk factors for 
breast cancer include age, genetics, obesity, increased breast density, early onset of 
menarche, late menopause, nulliparity, and late full-term pregnancy (Brooks et al., 2018; 
Samavat and Kurzer, 2015; Travis and Key, 2003).  
Many of these risk factors are related to endogenous estrogen levels. Chronic 
lifetime exposure to estrogen, through early menarche (RR = 1.3), late menopause (RR = 
1.2-2.0), hormone replacement therapy with estrogen and progesterone (RR = 1.2) or 
having the highest quartile of serum estrogen levels (RR = 1.8-5.0) all increase breast 
cancer risk in women (Brinton et al., 2009, 1983; Clemons and Goss, 2001; Dall and Britt, 
2017; Eliassen et al., 2006; Rossouw et al., 2002; Trichopoulos et al., 1972). These suggest 
that lifetime exposure to estrogen increases breast cancer risk. Treatment with selective 
estrogen receptor modulators (SERMs) to inhibit estrogen activity in the breast has been 




contribute to breast tumor initiation and proliferation (Russo and Russo, 2006; J.-M. Tian 
et al., 2018).  
 
Estrogen Sensitivity in Rodents  
 
Previous work has identified rodent strains with increased sensitivity or resistance 
to mammary tumor development in response to carcinogen or estrogen treatment. In 
DMBA induced models of mammary tumors, the Wistar-Kyoto rat strain is resistant to 
tumor development while the Wistar-Furth strain is uniquely susceptible (Gould, 1986; 
Lan et al., 2001). For estrogen-induced mammary tumor models, the ACI strain is uniquely 
susceptible to estrogen-induced mammary tumors while the Copenhagen and Brown 
Norway strains are resistant (Dennison et al., 2015; Shull et al., 2018, 1997; Spady et al., 
1998). Treatment of susceptible ACI rats with tamoxifen reduces the development of 
estrogen-induced mammary tumors (Li et al., 2002; Singh et al., 2011), demonstrating the 
involvement of estrogen receptor signaling in mammary tumor development in the ACI 
strain. These studies have also identified quantitative trait loci (QTL), regions of the 
chromosomes linked to mammary tumor susceptibility and resistance (Gould et al., 2004; 
Haag et al., 2003; Lan et al., 2001; Schaffer et al., 2006).  
BALB/c and C57BL/6 strains of mice differ in their responses to E2 and 
progesterone (P4) (Aupperlee et al., 2008). Hormone-induced mammary tumors have been 
shown to develop in BALB/c mice whereas C57BL/6 mice are resistant (Girard et al., 2007; 
Kordon et al., 1993; Lanari et al., 1986; Molinolo et al., 1987). BALB/c mice are also 
sensitive to radiation-induced mammary tumors when compared with C57BL/6 mice 




the p53 tumor suppressor gene (Trp53) develop spontaneous mammary tumors similar to 
the susceptibility to breast cancer among women with inherited mutations in TP53. In 
contrast, mammary tumors in C57BL/6-Trp53+/- mice are rare (Kuperwasser et al., 2000). 
This difference in susceptibility to mammary tumors was genetically linked to a locus on 
mouse chromosome 7 (Blackburn et al., 2007) and involves a greater reliance on repair 
DSBs in BALB/c-Trp53+/- mice through error-prone repair pathways (Böhringer et al., 
2013). Taken together, these results illustrate the potential for estrogen to contribute to 
breast cancer development in certain genetic backgrounds, suggesting unique sensitivity to 
estrogen exposure. Similarly, genetic polymorphisms and epigenetic alterations may 
render a subset of women susceptible to carcinogenic effects of estrogens resulting in breast 
cancer. 
 
Mechanism of Estrogen Signaling: Interplay of Estrogen receptors.  
 Biological responses to estrogen exposure are mediated through the two nuclear 
hormone estrogen receptors: estrogen receptor alpha (ERα) and estrogen receptor beta 
(ERβ). ERα and ERβ are ligand activated transcription factors in the steroid nuclear 
receptor family encoded by ESR1 and ESR2 gene respectively (Heldring et al., 2007). 
Studies from estrogen receptor knockout mice demonstrate that ERα function is crucial to 
mammary gland development. ERα knockout mice (αERKO) have rudimentary ductal 
mammary gland development similar to newborn mice (Bocchinfuso and Korach, 1997). 
Conversely, ERβ knockout mice (βERKO) mammary glands are indistinguishable from 
wild type mice (Krege et al., 1998). While ERβ appears dispensible with respect to 




tumors when the p53 tumor suppressor gene is disrupted (Bardo et al., 2017). Therefore, it 
is possible that ER and ERβ may play antagonistic roles with respect to the carcinogenic 
actions of estrogens.  
In the classical mechanism, ligand-bound estrogen receptors form homodimers or 
heterodimers that bind estrogen response elements (ERE) in the DNA (Figure 1.1). The 
estrogen receptor dimers form complexes with other transcriptional coregulatory factors to 
drive expression of estrogen target genes (Marino et al., 2006; Saville et al., 2000; Yaşar 
et al., 2017; Yi et al., 2017). Other pathways for estrogen signaling have been identified, 
including tethered, non-genomic, and ligand-independent pathways (Heldring et al., 2007). 
The tethered pathway involves ligand-bound estrogen receptor dimer binding to other 
transcription factors bound to DNA, instead of EREs (Gaub et al., 1990; Saville et al., 
2000). Non-genomic estrogen receptor signaling involves either membrane bound estrogen 
receptors or other membrane bound receptors which in turn activate the estrogen receptors 
(Heldring et al., 2007; Levin, 2009). However, membrane-bound estrogen receptors are 
not sufficient to rescue mammary gland development in ERα knockout mice (Pedram et 
al., 2009). Therefore, it is unclear whether the non-genomic pathway plays a significant 
role in normal mammary tissue. Ligand-independent pathways involve estrogen receptor 
phosphorylation by kinases activated by growth factor signaling and are hypothesized to 
be involved in hormone-independent growth of breast tumors (Coutts and Murphy, 1998; 
Kato et al., 1995; Shim et al., 2000). Recent work has highlighted the increased complexity 
of classical estrogen receptor signaling, where estrogen receptors can control the 




range chromatin looping, which brings distant genes into close proximity to where estrogen 
receptors are bound (Fullwood et al., 2009). 
 
Endocrine Disrupting Chemicals.   
Endocrine disrupting chemicals (EDCs) can interfere with normal hormone 
signaling by mimicking or antagonizing the effects of endogenous hormones but can also 
alter the synthesis and metabolism of endogenous hormones and their receptors (Fernandez 
and Russo, 2010; Sonnenschein and Soto, 1998).  Xenoestrogens are structurally diverse 
EDCs that affect estrogen receptor (ER) signaling pathways (Singleton and Khan, 2003). 
Estrogenic responses to putative xenoestrogens are most often determined by 
transactivation of ERE-reporters, endogenous gene expression and cell proliferation in ER-
expressing MCF-7 and T47D cell lines, where ERα is the dominant subtype (Buteau-
Lozano et al., 2002; Vladusic et al., 2000).  
Benzophenone-3 (BP-3) is a UV-filter used in personal care products, such as 
sunscreens, cosmetics and lotions. BP-3 was detected in the urine samples of 96.8% of U.S. 
population in the National Health and Nutrition Examination Survey (Calafat et al., 2008).  
BP3 was shown to be a weak agonist of ER at 1 µM levels (Kerdivel et al., 2013; Schlotz 
et al., 2017; Schlumpf et al., 2010). Exposure to BP3 during pregnancy and lactation in 
mice resulted in altered mammary gland ductal architecture (LaPlante et al., 2018). Propyl 
Paraben (PP) is widely used as an anti-microbial agent in food and personal care products. 
PP was detected in the urine samples of >96% of U.S. population surveyed during 2003-
2005 (Ye et al., 2006). PP was shown to be an effective ER-agonist with 1.3-fold induction 




expression of estrogen-responsive gene Trefoil Factor 1 (TFF1, also known as pS2) and 
increased proliferation of MCF-7 cells at 1 µM (Byford et al., 2002). Proliferation induced 
by PP was inhibited by ER antagonist (fulvestrant) indicating dependence on ER. 
Xenoestrogens, therefore, have the potential to disrupt estrogen receptor signaling by 
acting as ligands and could either amplify or mitigate the risk of breast cancer posed by 
estrogen exposure.  
 
Genotoxicity by Estrogen.   
 Estrogen induces genotoxicity and DNA damage which is considered a major risk 
factor in breast cancer etiology (Roy and Liehr, 1999; Yager and Davidson, 2006). 
However, the mechanisms by which estrogen induces carcinogenesis continue to be 
debated (Figure 1.2). First, estrogen has the potential to act as a direct carcinogen. Estrogen 
is metabolized by phase I P450 enzymes to form catechol estrogens (16α-ΟΗΕ2 or 2-OHE2 
and 4-OHE2), which can be oxidized to form reactive semiquinone (SQ) intermediates and 
quinone derivatives. Two such compounds, E2-3-4-Q and E2-2-3-Q form stable DNA 
adduct or depurinating adducts such as 4-OHE2-1N7Gua and 4-OHE2-1N3Ade, which 
were associated with increased breast cancer risk (Cavalieri and Rogan, 2016) . The 
formation of DNA adducts can also generate ROS through redox cycling and are potent 
inducers of oxidized bases. The oxidized bases can promote DNA single strand breaks 
(Fussell et al., 2011; Wang et al., 2010). DNA adducts have been correlated with increased 
cancer risk and act as carcinogenic metabolites. Therefore, apurinic/apyrimidinic sites (AP) 
are mutagenic if not faithfully processed (Cavalieri et al., 1997; Cavalieri and Rogan, 2016; 




ER. ER promotes proliferation of the breast epithelium which causes replication-
associated DNA damage (Henderson and Feigelson, 2000; Preston-Martin et al., 1990). 
However, ER has been shown to recruit Topoisomerase-2β, stimulating DNA double-
strand breaks to facilitate transcription of ER target genes (Ju et al., 2006; Williamson and 
Lees-Miller, 2011). Another mechanism observed in breast cancer cell lines showed that 
ER induces expression of APOBEC3B which causes cytidine deamination leading to 
DNA damage (Periyasamy et al., 2015; Udquim et al., 2020). Recently, 17-estradiol (E2) 
was shown to induce DNA damage by promoting ER-mediated co-transcriptional 
structures called R loops (Stork et al., 2016). Therefore, estrogen can stimulate 
carcinogenesis by initiating direct DNA damage as well as through mechanisms mediated 
by ER.  
 
R loops: A double edged sword. 
R loops are non-B DNA structures that are formed when the nascent RNA 
hybridizes with the template DNA strand and causes transient displacement of the non-
template DNA strand. The term R loop refers to the three-stranded structure formed by the 
DNA-RNA hybrid and the displaced single-stranded DNA (ssDNA). R loops are a normal 
consequence of transcription, but the persistence of R loops can induce DNA damage 
responses that result in DNA double-strand breaks (Aguilera and García-Muse, 2012a; 
Skourti-Stathaki and Proudfoot, 2014; Sollier and Cimprich, 2015). There are two different 





Physiological R loops:  Programmed R loops is a process which requires specific 
factors and enhanced specifically at certain regions to play a physiological role. 
Physiological R loops are intermediates that regulate several processes such as 
Immunoglobulin (Ig) class switch recombination (CSR) of B cells in vertebrates, CRISPR-
Cas9 genome editing where guide-RNA forms a DNA:RNA hybrid to mediate Cas9 
cleavage, transcription initiation and termination or mitochondrial and bacterial DNA 
replication (Aguilera and García-Muse, 2012b; Baldacci et al., 1984; García-Muse and 
Aguilera, 2019; Itoh and Tomizawa, 1980; Jinek et al., 2012; Kreuzer and Brister, 2010; 
Pohjoismäki et al., 2010; Xu and Clayton, 1996; Yu et al., 2003).  
 
Pathological R loops: R loops play an important role in many cellular processes; 
however, persistent/unscheduled R loop formation due to defects in R loop resolving or 
preventing factors is linked towards DNA damage and genomic instability. The relevant 
mechanism by which unscheduled R loops causes genomic instability is its potential to act 
as an obstacle to replication fork progression, and therefore, cause fork collapse 
(Azvolinsky et al., 2009). Several studies have reported DNA damage generated by 
collisions between replication fork and the transcriptional machinery (Boubakri et al., 
2010; Gottipati et al., 2008; Prado and Aguilera, 2005). The displaced ssDNA that is 
exposed during R loop formation is an excellent substrate and an open target to DNA 
editing enzymes such as activation induced cytidine deaminase (AID) or Apolipoprotein B 
mRNA editing enzyme (APOBEC). The DNA modifications activate base excision repair 
(BER) which creates an abasic site and ultimately a DNA lesion (Burns et al., 2013; Chiarle 




DNA double strand breaks (DSBs) by XPF and XPG endonucleases (xeroderma 
pigmentosum types F and G) involved in nucleotide excision repair (NER) (Sollier et al., 
2014) to promote genomic instability. R loops as a source of DSBs can promote 
chromosomal translocations to promote carcinogenesis (Gostissa et al., 2011; Yang et al., 
2014).  
 Multiple RNA processing factors and helicases have been shown to be involved in 
the resolution of R loops. Several proteins involved in Fanconi Anemia (FA) pathway such 
as BRCA1, BRCA2, FANCD2, FANCM and FANCA are recruited to R loop forming 
regions and their inactivation causes R loop accumulation and DNA damage  (Bhatia et al., 
2014; Hatchi et al., 2015; Madireddy et al., 2016; Okamoto et al., 2019; Schwab et al., 
2015; Silva et al., 2019). In addition, BRCA1 and BRCA2 interact with DNA: RNA hybrid 
unwinding helicases such as SETX, DDX5 and RNase H2 to promote the efficient 
resolution of R loops (D’Alessandro et al., 2018; Hatchi et al., 2015; Sessa et al., 2021). 
Blocking DNA damage response and DNA repair genes (ATR, ATM, CHK1, CHK2, 
UBE2B, and RAD18) causes R loop accumulation (Barroso et al., 2019). Thus, several 
mechanisms are used to ensure the stability of the genome and protect from DNA damage 
mediated by R loops.  
  
DNA G quadruplexes (G4s).  
 
 Another non-canonical DNA secondary structure known as G quadruplexes (G4s) 
is formed at single-stranded guanine-rich DNA sequences. DNA G4s arise from Hoogsteen 
hydrogen bonding of four guanine residues arranged within a planar G-quartet. Self-




monovalent cations such as K+ and Na+ (Kwok and Merrick, 2017). G4 structures are 
topologically very polymorphic and can arise from the intra- or inter- molecular folding of 
G-rich strands. Intra-molecular folding requires the presence of four or more G-tracts in 
one strand, whereas inter-molecular folding can arise from two or more strands giving rise 
to parallel or anti-parallel structures depending on the orientation of the strands in a G4 
(Kwok and Merrick, 2017; Lejault et al., 2021).  
 
Biological functions of DNA G4s.  
  Protection of Telomeres: In vertebrates, the telomeric repeats (TTAGGG)n with a 
double stranded portion that is several kilobases in length and a 3` single stranded overhang 
which is few hundred bases in length. Telomeres consists of telomeric DNA and telomere 
binding proteins including TRF1, TRF2, POT1, RAP1, TIN2 and TPP1 which constitute 
the shelterin protein complex. This complex prevents the ends of the telomere from being 
recognized as DNA break points by DNA repair machinery. Telomeric DNA repeats are 
guanine rich and can form alternative secondary structure – the G4 structures (Maizels and 
Gray, 2013; Rhodes and Lipps, 2015; T. Tian et al., 2018; Varshney et al., 2020). In S. 
cerevisiae, cdc13 knockdown (a component of telomere capping complex) results in 
telomere instability and rescued by drugs that stabilize G4 structures (Smith et al., 2011). 
G4s are very resistant to digestion by exonucleases and may provide stability to telomere 
deprived of capping complex. 
 
 Replication: G4 structures could have important roles in replication origins, both 




throughput sequencing of short nascent DNA strands in four human cells (fibroblasts, 
embryonic stem cells, induced pluripotent stem cells and HeLa cells) showed that the 
majority of 250,000 replication origins correspond to G4 structures (Besnard et al., 2012). 
In addition, human origin recognition complex (ORC) was shown to bind to G4 forming 
DNA and RNA sequences in vitro (Hoshina et al., 2013). Recently, by initiation site-
sequencing (ini-seq), using replicated DNA in a cell-free system, approximately 25,000 
origins were identified in the human genome and 12,000 overlapped with G4 structures 
(Langley et al., 2016). The mechanism through which G4s influence origin initiation 
processing is still poorly understood. G4s have also been shown to play a role in the 
suppression of late origin firing by acting as the binding target of Rap1-interacting factor 
1 (Rif1) in fission yeast, suggested to be a key factor in the regulation of DNA replication 
timing (Kanoh et al., 2015).  
 
 Transcription: G4s are considered to be significantly prevalent in human gene 
promoters. Computational analysis indicated the presence of 300,000 enriched putative 
quadruplex sequences (G3+N1-7G3+N1-7G3+N1-7G3+) in promoters, proximal to transcription 
start site (TSS) and revealed that 42.7% of human gene promoters contain one or more 
quadruplex motifs (Huppert and Balasubramanian, 2005). Primers targeting G4s followed 
by re-sequencing the templates treated with the G4 stabilizer Pyridostatin (PDS) to identify 
sites of polymerase pausing. This G4-seq method was used to directly identify 716,310 
distinct G4 structures in human B lymphocytes (Chambers et al., 2015). More recently, 
G4-specific antibodies were used to enrich and sequence endogenous G4 motifs (G4-




depleted promoter regions suggesting that G4 formation leads to increased transcription 
(Hänsel-Hertsch et al., 2016). In addition, G4s can contribute to CpG islands 
hypomethylation in promoter regions contributing to elevated gene expression (Mao et al., 
2018). Endogenous G4 DNA also acts as a site docking site for transcription factors (Lago 
et al., 2021; Spiegel et al., 2021). In patient-derived xenograft (PDX) models of breast 
cancer, increased G4 formation were found at the promoters of highly amplified genes that 
show increased expression (Hänsel-Hertsch et al., 2020).  
 
Genomic Instability by DNA G4s.  
Stable G4 structures can impede the progression of DNA polymerases and stall the 
replication fork progression leading to DNA damage and genomic instability (Puget et al., 
2019; Técher et al., 2017). G4s can acts as trapping sites of oxidative DNA damage caused 
by reactive oxygen species (ROS). 8-oxoG formation by ROS can affect stability of 
promoter G4 structures resulting in altered expression levels in reporter gene assays (Cogoi 
et al., 2010; Fleming et al., 2017; Fleming and Burrows, 2019; Roychoudhury et al., 2020). 
In the human genome, G4 DNA is enriched at the chromosomal translocational breakpoints 
associated with various type of cancers, confirming that G4 DNA is a contributing factor 
to oncogenic transformation (Bacolla et al., 2019, 2016).  
 
Factors resolving DNA G4s.  
Several helicases and proteins are involved in G4 resolution and suppressing G4 
mediated genomic instability (Lejault et al., 2021; Sauer and Paeschke, 2017).  The yeast 




strand breaks (Paeschke et al., 2013; Ribeyre et al., 2009). FANCJ helicase together with 
the ssDNA binding protein RPA facilitates G4 unwinding (Wu et al., 2008). Another G4 
helicase known as Bloom Syndrome (BLM) suppresses sister chromatid exchange events 
in the transcribed genes specifically at the sites of G4 motifs (Wietmarschen et al., 2018). 
In glioma cells, α-thalassemia mental retardation X-linked (ATRX) loss promotes G4 
formation, somatic copy-number alterations, and increased occupancy of BLM at DNA 
damage sites (Wang et al., 2019). BLM and Werner Syndrome (WRN) helicases interact 
with RPA mediated by the BRCA1-interacting E3 ubiquitin- protein ligase HERC2 to 
suppress G4 DNA formation (Wu et al., 2018; Zhu et al., 2021). Recently, regulator of 
telomere elongation helicase 1 (RTEL1) was shown to suppress both R loops and G4s to 
avoid transcription-replication conflicts (Kotsantis et al., 2020; Wu et al., 2020). Thus, the 
formation and resolution of G-quadruplexes need to be regulated in the genome for the 
appropriate biological function. 
 
When R loops and G4s come together – G loops. 
Multiple studies have shown that R loops are more prevalent in genomic regions 
that are G-rich. During transcription, the non-template DNA strand is displaced allowing 
G4 structures to form in the single-stranded DNA strand (Ginno et al., 2013, 2012; Reaban 
et al., 1994; Skourti-Stathaki and Proudfoot, 2014). Recent studies have shown the co-
existence of the R-loop and G4 to form a unique stable structure called as “G-loop”, where 
those G-rich sequences on the non-template strand fold into a G4 structure and R-loops on 
the template DNA strand (Figure 1.3)  (Lee et al., 2020). Using electron microscopy, 




vitro and in Escherichia coli. Another study used G4 ligands, such as Pyridostatin (PDS), 
to stabilize G4 structures in human cancer cells and observed that G4 ligands induce DNA 
damage by stabilization of R loops (Magis et al., 2018). In these studies, 50 - 60% of 
stabilized G4s colocalized with R-loops. Importantly, R loops allow G4 formation and 
those G4s reversibly stabilize the R loop structure indicating the interrelationship of G4 
and R-loop (Tan et al., 2020). The kinetics of R-loop and G4 formation was found to be 
similar in the cells at different timepoints and failure to resolve these structures promotes 
DNA damage and delays the repair process. G-loops can promote genomic instability by 
causing transcription-replication conflicts. Therefore, both G4 and R loops can be potential 
targets for cancer therapy. One classical example is G4 stabilizer CX-5461 causes synthetic 
lethality in BRCA deficient tumors and has advanced to clinical trials (Xu et al., 2017).  
 
Objectives in this study. 
We understand that estrogenic actions mediated by ERα plays a crucial role to 
breast carcinogenesis. Recently, co-transcriptional R loops came out to be a major player 
in terms of estrogen mediated genomic instability. All women are exposed to estrogens but 
only 1 in 8 women is expected to develop breast cancer which suggest that the genotoxic 
effects of estrogen could vary among individuals. In our studies, we tried to examine how 
estrogen and environmental disrupting chemicals can induce DNA damage. In the first part 
of our study, we investigated the mechanism of ER dependent DNA damage, R loop 
formation, transcriptional and proliferative responses by the endocrine disrupting 
chemicals BP3 and PP using in vitro and in vivo approach with E2 as a positive control. 




determine whether there is a genetic basis for differences in E2 induced DNA damage.  We 
also utilized patient derived breast explant model to determine the differences in E2 
mediated DNA damage among average and high-risk women. Lastly, we studied the 
underlying DNA damage mechanism of E2 and BP3. We hypothesized that E2 and BP3 
could favor G4 structures and especially G loop formation which could be the cause of 







































Figure 1.1: Estrogen receptor signaling. 
Overview of ligand-dependent and independent mechanisms of estrogen receptor 
signaling. Direct, ligand-dependent signaling involves ligand-bound estrogen receptor 
(ER) dimers and coactivators (CoA) binding to estrogen response elements (ERE) in the 
DNA. Tethered estrogen receptor signaling involves ligand-bound receptor dimers binding 
to other transcription factors (TF) on the DNA. Ligand-independent signaling involves 
other growth factor activation, which activates kinases and leads to phosphorylation (P site) 












Figure 1.2: Mechanisms of E2 induced genomic instability.  
Ligand dependent signaling. 
(Classical Signaling) 
Ligand dependent signaling. 
(Tethered signaling) 















Figure 1.3: Structure of a G loop. 
R loop formed on a template strand of DNA and on the non-template strand, a G quadruplex 
structure is formed. The simultaneous formation of R loop and G quadruplex structure is 




















EFFECTS OF BENZOPHENONE-3 AND PROPYL PARABEN ON ESTROGEN 
RECEPTOR – DEPENDENT R-LOOPS AND DNA DAMAGE IN BREAST 
EPITHELIAL CELLS AND MICE 
 
 







Endocrine-disrupting chemicals (EDCs) alter the endocrine system by binding 
directly to the receptors and modulating downstream signaling pathways. Xenoestrogens 
are structurally diverse EDCs that affect estrogen receptor (ER) signaling pathways. BP3 
(Oxybenzone, or 2-Hydroxy-4-methoxybenzophenone, CAS No. 131-57-7) is a UV-filter 
used in personal care products, such as sunscreens, cosmetics and lotions, with 
concentrations up to 0.148% (Liao and Kannan 2014) and a maximum allowed 
concentration of 6% by Food and Drug Administration (FDA) and European commission 
(EU 2017). BP3 was detected in the urine samples of 96.8% of U.S. population in the 
National Health and Nutrition Examination Survey (NHANES) 2003-2004 conducted by 
Centers for Disease Control (CDC) (Calafat et al. 2008). Similarly, PP (propyl 
parahydroxybenzoate, CAS No. 94-13-3) is widely used as an anti-microbial agent in food 
and personal care products. While the FDA limits PP to 0.1% in food, currently there is no 
specific limit for preservatives in personal care products. PP is banned as food preservative 




(European Commission 2015). PP was detected in the urine samples of >96% of U.S. 
population surveyed during 2003-2005 by the CDC (Ye et al. 2006).  
 Estrogenic responses are determined by the action of two distinct estrogen receptor 
(ER) subtypes, estrogen receptor α (ERα) and estrogen receptor β (ERβ). Ligand-activated 
ER recruits co-activators to estrogen response elements (ERE) in promoters of target genes 
leading to transcription initiation (Shang et al. 2000; Yi et al. 2017). In ERα expressing 
breast cancer cells, proliferation is among the cellular responses (Henderson et al. 1988; 
Musgrove and Sutherland 1994). Hence, estrogenic responses to putative xenoestrogens 
are most often determined by transactivation of ERE-reporters, endogenous gene 
expression and cell proliferation in ER-expressing MCF-7 and T47D cell lines, where ERα 
is the dominant subtype (Buteau-Lozano et al. 2002; Vladusic et al. 2000). These studies 
showed BP3 was a weak agonist of ER at 1 µM  (Kerdivel et al. 2013; Schlotz et al. 2017; 
Schlumpf et al. 2001). BP3 was found in the urine samples of 25 volunteers who used 
sunscreen containing 4% BP3 twice a day for 5 days suggesting it was readily absorbed 
through skin (Gonzalez et al. 2006). Metabolites of BP3, such as 2,4-diOH-BP and 2,3,4-
triOH BP, were shown to form by oxidation in rat and human liver microsomes (Okereke 
et al. 1994; Watanabe et al. 2015). 2,4-diOH-BP was detected in the urine samples of 
women scheduled undergo a diagnostic and/or therapeutic laparoscopy or laparotomy as 
part of the ENDO study (Kunisue et al. 2012) and was shown to have higher ER 
transactivation potential compared to BP3 (Watanabe et al. 2015). BP3 and BP3 metabolite 
4,4’-dihydroxybenzophenone were also detected in 27 of the 79 breast milk samples from 
mothers who had normal pregnancy and delivery and participated in the Breast Milk Bank 




of BP3 during pregnancy and lactation in mice resulted in altered mammary gland ductal 
architecture that persisted for weeks after exposures ended (LaPlante et al. 2018). Long-
term exposure of MCF-7 breast cancer cells to 100 µM BP3 for >20 weeks increased the 
motility of these cells (Alamer and Darbre 2018). This was also observed in estrogen non-
responsive cell line MDA-MB-231 suggesting alternate pathways of BP3 actions at this 
dose. Similarly, PP was shown to be an effective ER-agonist with 1.3-fold induction of 
gene expression using reporter assays (ERE-CAT reporter) at 10 µM, increased expression 
of estrogen-responsive gene Trefoil Factor 1 (TFF1, also known as pS2) and increased 
proliferation of MCF-7 cells at 1 µM (Byford et al. 2002). Proliferation induced by PP was 
inhibited by ER antagonist (fulvestrant) indicating dependence on ER. PP also increased 
cell motility (increased scratch closure) in both short-term (7 days) and long term (20 
weeks) treatments in the MCF-7 cell line (Khanna et al. 2014).  
 In addition to stimulating cell proliferation and motility, estrogen also induces 
genotoxicity and DNA damage and is considered a major risk factor in breast cancer 
etiology (Roy and Liehr 1999; Yager and Davidson 2006). Estrogen has been shown to 
induce DNA damage by 1) metabolic activation of estrogen and 2) hormonal 
carcinogenesis (Santen et al. 2009). E2 is metabolized to form catechol estrogens (16α-
ΟΗΕ2 or 2-OHE2 and 4-OHE2), which can be oxidized to form reactive semiquinone (SQ) 
intermediates and quinone derivatives. Two such compounds, E2-3-4-Q and E2-2-3-Q 
form stable DNA adduct or depurinating adducts such as 4-OHE2-1N7Gua and 4-OHE2-
1N3Ade, which were associated with increased breast cancer risk, but micromolar levels 
of E2-3-4-Q and E2-2-3-Q were required to show DNA adduct formation in vitro (Cavalieri 




cycling, which can be genotoxic (Fussell et al. 2011; Wang et al. 2010). Similarly, ER-
independent DNA damage was shown in ERα-negative cell lines using the COMET assay 
(Rajapakse et al. 2005), cII mutagenesis assay (Zhao et al. 2006) or LOH (Huang et al. 
2007; Russo et al. 2003). The concentrations of E2 or 4-OHE2 used in these studies were 
 70nM, with the exception of Russo et al. 2003 who reported increased clonal efficiency 
of MCF10F cells at 0.007nM. However, the median 17-estradiol level during pregnancy 
is 74 nM and < 2 nM in normal cycling women (Table 1.1) and the level of circulating 
estradiol metabolites are 100-fold lower (Xu et al. 2007; Ziegler et al. 2010). Clinical data 
show that in postmenopausal women with ER+ early breast cancer, endocrine therapy with 
an aromatase inhibitor was associated with significantly lower recurrence than tamoxifen 
therapy (EBCTCG 2015), which could be either because of lower levels of estrogen 
metabolites or reduced ER activation. Epidemiological data show that for a given level of 
total estrogen, increased levels of 4-OHE2, 2-OHE2 and 16-OHE2 are associated with 
reduced risk in breast cancer (Dallal et al. 2014; Moore et al. 2016; Sampson et al. 2017) 
or no independent association with risk (Sampson et al. 2017). Although an earlier study 
reported 4-OHE2 levels to be associated with higher breast cancer risk (Fuhrman et al. 
2012). Hence, the impact of metabolic activation of estrogen at physiologically relevant 
concentrations on DNA damage remains to be demonstrated. 
 Hormonal carcinogenesis is postulated to act through ER to initiate lesions as well 
as stimulate progression of tumors. E2 treatment stimulated renal tumors in male Syrian 
hamsters (Liehr et al. 1988). Tamoxifen (TAM) reduced tumors but did not alter levels of 
DNA-adducts suggesting the primary effect of E2 being mediated by ER. Similarly, 




as TAM and raloxifene reduced the incidence of breast cancer by 50-75 % in women 
(Cummings et al. 1999; Cuzick and International Breast Cancer Intervention 2001; Martino 
et al. 2004). Bilateral oophorectomy and hysterectomy in women under 40 years of age 
reduced breast cancer later in life by 75% (Feinleib 1968). Administration of aromatase 
inhibitor (exemestane) for 35 months to a cohort of post-menopausal women with Gail 
score of 1.66, prior atypical ductal/lobular hyperplasia or ductal carcinoma in situ treated 
with mastectomy but non-carriers for BRCA1/2 and no prior invasive ductal carcinoma 
resulted in 65% relative reduction of breast cancer (Goss et al. 2011). Mobley and 
Brueggemeier (2004) showed that 8-oxo-dG production with BSO (buthionine 
sulfoximine)+ E2 (10nM) + H2O2 treatment could be reduced with TAM treatment in ER-
positive MCF7 cells but not in ER-negative MDA-MB-231 cells suggesting DNA damage 
was at least partially ER-mediated (Mobley and Brueggemeier 2004). Stork et. al (2016) a 
showed lack of DNA damage marker γΗ2ΑΧ in MCF10A cells following treatment of 10 
nM and 100 nM E2 for 24 h (Stork et al. 2016). In T47D cells, E2 mediated γH2AX was 
diminished with treatment of ER inhibitors like TAM or fulvestrant (Periyasamy et al. 
2015). ER signaling stimulates proliferation which was causally linked to tumorigenesis 
by increasing the probability of replication errors which are propagated in daughter cells 
(Henderson and Feigelson 2000; Preston-Martin et al. 1990). Therefore, E2 can be 
considered as a carcinogen through its actions on progression of cancer that was initiated 
by other factors.  
 The studies involving DNA damage by E2 have used different cell lines, tissues 




dependent and ER-independent mechanisms across published studies. It is possible that 
both mechanisms contribute to E2 mediated carcinogenesis.  
Recent studies have shown that ER stimulation leads to transcription-coupled DNA 
damage suggesting a distinct mechanism. Interaction of ERα with chromatin forms 
transcriptional co-activator/co-repressor complexes to initiate transcription (Chao et al. 
2002; Fullwood et al. 2009; Shang et al. 2000). The open chromatin in these ERα 
complexes were susceptible to DNA damage by formation of RNA:DNA triplex structures 
called R-loops (Stork et al. 2016). Therefore, estrogen can stimulate carcinogenesis by 
initiating direct DNA damage mediated by ER and proliferation that expands the 
population of breast cells.  
Bioassays of transcriptional activities have been valuable in rapidly assessing the 
risk posed by xenoestrogens. However, it is unclear if the transcriptional activities of 
xenoestrogens reflect their potential mutagenic activity mediated by ERα. DNA damage 
by selective ER agonists such as Diethylstilbestrol (DES) and 4,4',4''-(4-Propyl-[1H]-
pyrazole-1,3,5-triyl) trisphenol (PPT) (Periyasamy et al. 2015) suggest that transcriptional 
DNA damage needs to be assessed to determine potential breast cancer risk posed by 
xenoestrogens. In this study, we evaluated effects of two xenoestrogens, BP3 and PP, 









Materials and Methods 
 
Cell culture:  
T47D (ATCC #HTB-1330), T47DKBluc (ATCC #CRL-2865) and MCF-7(ATCC 
#HTB 22) cells were passaged in growth media containing phenol-red free (PRF) DMEM-
F12 (Sigma #D6434) or MEM 1x (Gibco #51200-038) with 10% heat inactivated FBS 
(Omega Scientific # FB-02) and 10 μg/ml insulin (Sigma #9278), 2 mM L-glutamine 
(Hyclone # SH30034.01), gentamycin 15 μg/ml (Gibco #15750-060) and 1X 
antibiotics/antimycotics (AB/AM, Gibco #15240-062) and incubated at 37oC with 5% 
CO2. For experiments, cells were grown in clearing media with charcoal-stripped serum 
(CSS) (MEM 1x with 10% charcoal-dextran treated FBS (Omega Scientific #FB-04), 10 
µg/ml insulin and 2 mM L-glutamine) for 24-72 h before being plated for experiments.  
The 76N-Tert cell line, a human mammary epithelial cell line immortalized with 
expression of human telomerase reverse transcriptase (TERT), was a gift from Dr. Vimla 
Band (Zhao et al. 2010). These cells were grown in F-media (250 mL DMEM (- pyruvate) 
(Gibco #11965-092), 250 mL Ham’s F12 (Gibco #11765-054), 5% FBS, 250 ng/mL 
hydrocortisone (Sigma #H4001), 10 ng/mL human epidermal growth factor (Tonbo 
Biosciences # 21-8356-U100), 8.6 ng/mL cholera toxin vibrio (Millipore Sigma # 227035), 
1 µg/mL human insulin solution, and 1X antibiotic-antimycotic) and passaged every 2-3 
days.  
Generation of 76N-Tert-ESR1 cells. 
An inducible ERα (ESR1) construct was generated using the pINDUCER14 vector 




CMV-2 (Andersson et al. 1989) using forward primer 5’- 
ATACCGGTACCATGGACTACAAAGACGATGACGAC-3’ and reverse primer 5’- 
TCGACCGGTACGCGTGCGATCGCTGAATTCGCGGCAAG-3’.  The amplified 
FLAG sequence was then cleaned using the Monarch PCR & DNA Cleanup Kit (NEB 
#T1030) and ligated into pINDUCER14 by digesting both plasmids with AgeI, performing 
dephosphorylation with shrimp alkaline phosphatase (NEB #M0371S), gel electrophoresis, 
and extracting from agarose gel (DNAland Scientific #GP1001). Sequencing of 
pINDUCER14-FLAG confirmed the FLAG sequence was inserted. 
ESR1 was amplified from a plasmid expressing ESR1 made in our lab (pIRES-
hrGFPII-ESR1, unpublished data).  pIRES-hrGFPII-ESR1 contained the ESR1 cDNA 
sequence (Open Biosystems #MHS6278-211691051) in the multiple cloning site of the 
pIRES-hrGFPII vector (Stratagene #240157). ESR1 was amplified from pIRES-hrGFPII-
ESR1 using forward primer 5- GCAGAAATGACCATGACCCTCCACACCAAAGC-3 
and reverse primer 5- TAAACGCGTTCAGACCGTGGCAGGGAAACCCT-3. Ligation 
of ESR1 into pINDUCER14-FLAG was done by digesting both plasmids with EcoRI and 
MluI and then performing dephosphorylation, cleanup, and extraction as described above. 
Two linker sequences (Linker A: AATTGCGCGATCGCGG, Linker B: 
AATTCCGCGATCGCGC) between FLAG and ESR1 were added to keep the ESR1 
sequence in-frame. Sequencing of this final pINDUCER14-FLAG-ESR1 confirmed that all 
inserts were in the correct orientation relative to the vector, both FLAG and ESR1 were in 
frame, and the ESR1 sequence was identical to the Homo sapiens ESR1 gene (Sequencing 




ACTTATATACGGTTCTCCCC). This final construct was referred to as pIND-ESR1 and 
expressed a constitutive GFP reporter and ERα with N-terminal FLAG tag.  
In addition, 293T cells were cultured in DMEM: F12 (Sigma #D8900) 
supplemented with 10% FBS, 15 µg/mL gentamycin (Gibco #15750-060), and 1X 
antibiotic/antimycotic. Cells were lifted with 0.05% trypsin and plated in 60 mm tissue 
culture dishes at 2.5 x 106 cells per dish for next day use. 293T cells were then transfected 
with 3.5 µg pIND-ESR1, 3 µg psPAX2 (Addgene #12260) (gag, pol, and rev packaging 
vector) and 2 µg pMD2.G (Addgene #12259) (vsv-g packaging vector) in antibiotic free 
media using Lipofectamine 2000 (Thermo Fisher Scientific). Media was refreshed after 24 
hours and viral media was collected at 48 and 54 hours post initial transfection. Viral media 
from transfected 293T was filtered using a 0.45 µM filter (Corning #431220) and added to 
76N-Tert cells twice, 6 hours apart, in a 1:1 ratio with F-media. After 24 hours, viral media 
was removed and replaced with F-media. Following cell expansion, the cells were pooled 
and resuspended in 1% FBS/PBS. Selection of the stably transduced cells was performed 
by FACS for GFP+ cells using FACSAria II (Becton-Dickinson). 76N-Tert uninfected 
cells were used as a control to set the background fluorescence. Approximately 5% cells 
were GFP+ suggesting pINDUCER14-FLAG-ESR1 expression. The GFP+ cells were 
collected to 90% purity. These cells were expanded and referred to as 76N-Tert-ESR1.  
Luciferase reporter assay 
T47DKBluc cells were grown in clearing media for 72 h and plated in a 24 well 
plate at 10 x 105 cells/well density.  After 24 h cells were treated with 10 nM E2 (17β-




BP3 (Sigma #H36206) or 0.5 to 50μM PP (Sigma #P53357). Stock solutions were prepared 
in DMSO (Sigma #D8418), then diluted to working concentrations in media. Luciferase 
assays were performed using the Promega Dual-Luciferase Reporter Assay (Promega # 
E1910). Cells were lysed in 1X Passive Lysis Buffer after treatment for 24 h and then 
stored at -20C. Luciferase activity was determined in lysates by using the Polar Star 
OPTIMA plate reader (BMG Labtech) and expressed in relative light units (RLU). 
Treatments were compared to 10nM E2 included on the plate and relative transactivation 
activity (RTA) is defined as percent transactivation compared to 10nM E2.  
 
RT-qPCR 
RNA from T47D cells, MCF-7 Cells or flash-frozen 4th mammary gland was 
isolated with TRIzol (Thermofisher Scientific #15596018) and Direct-zol RNA MiniPrep 
Plus (Zymo Research #R2072). cDNA was prepared from 1 µL of RNA in 20 µL reaction 
mix with Protoscript II First Strand cDNA Synthesis Kit (New England Biolabs #E6560S) 
following the standard protocol provided by manufacturer. qPCR for TFF1, progesterone 
receptor (PGR/Pgr) and Amphiregulin (AREG/Areg) was performed using primers in 
Table 2.3 (Integrated DNA Technology) and iTaq Universal SYBR Green Supermix 
(Biorad, #1725121) on CFX96 Real-Time System thermocycler (Bio-Rad). Each run (96 
well qPCR plate) included an inter-run calibrator to normalize across experiments. No 
house-keeping gene was included in the experiment to avoid possible variation due to 
treatments. Results represent average of 3 experiments. Data was analyzed with Ct 
method and relative fold change in expression of target gene was compared between 




Cell proliferation assay 
T47D cells grown in clearing media for 72 h was plated as 100μl of cells suspension 
having 5000 or 10000 cells per well on five 96 well plates (one for each day). The 96 well 
plate had 12 cell-free wells for a blank and 7 wells per treatment on each plate. After 24h, 
media was changed in appropriate wells on each plate to reach the desired final 
concentration of E2 (0.5 nM), BP3 (5, 50 µM) or PP (1, 10 µM) in the given wells.  All 
plates were maintained in a 37oC, 5% CO2 incubator until media was exchanged, on one 
plate per day, for 10% Alamar Blue in plating media. Plates were read at the same time 
each day at 4 hr and 8 hr after media exchange on a BioTek Synergy 2 plate reader 
(Winooski, VT) at 570nm and 600nm. Percent alamar blue reduction was calculated as per 




(117216 × test well A570)−(80586 × test well A600)
(155677 × mean (negative control wells A600))−(14652 × mean ( negative control wells A570 ))
 × 100 
 
Immunostaining 
T47D, MCF7, 76N-Tert or 76N-Tert-ESR1 cells were grown in clearing media for 
48 h and plated on 20 mm glass uncoated coverslips in 12 well plates with a density of 2 x 
105 cells/well. After 24h of growth, cells were treated with 10 nM E2, 1 or 5 µM BP3, and 
1 or 5 µM PP with or without 1 µM fulvestrant for 24h. γH2AX/53BP1/ERα: Cells were 




mins. Cells were washed with 1X PBS, blocked in 2% BSA/PBS with 0.1% Triton-X 100 
for 1hr at room temperature (RT), incubated overnight with anti-γH2AX antibody (Cell 
Signaling # 9718S), anti-ERα antibody (Santa Cruz Biotechnology #sc-8002) or anti-
53BP1 antibody (Abcam # ab36823) at 4°C followed by 1 hour with anti-rabbit 
AlexaFluoro-488-conjugated secondary antibody (Cell Signaling #8889S) or anti-mouse 
AlexaFluoro-488-conjugated (Cell Signaling #4408S) at RT. S9.6: Cells were fixed in ice-
cold 100% methanol for 10 min at -20°C, permeabilized in 100% acetone for 1 min at RT, 
blocked for 30 min in saline sodium citrate pH 7 (SSC, 4X), 3% BSA, 0.1% Triton-X and 
incubated with S9.6 antibody (Kerafast #ENH001) for 2hr at RT followed by 1h with anti-
mouse AlexaFluoro-596-conjugated secondary antibody (Life Technologies #A11062) or 
anti-mouse AlexaFluoro-488-conjugated (Cell Signaling #4408S). For each treatment, two 
replicates of slides were stained with one set of replicates treated with RNase H (NEB 
#M0297L) for 4hr at 37°C prior to incubation with primary antibody. Stained cells were 
mounted with Vectashield mounting medium containing DAPI (Vector Laboratories # H-
1200). Slides were imaged at 60X (immersion oil) with Nikon A1 Spectral Confocal 
microscope. Analysis of γH2AX and S9.6 intensity per nucleus or foci per nucleus was 
calculated using Nikon analysis software, where DAPI was used as a mask for the nucleus.   
 
Western blot 
Cells from MCF7 grown in growth media, 76N-Tert (parental), 76N-Tert-ESR1, 
76N-Tert-ESR1 grown in F-media treated with doxycycline for 24h and 76N-Tert-ESR1 
treated with doxycycline and 10nM E2 for 24h were lysed with ice cold RIPA lysis buffer 




deoxycholate; 0.1% SDS; 1% protease inhibitors (Sigma-Aldrich # P8340), 1% 
phosphatase inhibitor #2 (Sigma-Aldrich # P5726), and 1% phosphatase inhibitor #3 
(Sigma-Aldrich # P0044).  Homogenate was centrifuged at 13,000 rpm for 15 minutes at 
4°C to remove cellular debris. Protein quantification was performed using BCA protein 
assay (Thermo Scientific # 23225).  Equal amounts of protein (28 μg) were separated by 
SDS-PAGE on 10% acrylamide under denaturating conditions and then blotted onto PVDF 
membrane (Millipore # IPVH00010).  Non-specific binding was blocked with 5% non-fat 
dry milk in TBST (Tris-buffered saline and Tween 20 containing 10 mM Tris-HCl, pH 7.5; 
150 mM NaCl; 0.05% Tween-20) for 1 hour. The blot was incubated with 1:100 anti-ERα 
antibody (Abcam # ab16660) overnight at 4°C. After incubation, the blot was washed with 
TBST and then incubated with HRP-conjugated secondary antibody (1:5000, GE 
Healthcare # NA934V) for 1 hour. Bands were detected using enhanced 
chemiluminescence solution and visualized using G-box imaging system (Syngene).  The 
blot was washed with TBST and incubated with anti-β actin antibody (1:5000, Sigma # 
A1978) overnight at 4°C. After washing with TBST and HRP secondary antibody 
incubation for 1hour (1:5000, GE Healthcare # NA931C) bands were detected with 
enhanced chemiluminescence and G-box system.  Expected molecular weights were 67 
kDa (ERα) and 42 kDa (β actin).   
 
Animal treatment 
Forty mature female mice (8 weeks old) BALB/c mice were purchased from 
Jackson Laboratory and housed in temperature-controlled facilities with a set temperature 




LabChow 5058 ad libitum. All procedures were in accordance with the national guidelines 
for the care and use of animals and approved by the University of Massachusetts Amherst’s 
Institutional Animal Care and Use Committee. 
The mice were ovariectomized before treatment. Briefly, each mouse was 
anaesthetized with a mix of isoflurane and oxygen. The flanks were shaved, sterilized with 
betadine, and cleaned with alcohol. An incision was made to the skin on the right flank. 
The underlying muscle layer was nicked to reveal a small hole through which ovary was 
pulled out by grasping the periovarian fat. A Serrifin clamp was used to hold the ovary. 
After making sure the blood vessels were constricted to prevent breeding, the ovary was 
cut from the uterine horn. The periovarian fat was restored into the peritoneum. The 
peritoneum was closed with one or two stiches and the skin was closed with 9 mm wound 
clips.  The procedure was repeated on the contralateral side. The mouse was monitored for 
a week post-procedure and wound clips were removed after 10 days. After 1 week of 
recovery, the mice were randomized to four groups and began an acute oral treatment via 
pipette with vehicle control (tocopherol-stripped corn oil) (n = 7) or one of three different 
compounds E2 (n = 8), BP3 (n = 12) and PP (n =12) for 4 days. Each mouse was 
administered 1 μL of oil per gram of body weight to deliver 250 µg/kg/d E2, 3000 µg/kg/d 
BP3 or 10000 µg/kg/d PP or vehicle control. For BP3 and PP, these doses represent the 
toxicologically no-adverse-effect-level (NOAEL) doses for each compound based on 
development and reproductive toxicity assays (Scientific Committee on Consumer 
Products 2005, 2008; Soni et al. 2001).  
Six hours prior to sacrifice all of the mice were treated with 5 Gy dose of γ-




70 µg/g body weight of BrdU (Sigma Aldrich; Cat# B5002) that was previously prepared 
at 10 mg/ml in PBS and filter sterilized. The mice were sacrificed using carbon dioxide 
followed by cervical dislocation. Whole blood was collected by cardiac puncture and 
tissues were harvested. One of the 4th mammary gland was fixed in 10% NBF and 
transferred to 70% alcohol prior to paraffin-embedding. The other 4th mammary gland was 
cleared of lymph node and stored in -70C.  The whole blood was allowed to coagulate at 
RT for 20 min and then spun down at 2000 x g for 10 min at 4C to retrieve the serum. 
 
Immunostaining of mouse mammary gland 
Freshly cut 4 μM paraffin-embedded sections were deparaffinized/rehydrated with 
100% xylenes 3 times for 5 min each, 2 times with 100% ethanol for 5 min each, 95% 
ethanol for 3 min and 70% ethanol for 3 min. Samples were rinsed with PBS. Antigen-
unmasking was performed by boiling the samples in 1 mM EDTA for 1 hr. Samples were 
cooled down to RT and then treated with SSC 0.2X with gentle shaking at RT for 20 min. 
Samples were blocked in 3% BSA in PBS with 0.5% Tween-20 for 1 hr at RT. Primary 
antibody incubation was done with monoclonal S9.6 antibody (Kerafast #ENH001) or anti-
H2AX antibody (Cell Signaling # 9718S) for overnight at 4°C. After primary incubation, 
samples were washed 3 times with PBS containing 0.5% Tween-20 and then incubated 
with anti-mouse AlexaFluoro-488-conjugated (Cell Signaling #4408S) or anti-rabbit 
AlexaFluoro-488-conjugated secondary antibody (Cell Signaling #8889S) for 1 hr at RT. 
Samples were washed 2 times with PBS containing 0.5% Tween-20 and 2 times with PBS 
and then mounted with Vectashield mounting medium containing DAPI. Slides were 




per nucleus or foci per nucleus were calculated using Nikon analysis software, where DAPI 
was used as a mask for the nucleus. IHC for Ki-67 was performed on a DakoCytomation 
autostainer using 1:1000 D2H10 primary antibody (cell signaling #9027T) and the 
Envision HRP detection system (Dako, Carpinteria, CA). Positive cells were counted using 




The serum from whole blood that was harvested from all the mice were quantified 
using a 17β-estradiol specific enzyme-linked immunosorbent assay (ELISA) (Calbiotech 
# ES 180S- 100).  
 
Statistical analyses 
Unless specified, data were analyzed by one-way analysis of variance (ANOVA) 
followed by Tukey's honestly significant difference (HSD) multiple-range test using 
GraphPad Prism 8 statistical analysis software or R program (R Core Team 2013). The 
difference between control and fulvestrant/RNase H treated groups were evaluated with 
two-way ANOVA followed by Bonferroni correction. Results are presented as mean ± 
standard error of the mean (SEM). Data were considered statistically significant at p <0.05. 
Growth curves were fitted to linear regression model and slopes were compared between 








DNA damage and TFF1 gene expression in cells treated with E2, BP3 or PP 
We monitored γΗ2AX foci as a measure of DNA damage in T47D cells treated 
with the compounds for 24h. A dose-dependent increase in γH2AX intensity was observed 
following E2 treatment (Figure 2.1A). Treatment with either BP3 or PP also led to an 
increase in γH2AX intensity. Treatment with BP3 at 1 or 5 µM increased γΗ2ΑΧ intensity 
compared to the control (p < 0.0001) although we did not observe a dose-dependent 
increase (1μM BP3 vs 5μM BP3, Figure 2.1B). PP treatment also resulted in significantly 
increased γH2AX intensity at 1 and 5μM compared to the control (p < 0.0001). The γH2AX 
intensity due to PP treatment was dose-dependent, similar to E2 treatment (1μΜ PP vs 
5μM PP, p < 0.0001) (Figure 2.1C). We confirmed the DNA damage with immunostaining 
of 53BP1, a DNA damage response factor, which localizes to the sites of DNA damage 
and forms ionization radiation induced foci. Similar to γH2AX intensity, we observed 
dose-dependent increases in 53BP1 nuclear intensity following treatment with E2 (10-100 
nM) and PP (1-5µM) compared to control in both T47D and MCF-7. BP3 treatment (1-5 
µM) showed increased nuclear 53BP1 intensity over control in both T47D and MCF-7, but 
only MCF-7 showed dose-dependent increase (Figure 2.1D and E). We also observed a 
dose-dependent increase in nuclear γH2AX intensity in MCF-7 with treatment of E2 (10 – 
100 nM), BP3 (1 – 30µM) and PP (1 – 30µM) (Figure 2.1F). 
The effect on γH2AX by these compounds was contrasted with the mRNA 
expression of estrogen-responsive gene TFF1. Treatment with 10nM E2 stimulated a 13.1-




µM BP3 or PP did not differ significantly from the control (Figure 2.2A). The 
transcriptional responses to E2 were blocked by treatment with fulvestrant (ICI 182,780, 1 
µM) demonstrating the dependence on ER. Blocking ER with fulvestrant also significantly 
reduced the effect of E2 on γH2AX intensity (Figure 2.2B, p < 0.0001) and inhibited 
γH2AX intensity in response to 5µM BP3 (p < 0.0001) and 5µM PP (p <0.0001) suggesting 
that the induction of DNA damage was, in part, dependent upon ER. However, the γH2AX 
foci induced by E2 and BP3 was incompletely blocked by fulvestrant compared to its 
inhibition of TFF1 expression.  
 
Estrogenic response in cells treated with BP3 and PP. 
Reporter assays provide a sensitive means to evaluate estrogenic activity on a 
minimal promoter whereas endogenous genes containing estrogen responsive elements 
provide physiologically relevant targets. 10nM E2 is sufficient to saturate ER responses in 
these assays, hence it was used as positive control that is relevant to physiologic E2 levels 
(2-70nM) in women (Table 2.1). T47D-KBluc cells harbor an integrated ERE-luciferase 
reporter in which BP3 showed a lowest-observed-effect at 5µM with transactivation 
increasing to a maximum 37% relative transactivation activity (RTA) compared to 10nM 
E2 (Figure 2.3A left). In contrast, PP showed 4.7% RTA at 0.5 µM and increased to 288% 
at 50 µM. To estimate the transactivation activity of the compounds at levels that are 
relevant to human exposure, we used the published urinary levels of BP3 and PP (Table 
2.1). At concentrations measured in the 95th percentile of pregnant women, BP3 had 
27.166.2% and PP had 104.0720.98% RTA (Figure 2.3A right, white, and black arrows 




quantified in T47D and MCF-7 cell lines (Figure 2.3B and C). Treatment of BP3 and PP 
at 1 µM resulted in no significant changes in mRNA expression of AREG and PGR, a 
concentration that led to significant increases in DNA damage in both T47D and MCF7 
cells (Figure 2.1). Proliferation induced by these compounds was also compared to control 
treatment to provide an additional measure of their bioactivity (Figure 2.3D, Table 2.2). 
PP stimulated significant proliferation of T47D cells at 10µM but not at 1µM PP. However, 
BP3 had marginal effect at 5 or 50µM. Low concentrations of BP3 and PP only marginally 
increased cell numbers compared to control.  
 
R-loop formation in cells treated with E2, BP3 or PP 
R-loop formation was investigated as a possible mechanism of DNA damage using 
the S9.6 antibody to specifically detect DNA: RNA hybrids. While we observed a basal 
level of R-loop foci in the vehicle-treated control in T47D cells, nuclear S9.6 foci were 
significantly increased with 5µM of BP3 or PP treatment and comparable to responses with 
10nM E2. Addition of RNase H to the cells treated with 5µM BP3 or PP or 10nM E2 
abolished the S9.6 intensities, confirming the specificity of S9.6 nuclear staining (Figure 
2.4A and B). Similarly, increased of R-loops formation was obtained with 10nM E2, 5µM 
BP3 or 5µM PP treatment of MCF-7 cells which was abrogated following RNase H 








R-loop formation in normal breast epithelial cell line treated with E2, BP3 or PP 
Next, we asked if R-loops form in normal breast epithelial cells in response to 
exposures of BP3 and PP. The 76N-Tert cells do not express endogenous ESR1 providing 
a null background to test ERα-stimulated R-loops. The cells were stably infected with an 
inducible human ESR1 (pINDUCER-ESR1, Figure 2.5A). ERα expression in 76N-Tert-
ESR1 was confirmed with western blot (Figure 2.5B).  MCF-7 cell lysate was used as a 
positive control. Immunofluorescence showed 90% of the 76N-Tert-ESR1 cell population 
were GFP+ (ERα expressing) (Figure 2.5B).   
In the parental 76N-Tert cell line, which does not express ERα, treatment with 
10nM E2, 5µM BP3 or 5µM PP showed low nuclear S9.6 staining. After induction of ERα 
with doxycycline, 5µM BP3 or PP increased number of nuclear S9.6 foci significantly over 
vehicle-treated control and comparable to 10nM E2 treatment. RNase H treatment reduced 
nuclear S9.6 foci in 10nM E2 treated as well as 5 µM BP3 or PP treated 76N-Tert-ESR1 
cell line induced with doxycycline (p<0.0001, Figure 2.5C & D).  
 
Evaluation of R-loop formation and DNA damage in mice treated with E2, BP3 or PP 
To evaluate the relevance of exposure to xenoestrogens in vivo, we treated 
ovariectomized BALB/c mice orally with E2 (250µg/kg/day), BP3 (3,000 µg/kg/day) or 
PP (10,000 µg/kg/day) for 4 days (Figure 2.6A). These doses were used in experiments 
evaluating effects of chronic exposures on mammary gland development (LaPlante et al., 
2018). We observed 3.8-fold higher nuclear S9.6 staining in the mammary epithelium of 




higher nuclear S9.6 staining in the mammary epithelial cells whereas PP induced 3.8-fold 
higher compared to control-treated animals (Figure 2.6B & C). Nuclear γΗ2AX intensity 
in the mammary gland of E2 and BP3 treated animals was significantly higher than animals 
treated with vehicle control (Figure 2.6D). While oral treatment of E2 stimulated 
proliferation as shown by higher Ki-67 straining and transcriptional activation of ER-target 
genes (Areg and Pgr) in the mammary gland, neither BP3 nor PP elicited significant 
responses (Figure 2.6 E-H). Similarly, elevated serum levels of 17β-estradiol and uterine 




















Exposure of xenoestrogens was implicated in breast cancer risk (Pastor-Barriuso et 
al. 2016) as well as resistance to breast cancer treatment (Goodson et al. 2011; Warth et al. 
2018) due to their endocrine actions. The median urinary level of BP3 was 0.137µM and 
PP was 0.161µM in non-pregnant women in participating in the NHANES by CDC 
(Calafat et al. 2010; Woodruff et al. 2011). The serum levels of BP3 were reported to be 
approximately 0.87µM (200 µg/L) following exposure in women (Janjua et al. 2004; Matta 
et al. 2019; Tarazona et al. 2013). In addition, the urinary concentrations of xenoestrogens 
observed in pregnant women was higher than the general population with median urinary 
concentrations of BP3 and PP being 0.47µM and 0.253 µM, respectively and the 95th 
percentile concentrations in pregnant women being 29.5µM BP3 and 3.26µM PP (Table 
2.1). This raises the possibility that women may have higher exposure during pregnancy 
due to use of creams and lotions or that absorption and metabolism may be altered in 
pregnancy. These compounds were also found in normal tissues of women undergoing 
mastectomy for primary breast cancer (Barr et al. 2012; Barr et al. 2018) and in milk 
collected during the period of sunscreen use from 3 different cohorts of mothers of 
singleton child (Schlumpf et al. 2010). However, based on measures of transcriptional 
activity in MCF7 human breast cancer cell lines (Byford et al. 2002; Kerdivel et al. 2013), 
typical exposures to BP3 and PP would appear to pose a minimal risk for breast cancer 
through ER mediated transcriptional activation of target genes. 
Estrogens and their metabolites have been shown to induce direct DNA damage. 
However, DNA damage by catechol estrogens from ER-negative cell lines requires 




women (Cavalieri and Rogan 2016; Savage et al. 2014; Xu et al. 2007).  BP3 and PP were 
shown to have the potential to cause DNA damage independent of ER transactivation, 
based on experiments on ER-negative cell lines. For example, treatment of BP3 (10 µM) 
induced γH2AX foci in normal human keratin cell lines (Kim et al. 2018) and PP (50 µM) 
showed 8-hydroxy-2-deoxyguanosine (8-OHdG) release in Vero cells (derived from 
Monkey kidney) (Martín et al. 2010). However, these levels exceeded typical 
concentrations measured in human populations (Table 2.1).  
In the breast, epithelial cells with functional ERα, we observed DNA damage at 
physiologic concentrations of E2. BP3 and PP also caused DNA damage at low 
concentrations (1-5µM) (Figure 2.1). Both the nuclear γΗ2ΑΧ and 53BP1 foci were 
diminished by fulvestrant suggesting ERα dependency of DNA damage.  At these low 
concentrations (1µM of PP and 1-5µM of BP3), we did not observe ER-mediated 
transcriptional response in target genes. Instead, we observed R-loop formation. We also 
observed increases in R-loops and γH2AX in the mammary epithelial cells of 
ovariectomized BALB/c mice orally treated with BP3 or PP at doses designed to model 
environmental exposures in humans (Figure 2.6D). The doses of BP3 and PP used in mice 
were not sufficient to affect transcription of Areg or Pgr (Figure 2.6E-F) or proliferation 
of mammary epithelium (Figure 2.6G-H) compared to control treatments. Nor were they 
sufficient to alter uterine weights compared to the control treatment in ovariectomized mice 
(Figure 2.6J). This finding for BP3 was supported by a previous study (LaPlante et al. 
2018). These results with BP3 and PP are consistent with the idea that in mammary 
epithelial cells of human and mice the formation of R-loops and DNA damage is ER-




ER-mediated DNA double strand breaks was shown to form by collision of R-loop 
formed during active transcription (co-transcriptional R-loop) and replication fork in 
MCF7 cells (Stork et al. 2016). Alternatively, R-loop formation can occur with RNA 
Polymerase II pausing which results in no increase of gene expression but leads to DNA 
damage (Hatchi et al. 2015; Shivji et al. 2018; Zhang et al. 2017). Indeed, our results 
showed that, BP3 and PP induced formation of R-loops and DNA damage (Figure 1.7) but 
did not lead to detectable increases in full-length transcripts of TFF1, AREG or PGR.  
Experiment performed using a normal breast epithelial cell line 76N-Tert 
expressing inducible ERα treated with E2, BP3 and PP provided: 1) additional evidence 
that the R-loop formation and DNA damage were ΕRα-dependent and 2) that normal breast 
epithelial cells were susceptible to DNA damage by xenoestrogens. This raises the 
possibility that a subset of women bearing variants of R-loop processing factors may be 
particularly susceptible to the genotoxic effects of xenoestrogens such as BP3 and PP. 
More than 300 R-loop binding proteins have been identified (Wang et al. 2018). A number 
of such factors were recently shown to be involved in the resolution of R-loops to limit 
DNA damage including TopI (Tuduri et al. 2009), BRCA1(Hatchi et al. 2015), BRCA2 
(Shivji et al. 2018), SETX (Cohen et al. 2018; Hatchi et al. 2015), Aquaris (Sollier et al. 
2014), THO/THREX complex (Bhatia et al. 2014; Gómez‐González et al. 2011),  BuGZ, 
Bub (Wan et al. 2015). For example, recruitment of BRCA1/SETX was important for R-
loop mediated transcriptional termination. As a consequence, the mutational rate of 
termination regions where BRCA/SETX co-localize was higher in BRCA1-deficient 
tumors compared to BRCA1-WT tumors (Hatchi et al. 2015). Premalignant breast lesions 




thus, may be especially sensitive to the genotoxic effects of these xenoestrogens. Therefore, 
limiting exposure to personal care products and foods containing these chemicals may be 
valuable for this subset of women.  
However, the present studies do not show a direct risk of exposure to these 
compounds on subsequent breast cancer. While chronic exposure to low levels of DNA 
damage has the potential to induce mutations that either initiate or promote carcinogenesis, 
the experiments were not designed demonstrate a causal effect of BP3 or PP on mammary 
tumors or breast carcinogenesis. The DNA damage observed was associated with the 
formation of ERα-dependent R-loops, but it is unclear whether ER also contributes to the 
formation of R-loops or may mitigate this. While many tissues express ERs, they vary in 
the levels of ERα and ER as well as expression of DNA repair factors and proficiency of 
resolving R-loops. Therefore, this mechanism of DNA damage may be limited to the breast 
epithelium of a subset of individuals. It is also unclear how combinations of environmental 
xenoestrogens may interact to augment or dissipate the genotoxicity through competing 
actions on ER. Nonetheless, the data presented here reveal a need to consider the unique 
potential for genotoxicity of environmental xenoestrogens in tissues expressing ERs.  
These studies demonstrated that xenoestrogens possessed the potential for 
genotoxic activity that was mediated by ER through the formation of R-loops and DNA 
double strand breaks. These genotoxic effects were observed at concentrations well below 
those necessary for detectable transcriptional activation. Therefore, R-loop forming 
capacity provides a valuable endpoint to consider when evaluating the safety and activity 
of environmental chemicals. The inducible expression of ER in normal breast cells 




among individuals and to determine if a subset of individuals is preferentially susceptible 
























Table 2.1: Estimation of estrogen and xenoestrogens concentrations of estradiol(E2), 







Table 2.2: Slopes of growth curve effect of Estradiol (E2), Benzophenone-3 (BP3), or 
Propylparaben (PP) on T47D cells.  
 
Growth Curve Slope 95% CI 
Control DMSO 0.0107 -0.006811 to 0.02821 
0.5nM E2 0.08495 0.06604 to 0.1039 
1µM PP 0.01856 0.003943 to 0.03318 
10 µM PP 0.06387 0.05225 to 0.07550 
5µM BP3 0.0202 0.008131 to 0.03226 










Table 2.3: Sequences of primers.  
 
 




























F:  GACCACATCAGGCTCAATGCT 



















































Figure 2.1. Evaluation of DNA damage in cells treated with 17β-Estradiol (E2), 
Benzophenone-3 (BP3), or Propylparaben (PP) for 24 hours.  
Immunofluorescence (upper panel) and quantification (lower panel) of nuclear γH2AX 
intensity in T47D cells treated with (A) 10 or 100nM E2 (B) 1 or 5μM BP3 and (C) 1 or 
5μM PP. (D). Immunofluorescence of 53BP1 staining with 10 or 100nM E2, 1 or 5µM 
BP3 and 1 or 5µM PP in T47D (upper panel) and MCF-7 (lower panel). (E) Quantification 
of nuclear 53BP1 of treatments in (D) in T47D (left panel) and MCF-7 (right panel). (F) 
Quantification of nuclear γH2AX intensity in MCF-7 cells following 17β-estradiol (E2) 
10-100nM, Benzophenone-3 (BP3) 1-30μM or Propylparaben (PP) 1-30μM treatment.  
***p < 0.0001, *p < 0.01 compared control with treatments using one-way analysis of 
variance (ANOVA) followed by Tukey's honestly significant difference (HSD) multiple-
range test. n = 3 biological replicates. Scale bar = 50 µM (A-C), 10 µM (D). All graphs 





































































































Figure 2.2. TFF1 expression and γ-H2AX intensity in T47D cells treated with 17β-
estradiol (E2), benzophenone-3 (BP-3), or propylparaben (PP) for 24h with or 
without the ER antagonist fulvestrant.  
(A) Inhibition of TFF1 expression following treatment of 10 nM E2, 5μM BP-3, and 5μM 
PP when cotreated with fulvestrant (ICI 182 780, 1μM) compared with 10 nM E2, 5μM 
BP-3, and 5μM PP treatments without fulvestrant. (B) Quantification of nuclear γ-H2AX 
following cotreatment of fulvestrant (1μM) with E2 (10 nM), BP-3 (5μM), or PP (5μM) 
compared with E2 (10 nM), BP-3 (5μM), or PP (5μM) without fulvestrant treatment, 
respectively. ***p<0.0001 compared control to xenoestrogens treatment and ###p<0.001 
compared with negative fulvestrant and with positive fulvestrant using multiple 
comparison for 2-way ANOVA. n=3 biological replicates. All graphs show mean ± SEM. 























































Figure 2.3. Evaluation of estrogen receptor transactivation and proliferation in cells 
treated with 17β-estradiol (E2), benzophenone-3 (BP-3), or propylparaben (PP) 
for 24h.  
































(A) (Left) Transactivation response (in relative light unit, RLU) of T47D-KBluc cells in 
response to 10nM E2 (green), 0.5–100μM BP-3 (brown), and 0.5–100μM PP (violet) 
treatment. (Right) Dose-response curve of luciferase reporter assay in T47D-KBluc cells 
treated with 17β-estradiol (E2) 10-100nM, Benzophenone-3 (BP3) 1-30μM or 
Propylparaben (PP) 1-30μM treatment. Dose-response curves were plotted using three-
parameter dose response curve. Error bars represent standard deviation (SD). n = 3 
biological replicates. The arrows represent the levels of 95%ile exposure in pregnant 
women i.e., BP3 (white arrow; 29.5 µM) PP (Black, 3.26 µM). Expression of endogenous 
genes AREG (B) and PGR (C) with E2 (10 nM), BP-3 (1 or 5μM), or PP (1 or 10μM) 
treatment as relative fold change over control in T47D (left panel) and MCF-7 (right panel). 
*p<0.05 and ***p<0.0001 compared control with treatments using one-way analysis of 
variance (ANOVA) followed by Tukey's honestly significant difference (HSD) multiple-
range test. n=3 biological replicates. (D) Proliferation of 47D cell as percent of Alamar 
Blue reduction in response to E2 (0.5nM), PP (1 or 10μM), BP-3 (5μM), or control. The 
confidence intervals of the slope are reported in Table 2. All graphs show mean ± SEM. 






Figure 2.4. R-loop formation in T47D and MCF7 cells treated with 17β-estradiol (E2), 
benzophenone-3 (BP-3), or propylparaben (PP) or vehicle with or without RNase H.  
(A) Immunostaining of R-loop with S9.6 antibody and DAPI in T47D cells treated with E2 
(10nM), BP-3 (5μM) or PP (5μM) without and with RNase H treatment following fixation. 
Scale bar=20μM. (B) Quantification of the nuclear S9.6 intensity in T47D. (C) 
Quantification of nuclear S9.6 intensity in MCF-7. ***p<0.0001 compared control with 
xenoestrogens treatment and ###p<0.001 compared negative RNase H and with positive 
RNase H using multiple comparison for 2-way ANOVA. n=3 biological replicates. All 





















































Figure 2.5. Characterization of 76N-Tert-ESR1 and R-loop formation in 76N-Tert-
ESR1 following treatment with 17β-estradiol (E2), benzophenone-3 (BP-3) or 
propylparaben (PP) with and without RNase H.  
(A) Map of pIN-ESR1 construct ESR1 insertion next to doxycycline(dox) inducible TRE2 
promoter. (B) (Left) Western blot ERα (upper panel) with MCF-7 as positive control (lane 
1), 76N-Tert parental (lane 2), 76N-Tert-ESR1 without dox (lane 3), 76N-Tert-ESR1 with 
dox (lane 4), and 76N-Tert-ESR1 with dox and E2 (10nM) treatment and β-actin as loading 
control (lower panel). (Right) Immunofluorescence with anti- ERα (green) and DAPI 
(blue) showing ERα expression in > 90% of the 76N- Tert-ESR1 cell population. Scale bar 
= 10 µM (C) Immunostaining with S9.6 antibody and DAPI with 10nM E2, 5μM BP-3, 
or 5μM PP treatment to parental 76N-Tert cells (upper panel), to 76N-Tert-ESR1 with dox 
induction (middle panel) without or with RNase H treatment (lower panel). 
Scale bar=20μM. (D) Quantification of nuclear S9.6 intensity in (C). ***p<0.0001 
compared control with xenoestrogens treatment and ###p<0.001 compared among 76N-Tert 
Parental, 76N-Tert with dox and E2 (10nM) negative RNase H and 76N-Tert with dox 
and E2 (10 nM) positive RNase H using multiple comparison for 2-way ANOVA. n=3 
biological replicates. All graphs show mean ± SEM. Data collection in collaboration with 
























Figure 2.6. Acute exposure of xenoestrogens in mice.  
(A) Schematic of experimental design and exposure period. (B) Immunostaining of mouse 
mammary epithelium with S9.6 antibody harvested from mice treated with E2, BP-3, or 
PP. Each image shows a ductal structure with luminal and myo-epithelial cell nucleus 
(blue) and R-loop (green) inside the nucleus. Scale bar =10μM. Quantification of the 
immunostaining data for S9.6 (C) and γ-H2AX (D). Expression of Areg (E) and Pgr (F) 
from mouse mammary gland. n=3 biological replicates. (H). Ki67 straining of luminal 
epithelial cells (G) and percent of Ki67 strained cells per luminal cells counted. (I) Serum 
17-β-estradiol (E2) levels (A) and uterine weight (B) from mice treated with E2 
(250μg/ml), Benzophenone-3 (BP3, 3000μg/ml) or Propylparaben (PP, 10000 μg/ml) 
treatment.  Scale bar=50μM [Number of biological replicates (n): control (5), E2 (8), BP-
3 (12), PP (10)] ***p<0.0001, **p<0.01 compared control with treatments using one-way 
analysis of variance (ANOVA) followed by Tukey's honestly significant difference (HSD) 
multiple-range test. All graphs show mean ± SEM. Data collection in collaboration with 













































































































Figure 2.7.  A schematic model for ER-dependent DNA damage.  
E2 or xenoestrogens binding to the ER recruit ER to the estrogen response element (ERE) 























Estrogen mediated DNA damage in the mammary epithelium differs among strains 







Estrogens play a central role in mammary gland development by promoting 
epithelial cell proliferation and ductal elongation during puberty (Manavathi et al., 2013; 
Vrtačnik et al., 2014). However, longer lifetime exposure to estrogens due to early 
menarche and late menopause are associated with increased breast cancer risk (Clemons 
and Goss, 2001; Dall and Britt, 2017). Women with estradiol levels in the highest quartile 
had 2.1-fold higher relative risk compared to the lowest quartile (Eliassen et al., 2006). 
This carcinogenic effect of estrogen may, in part, be due to reactive metabolites that cause 
depurination or form stable DNA adducts. But the concentrations of estrogens that induce 
these effects in vitro exceed the levels typically found in women (Cavalieri and Rogan, 
2016; Okoh et al., 2011; Santen et al., 2009). This mechanism does not account for the 
preferential risk of breast cancer as cells in all tissues would be similarly vulnerable to the 
direct mutagenic consequences of these adducts. The breast epithelial cells expressing 
estrogen receptor alpha (ERα) appear to be particularly susceptible as approximately 70% 
of breast cancer cases are positive for ER (Waks and Winer, 2019). This is a striking 
enrichment as only 5-10% of normal breast epithelial cells are ER-positive (Clarke et al., 




the breast cancer incidence by 50% – 75% in women (Cummings et al., 1999; Cuzick et 
al., 2013; Martino et al., 2004). Therefore, the ER+ breast epithelial cells appear to be 
vulnerable to pathogenic actions of estrogens.   
Estrogen receptors have been shown to be involved in mutagenic actions caused by 
exposure to estrogens. Two nuclear estrogen receptors, estrogen receptor alpha (ERα) and 
estrogen receptor beta (ERβ), contribute to the intracellular responses to estrogens. The 
ligand-bound estrogen receptor complex can form homodimers or heterodimers that bind 
estrogen response elements (ERE) in the DNA forming complexes with other 
transcriptional coregulatory factors to drive expression of estrogen target genes (Marino et 
al., 2006; Saville et al., 2000; Yaşar et al., 2017; Yi et al., 2017). The genes encoding the 
progesterone receptor (PGR) and amphiregulin (AREG) growth factor have EREs that have 
been well-characterized (Ciarloni et al., 2007; Lin et al., 2007; Manavathi et al., 2013; 
Palaniappan et al., 2019). ER is a primary effector of estrogen actions in mammary tissue 
and has been shown to participate in DNA damage by several mechanisms. First, ER is 
necessary for the proliferation of the breast epithelium which can also cause replication-
associated DNA damage (Henderson and Feigelson, 2000; Preston-Martin et al., 1990). 
Second, ER has been shown to recruit Topoisomerase-2β, stimulating DNA double-
strand breaks which facilitate transcription of ER target genes (Ju et al., 2006; Williamson 
and Lees-Miller, 2011). A third mechanism observed in breast cancer cell lines showed 
that ER induces expression of APOBEC3B which causes cytidine deamination leading 
to DNA damage (Periyasamy et al., 2015; Udquim et al., 2020). Recently, 17-estradiol 




promoting ER-mediated co-transcriptional structures called R loops (Majhi et al., 2020; 
Stork et al., 2016). R loops are formed when the nascent RNA hybridizes with the template 
DNA strand causing transient displacement of the non-template strand. R loops are a 
normal consequence of transcription, but if they persist due to either the genomic context 
or a lack of resolvases, the single-stranded non-template strand can cause DNA damage 
responses that result in DNA double-strand breaks (Aguilera and García-Muse, 2012a; 
Skourti-Stathaki and Proudfoot, 2014; Sollier and Cimprich, 2015). These ER-mediated 
DNA damage mechanisms would result in preferential mutagenesis of the ER+ luminal 
breast epithelial cells and contribute to carcinogenesis.  
While all women are exposed to endogenous and exogenous estrogens, only 1 in 8 
women is expected to develop breast cancer suggesting that the cancer-promoting effects 
of estrogen exposure vary among individuals. Genome-wide association studies have 
identified >180 alleles that modify the risk of breast cancer (Ahmed et al., 2009; Easton et 
al., 2007; Hunter et al., 2007; Stacey et al., 2007; Wendt and Margolin, 2019). 
Polymorphisms in ER have been identified that contribute to inherited breast cancer risk 
(Hu et al., 2017; Lipphardt et al., 2013; Yu et al., 2011). However, differences in 
environmental and lifestyle factors account for nearly 70% of breast cancer risk (Möller et 
al., 2016; Mucci et al., 2016). Therefore, interactions between inherited risk alleles and 
environmental exposure to estrogenic chemicals may play a significant role in the 
development of breast cancer but have remained elusive due to the challenges in measuring 
environmental exposures across a woman’s lifetime and limitations in statistical power to 




Studies in rodents provide a powerful alternative approach for understanding the 
combined effects of estrogen exposure and heritable differences in sensitivity to 
environmental exposures(Jerry et al., 2018). BALB/c and C57BL/6 strains of mice differ 
in their responses to E2 and progesterone (P4) (Aupperlee et al., 2008). Hormone-induced 
mammary tumors have been shown to develop in BALB/c mice whereas C57BL/6 mice 
are resistant (Girard et al., 2007; Kordon et al., 1993; Lanari et al., 1986; Molinolo et al., 
1987). BALB/c mice are also sensitive to radiation-induced mammary tumors when 
compared with C57BL/6 mice (Ponnaiya et al., 1997; Ullrich et al., 1996). BALB/c mice 
with heterozygous mutations in the p53 tumor suppressor gene (Trp53) develop 
spontaneous mammary tumors similar to the susceptibility to breast cancer among women 
with inherited mutations in TP53. In contrast, mammary tumors in C57BL/6-Trp53+/- 
mice are rare (Kuperwasser et al., 2000). This difference in susceptibility to mammary 
tumors was genetically linked to a locus on mouse chromosome 7 (Blackburn et al., 2007) 
and involves a greater reliance on repair DSBs in BALB/c-Trp53+/- mice through error-
prone repair pathways (Böhringer et al., 2013). Therefore, hormonal exposures and 
mechanisms affecting proficiency of DNA repair play important roles in determining risk 
of mammary tumorigenesis. 
Rats also exhibit striking differences in susceptibility to mammary tumors. The 
Brown Norway (BN) strain is resistant to estrogen-induced mammary tumors while the 
August Copenhagen Irish (ACI) strain is susceptible.  Genetic loci that modify 
susceptibility to E2 have been mapped in crosses between the ACI and BN strains rats 
(Shull et al., 2018). Using comparative genomic hybridization (CGH), the tumors in ACI 




that differences in the fidelity of DNA repair may contribute to susceptibility to mammary 
tumors in ACI rats.  
The goal of our study was to investigate the effects of genetic background on E2-
mediated DNA damage, R loop formation, and transcriptional responses in the mammary 
epithelium of rodents. DNA damage and R loops were significantly higher in BALB/c mice 
compared to C57BL/6 mice in response to acute treatment with E2 for 4 days or chronic 
exposure for 28 days. Accumulation of H2AX foci were most pronounced in the ER+ 
cells of BALB/c mice. Higher doses of E2 (0.25 vs 0.75mg/kg/d) stimulated greater 
proliferation in both strains, but levels of H2AX were increased in only the BALB/c mice. 
The differences in DNA damage and R loops between strains were not associated with 
differences in levels of ER. Elevated levels of H2AX were also observed in the 
mammary epithelium of ACI rats following E2 treatment, but not in the BN strain. Breast 
tissue explant cultures from women also exhibited striking variation in levels of E2-
induced DNA damage in the epithelial cells. In breast explant cultures from donors with 
inherited breast cancer risk, E2 stimulated significantly higher levels of DSBs. In contrast, 
only 1 in 5 of average risk donors exhibited a significant increase in DSBs in the presence 
of E2. Together, these data demonstrate genetic differences in sensitivity to E2-stimulated 
DNA damage in rodents and that similar variation is also observed in normal breast tissues 
from women. Variation in levels of the pathogenic effects of E2 may provide a biomarker 







Materials and Methods 
 
Experiments in mice 
Female BALB/c and C57BL/6 mice (7 weeks old) were purchased from Jackson 
Laboratory. The mice were housed in temperature-controlled facilities with a set 
temperature of 64-79 F and humidity of 30-70%, 12-hour alternating day/night light cycle 
and fed Lab Chow 5058 ad libitum for one week prior to use in experiments. The 17β-
estradiol (designated E2) used in these experiments was obtained from Sigma-Aldrich 
(E2758-250MG). All procedures were under the national guidelines for the care and use of 
animals and approved by the University of Massachusetts Amherst’s Institutional Animal 
Care and Use Committee. 
In experiments with ovariectomized, each mouse was anesthetized with a mix of 
isoflurane and oxygen. The flanks were shaved, sterilized with betadine, and cleaned with 
alcohol. An incision was made to the skin on the right flank. The underlying muscle layer 
was nicked to reveal a small opening through which the ovary was exteriorized by grasping 
the periovarian fat. A serrafin clamp was used to hold the ovary. A suture ligature was 
applied to prevent breeding, then the ovary was cut from the uterine horn. The periovarian 
fat was restored into the peritoneum. The peritoneum was closed with one or two stitches 
and the skin was closed with 9 mm wound clips.  The procedure was repeated on the 
contralateral side. The mouse was monitored for a week post-procedure and wound clips 
were removed after 10 days. After 1 week of recovery, the mice of strain were randomized 




(tocopherol-stripped corn oil) (n = 5) or E2 (n = 5) for 4 days. Each mouse was administered 
1μL of oil per gram of body weight to deliver 0.25 mg/kg/day E2 or vehicle control.  
For ovary intact animals, ovariectomy was not performed and the E2 dose was 
increased to 0.75 mg/kg/day. For acute treatment of 4 days, mice of each strain were simply 
randomized to two groups and began treatment via drinking water with vehicle control 
(only water) (n=5) or E2 (n=5) for 4 days. For chronic treatment of 28 days, mice were 
treated with vehicle control (only water) (n=5) or E2 (n=10) for 28 days.  
The mice were sacrificed using carbon dioxide followed by cervical dislocation. 
One 4th mammary gland was fixed in 10% NBF and transferred to 70% alcohol within 12 
h followed by paraffin-embedding. The contralateral 4th mammary gland was cleared of 
lymph node and stored in -80C for RNA isolation. 
 
Experiments in rats  
Details of animal care, treatment, tissue collection, fixation, and processing of 
samples were explained in (Ding et al., 2013). Slides of ACI and BN mammary gland tissue 
samples were received from Dr. Shull’s lab. Briefly, 9 weeks old female rats of each strain 
were treated with E2 for 7 days, released from subcutaneous Silastic implants containing 
27.5 mg of E2. Methods for preparing and surgically implanting the hormone delivery 
tubes have been described previously (Shull et al., 1997).  Control-treated rats from each 
strain received empty implants. The rats were euthanized (by decapitation with a rodent 
guillotine) following 7 days of treatment. Mammary gland tissues were collected, fixed, 





Human breast patient-derived explant cultures (PDEs) 
Explant culture and treatment were described previously in detail (Dunphy et al., 
2020) Briefly, human breast tissue samples were collected from female donors undergoing 
reduction mammoplasty or mastectomy surgery. Fresh breast tissues were cut using 
microtome and sections were placed on top of surgical foam (Ethicon) in 60mm plastic 
dishes and maintained in Basal Media in a humidified incubator with 5% CO2 at 37 °C.  
Tissues were cultured in Basal Media containing phenol red-free DMEM: F12 (Sigma-
Aldrich), 10% charcoal-stripped fetal bovine serum (FB-04, Omega Scientific), 10ng/mL 
human epidermal growth factor (21–8356-U100, Tonobo Biosciences), and antibiotic-
antimycotic (15,240,062, Gibco) for up to 3 days to clear from endogenous hormones. 
Tissues were maintained in either Basal or supplemented with 10nM E2 for up to additional 
4 days. Tissues were processed and paraffin embedded. Fresh sections were cut and 
mounted on slides. 
 
Immunostaining 
Freshly cut 4-5 μM paraffin-embedded sections were deparaffinized/rehydrated 
with 100% xylenes 3 times for 5 min each, 2 times with 100% ethanol for 5 min each, 95% 
ethanol for 3 min and 70% ethanol for 3 min. Samples were rinsed with PBS. Antigen 
retrieval was performed by boiling the samples in 1 mM EDTA (pH 8.0) for 30 mins and 
cooled for 30 mins at RT. For dual staining of ERα and γH2AX, antigen retrieval was 
performed using 10mM Sodium Citrate buffer containing 0.05% Tween-20 (pH 6.0). 
Tissues were incubated in 1% Triton-X 100 in PBS for 30 mins at RT. Samples were then 




with TBS containing 0.5% Tween20. Samples were blocked in 10% goat or rabbit serum 
in PBS with 0.5% Tween-20 for 1 hr at RT. Primary antibody incubation was done with 
monoclonal S9.6 antibody (Kerafast #ENH001), anti-H2AX antibody (Cell Signaling # 
9718S), or anti-ERα (Millipore, 06-935) for overnight at 4°C. After primary incubation, 
samples were washed 3 times with TBS containing 0.5% Tween-20 and then incubated 
with anti-mouse AlexaFluoro-488-conjugated (Cell Signaling #4408S) or anti-rabbit 
AlexaFluoro-488-conjugated secondary antibody (Cell Signaling #8889S) for 2 hr. 
Samples were washed 3 times with TBS containing 0.5% Tween-20 and then mounted with 
Vectashield mounting medium containing DAPI. Slides were imaged at 60X with a Nikon 
A1 Spectral Confocal microscope. Analysis of S9.6 or γH2AX foci per nucleus and ERα 
positive cells were calculated using Nikon analysis software, where DAPI was used as a 
mask for the nucleus. IHC for Ki-67 was performed on a Dako Cytomation autostainer 
using 1:1000 D2H10 primary antibody (cell signaling #9027T) and the Envision HRP 
detection system (Dako, Carpinteria, CA). Positive cells were counted using ImageJ 
software. A total of 1200 cells were counted per slide to determine percent Ki-67 positive.  
 
RT-qPCR 
RNA from the mammary gland was isolated with TRIzol (Thermofisher Scientific 
#15596018) and Direct-zol RNA Miniprep Plus (Zymo Research #R2072). cDNA was 
prepared from 1 µL of RNA in 20 µL reaction mix with Protoscript II First Strand cDNA 
Synthesis Kit (New England Biolabs #E6560S) following the standard protocol provided 
by the manufacturer. qPCR for Estrogen receptor alpha (ESR1), progesterone receptor 




Cytokeratin18 (Krt18) was performed using primers in Table 1 (Integrated DNA 
Technology) and iTaq Universal SYBR Green Supermix (Biorad, #1725121) on CFX96 
Real-Time System thermocycler (Bio-Rad). Each run (96 well qPCR plate) included an 
inter-run calibrator to normalize across experiments. Data were analyzed with Ct 
method and relative fold change in expression of the target gene was compared between 
control and treatments.  
 
Statistical Analysis 
Unless specified, data were analyzed by one-way analysis of variance (ANOVA) 
followed by Tukey's honestly significant difference (HSD) multiple-range test using 
GraphPad Prism 9 statistical analysis software. Results are presented as mean ± standard 



























E2 induces DNA damage and R loops in BALB/c mice but not C57BL/6 mice. 
Effects of estrogen were compared in BALB/cJ and C57BL/6J mice because they 
differ in their susceptibility to mammary tumors. Female mice were ovariectomized and 
endogenous hormones were allowed to clear for 7 days. The mice were then treated with 
E2 (0.25 mg/kg/d) for 4 days (Figure 3.1A). This dose of E2 mimics levels during early 
pregnancy (Majewski et al., 2018; Majhi et al., 2020). First, we compared proliferation in 
the mammary epithelium using Ki-67. The frequency of cells positive for Ki-67 was 
increased significantly with E2 treatment as compared to the control treatments (Figure 
3.1B). The proliferative responses to E2 treatment in the mammary epithelium were similar 
for both strains (Figure 3.1B and C). Immunostaining with phosphorylated histone H2AX 
(γH2AX), a marker of DNA-double stranded breaks, was used to assess E2-induced DNA 
damage in the luminal mammary epithelium. The number of γH2AX foci was increased 
significantly in BALB/cJ with E2 treatment compared to the control-treated mice. 
However, the C57BL/6J showed no increase in γH2AX foci with E2 treatment (Figure 
3.1D and E). Co-transcriptional R loop (DNA: RNA hybrid) structures were shown to be 
precursors of E2- induced DNA double-strand breaks (Majhi et al., 2020; Stork et al., 
2016). Therefore, immunostaining with an R loop-specific antibody (S9.6) was used to 
detect the presence of these structures in the mammary epithelium. BALB/cJ mice showed 
a significant increase in S9.6 foci with E2 treatment as compared to the control mice. In 
contrast, we did not observe any induction of S9.6 foci by E2 treatment in C57BL/6J mice 




in the mammary tissues of both strains by E2 treatment (Figure 3.1H and I). However, the 
levels of Pgr and Areg were increased to a greater extent (p<0.001) in BALB/cJ mice when 
compared with C57BL/6J mice. These data show that E2 stimulates R loops and DNA 
double strand breaks in BALB/cJ, but not C57BL/6J mice. As both strains had equivalent 
proliferation at 4 days of E2 treatment, the differences in γH2AX is not attributed to 
replication-associated DNA damage.   
 
Enrichment of E2-induced DNA damage in ERα positive mammary epithelial cells in 
BALB/c mice.  
To determine which mammary epithelial cells are experiencing E2-induced DNA 
damage, we performed dual immunofluorescence to detect both γH2AX and estrogen 
receptor alpha (ERα) in the luminal mammary epithelial cells of ovariectomized mice 
treated with or without E2 for 4 days as described in Figure 1A. Both strains had similar 
proportions of ER-α positive cells (37-40%) in the luminal epithelium and were unchanged 
by E2 treatment (Figure 3.2A and B). The number of γH2AX foci/nucleus was greater in 
the ER-α positive cells in both strains compared to the ER-α negative cells, but E2-induced 
γH2AX foci were only observed in BALB/cJ mammary epithelium (Figure 3.2A and 
3.2C). While the number of γH2AX foci was greatest in mammary epithelial cells with 
detectable levels of ERα, there was also a significant increase of γH2AX foci in the ER-α 
negative population of cells in BALB/cJ mice. However, the levels of γH2AX foci in ERα-
negative cells of C57BL/6J mice were not increased (Figure 3.2C) despite similar 




proportions of cells with increasing numbers of γH2AX foci to determine if there were 
different populations within the percentage of ERα positive cells (Figure 3.2D). In the 
control-treated mice, the majority of ERα-positive cells had fewer than 5 γH2AX foci 
(Figure 3.2E). There was a small shift in the distribution for C57BL/6J mice toward 
increased proportions of cells with up to 10 foci/cells but was not significant (Figure 3.2D 
and E). In contrast, E2 treatment in BALB/cJ mice resulted in 70% of the ERα-positive 
cells with >10 foci/nucleus. Therefore, ERα-positive cells in BALB/cJ mice are 
preferentially susceptible to DNA damage with physiologic levels of E2, while C57BL/6J 
mice were resistant.  
 
Effect of short-term high E2 dose on DNA damage and R loops in ovary intact mice. 
As elevated levels of E2 are associated with an increased risk of breast cancer in 
women, we wanted to determine if higher doses of E2 may be necessary to induce DNA 
damage in C57BL/6J mice. In this experiment, ovary-intact BALB/cJ and C57BL/6J mice 
treated with a 3-fold higher dose of E2 (0.75 mg/kg/day, referred to as 3xE2) in drinking 
water to allow continuous exposure for 4 days (Figure 3.3A). The proliferative response 
shown by Ki-67 staining indicates that treatment with 3xE2 significantly increased the 
proliferation rates (37.98% and 36.90% in BALB/cJ and C57BL/6J, respectively) in their 
mammary gland epithelium (Figures 3.3B and C). These levels of proliferation were 
greater than the 18% of Ki-67 positive cells observed in ovariectomized mice treated with 
0.25mg/kg/d (Figure 3.1C) indicating dose-dependent responses at up to 0.75mg/kg/d. 




difference in γH2AX foci in the mammary epithelium of C57BL/6J compared to control 
treatment (Figure 3.3D and 3E). There was a modest increase with E2 treatment in 
BALB/cJ mice, but it did not reach statistical significance. The difference may be blunted 
by the presence of endogenous estrogens in the ovary-intact mice. However, the number 
of S9.6 foci/nucleus were increased significantly in the mammary epithelium of both 
BALB/cJ and C57BL/6J mice by the 3xE2 treatment (Figures 3.3F and 3G). Though R 
loops appear to be induced by E2 in both strains, the number of foci/nucleus was higher in 
BALB/cJ compared to C57BL/6J. Overall, the effect of E2 on DNA damage and co-
transcriptional R loops was similar to that observed with the 0.25mg/kg/d dose in Figure 
2.1, but the fold changes appear to be blunted by the endogenous levels of E2 in the ovary-
intact mice.  
 
Effect of chronic exposure to high E2 dose on DNA damage and R loops in ovary 
intact mice. 
Pregnancy is a period during which there are sustained increases in estrogens as 
well as other growth factors. The mammary gland undergoes dramatic proliferation in 
response to these hormones followed by differentiation.  To evaluate the effect of sustained 
increases in E2, ovary intact BALB/cJ and C57BL/6J mice were treated for 28 days with 
E2 (0.75 mg/kg/day, 3x) in drinking water (Figure 3.4A). In contrast to the dramatic 
proliferation at 4 days (~37% in Figure 3.3C), the proliferative fraction of cells returned 
to near baseline levels (2% to 3%) in the mammary epithelium of both strains of mice 
treated with E2 for 28 days (Figure 3.4B and 4C). The Ki-67 levels did not differ between 




was a sustained elevation of γH2AX foci in E2-treated BALB/cJ mammary epithelium 
whereas there was no difference between Control- and E2 treated C57BL/6J mice (Figure 
3.4D and 4E). Chronic treatment with E2 also increased R loop levels in BALB/cJ mice 
compared to controls but no significant difference due to E2-treatment in C57BL/6 mice 
(Figure 3.4F and 4G). Therefore, the strain-specific sensitivity to E2-induced DNA 
damage in BALB/cJ but not C57BL6J mice was observed across the time course of 
treatments of 4 to 28 days and was not associated with changes in proliferation or 
physiologic states of the mammary gland.  
 
Expression of estrogen receptors and target genes with acute and chronic treatments. 
Transcriptional responses were also examined to compare the effects of the 3xE2 
dose in ovary-intact mice. As E2 stimulates proliferation of the luminal epithelium, 
expression of ERα target genes was normalized to Krt18 levels (Figure 3.5 G and H) to 
adjust for potential differences in populations of cells. Administration of E2 resulted in 
decreased Pgr mRNA levels at both 4 and 28 days in BALB/cJ mice (Figures 3.5 A and 
5B). Areg mRNA was also decreased by treatment with E2 for 28 days (Figures 3.5C and 
D).  In C57BL/6J mice, levels of Pgr were increased after 28 days of E2, but not at 4 days 
(Figure 3.5A and B). Areg expression was unchanged by E2 in C57BL/6J mammary 
tissues as well (Figures 3.5C and D).  Expression of Esr1 (encoding ERα) was decreased 
to varying degrees in both strains (Figures 3.5E and F) which may reflect feedback 
inhibition in response to administration of E2. The results in ovary-intact mice differ from 
responses in ovariectomized mice and indicate that endogenous levels of E2 in mice with 




and Pgr). Therefore, the increased numbers of γH2AX foci and R loops in mammary 
tissues of BALB/cJ mice following E2 treatment does not appear to be due to a global 
increase in transcription.  
The DNA editing enzyme APOBEC3B causes base damage and was induced by 
E2 in human breast cancer cells (Periyasamy et al., 2015; Udquim et al., 2020). Therefore, 
we compared the mRNA levels of Apobec3 in BALB/cJ and C57BL/6J mice. There were 
no significant changes in Apobec3 expression in the E2-treated mice compared to controls 
(Figure 3.5 I and J). Levels of Apobec3 differed between strains, but levels were lower in 
BALB/cJ mice. Therefore, Apobec3 does not appear associated with the greater DNA 
damage observed in BALB/cJ mammary tissues.  
 
E2 induced DNA damage in the mammary epithelium of susceptible ACI rat strain. 
Rat strains have also been shown to vary dramatically in their responses to E2. The 
ACI strain is susceptible to E2-induced mammary tumors and has led to the identification 
of genetic modifiers through crosses with the resistant BN strain. However, these strains 
have not been screened for differences in DNA damage and repair pathways. Ovary-intact 
rats from both ACI and BN strains were treated continuously with E2 for 7days, then tissues 
were harvested and analyzed for γH2AX foci. E2 treatment in ACI rats resulted in 
significant increases in γH2AX foci in the mammary epithelium compared to the control 
treated ACI rats (Figure 3.6A and B). In contrast, the BN strain did not show induction of 
γH2AX foci with E2 treatment. These results demonstrate that the DNA damaging effects 





DNA damage by E2 in human breast explant tissues 
Prior studies had observed E2-induced DNA damage in breast cancer cell lines but 
had not examined effects in normal breast tissues. We used the ex-vivo culture of patient-
derived explants (PDEs) to compare the effects of estrogen among women. PDEs were 
maintained in basal media or supplemented with 10nM E2 for up to 4 days. PDEs from 
donors undergoing prophylactic mastectomies due inherited genetic risk alleles were 
designated “High Risk”. Responses were compared with donors undergoing reduction 
mammoplasty and did not have familial risk, and therefore, were considered “Average 
Risk” of breast cancer. The mean number of γH2AX foci/nucleus was increased by E2 but 
was not statistically significant within the risk groups (Figure 3.7A). The High-Risk 
patients exhibited a higher baseline level of γH2AX as well as a further increase induced 
by E2. Comparison between the risk groups, the effect of E2-induced DNA damage was 
greater in this sample of High Risk compared to the Average Risk tissues (p=0.01). The 
range of γH2AX foci/nucleus was greater in the E2 treated breast epithelium (% of cells) 
of High-Risk donors when compared with Average Risk donors (Figure 3.7B). The results 
indicate that there is variation in DNA damage caused by E2 among women and may reach 
pathogenic levels in a subset of individuals.  
 To assess the variation in the general population, we analyzed PDEs from 3 
additional women undergoing reduction mammoplasty and did not have a family history 
of breast cancer, and therefore, presumed to be “Average Risk”. The tissues were 
maintained in basal media or treated with 10nM E2. The donors had similar baseline levels 
of γH2AX foci and variable increases in foci with E2 treatment (Figures 3.7C and D). 




in response to E2 compared to the basal media control (p<0.0001). The distribution of 
damage in donor 184 showed that increased H2AX foci/nucleus was broadly distributed 
across the breast epithelial cells (Figure 3.7E). In these experiments with tissues from 
Average Risk donors, we observed a significant increase in E2-induced DNA damage in 
the breast epithelium in only 1 out of 5 individuals suggesting that this method can provide 






















A wealth of data has demonstrated the critical role of estrogen in breast 
carcinogenesis. Both dose and duration of exposure to ovarian hormones are associated 
with differences in the incidence of breast cancer (Eliassen et al., 2006) (Tamimi et al., 
2016). The “pathogenic effect” of estrogens is often attributed to the mitogenic effects in 
ERα-positive breast cell tumors. While estrogen can have a promotional role in breast 
cancer cells, it is less clear how estrogen acts as an initiator of carcinogenesis. However, 
in normal mammary epithelium, ERα rarely colocalizes with markers of proliferation in 
mice, rats, or human breast (Anderson and Clarke, 2004; Blance et al., 2009; Clarke, 2004; 
Russo et al., 1999). In the normal epithelium, estrogens act indirectly by stimulating 
production of growth factors by the ERα-positive cells. The growth factors are secreted 
and act in a paracrine fashion to induce proliferation in the adjacent ERα-negative cells. 
Studies in genetically engineered mice have shown that epidermal growth factor receptor 
(EGFR) ligands such as amphiregulin (AREG) act as paracrine growth factors to mediate 
the mitogenic effects of estrogens (Ciarloni et al., 2007). Pregnancy is a period of intense 
proliferation needed to expand the ductal epithelium in preparation for lactation and 
estrogen concentrations are approximately ten-fold higher in women during pregnancy 
compared to postmenopausal women. Rather than increasing risk, the hormones during 
pregnancy ultimately confer a long-term reduction of risk by as much as 50% (Albrektsen 
et al., 2005; Chie et al., 2000; MacMahon et al., 1970). Indeed, we find no difference in 
proliferation between BALB/cJ and C57BL/6J mice in response to E2 after 4 days (Figures 
3.1C, 3.3C). This proliferative burst is quickly resolved, and tissues return to baseline 




prolonged proliferative response than in the BN strain (Harvell et al., 2000). Proliferative 
responses in PDEs of normal breast showed varied responses to E2 (Dunphy et al., 2020). 
Therefore, there is not a consistent relationship between the effect of E2 on proliferation 
and its activity initiating breast cancer.  
Recent studies in breast cancer cells have shown that estrogen can have genotoxic 
effects mediated by ERα that are not dependent on replication-induced DNA damage. E2 
was shown to have an initial induction of DNA double-strand breaks within 2 hours of 
stimulation (Ju et al., 2006; Sasanuma et al., 2018). The transcription-associated damage 
was shown to be important for the expression of target genes of ERα but was transient. In 
addition to the acute DNA damage response, E2 was shown to stimulate even higher levels 
of γH2AX foci at 24 h after E2 stimulation (Stork et al., 2016). Using ChIP-sequencing, 
both γH2AX and R loops were shown to be localized to transcribed regions indicating more 
persistent damage. The E2-induced damage at 24 h was suggested to be due to stalling of 
replication forks at sites of transcription resulting in DNA double-strand breaks to allow 
replication to be re-started. However, environmental xenoestrogens were shown to also 
stimulate nuclear γH2AX foci in ERα-positive cell lines (Majhi et al., 2020), but at 
concentrations 1/10th that required for proliferation. These experiments showed the 
presence of E2-induced the DNA damage that was ERα-dependent in the absence of 
proliferative responses.  
In our studies, we demonstrate that E2 stimulates DNA damage which provides a 
mutagenic stimulus for initiating a carcinogenic cascade. However, E2-induced DNA 




susceptible to mammary tumorigenesis (Blackburn et al., 2007; Lanari et al., 1986; 
Ponnaiya et al., 1997; Shull et al., 2018). These strains also showed greater numbers of 
γH2AX foci in the luminal mammary epithelium in response to E2 (Figures 3.1E and 
3.6B). In BALB/cJ mice, the DNA damage was enriched in the ERα-positive cells (Figure 
3.2C). In contrast, strains that are more resistant to mammary tumors, C57BL/6J mice and 
BN rats, showed little DNA damage following E2 treatment.  
BALB/cJ mice also had higher levels of R loops that are frequently associated with 
regions of nascent transcription. Therefore, the elevated expression of ERα target genes in 
BALB/cJ mice compared to C57BL/6J (Pgr and Areg; Figure 3.1) may reflect the 
underlying mechanisms regulating transcriptional activation of ERα. Suppression of 
transcription-associated DNA damage was shown to diminish expression of ER target 
genes such as TFF1 in breast cancer cell lines. Alternatively, APOBEC3B was shown to 
bind to ERα causing deamination near promoters which resulted in DNA double-strand 
breaks in breast cancer cell lines (Periyasamy et al., 2015). However, only one form of 
APOBEC3 is found in the mouse genome and it does not retain cytidine deaminase activity 
(MacMillan et al., 2013). The mouse APOBEC3 transcripts are polymorphic between 
BALB/c and C57BL/6 mice resulting in decreased translation and lower protein levels in 
BALB/c mice (MacMillan et al., 2013; Okeoma et al., 2009). There was no increase in 
expression of Apobec3 in response to E2 in the mouse tissues from either strain (Figure 
3.5I and J). Therefore, APOBEC3B is unlikely to account for the E2-induced γH2AX 




implicated as potential genomic threats, it is unclear if they provide a sufficiently sensitive 
biomarker of risk associated with estrogen exposure. 
The E2-induced DNA damage was evident with prolonged treatment with E2. 
Treatment of BALB/cJ mice with E2 for 28 days resulted in 3-fold more nuclear γH2AX 
foci in the mammary epithelium while there was no change from baseline in C57BL/6J 
mice (Figure 3.4E). At this time, proliferation had returned to baseline and transcriptional 
responses in ERα target genes were minimally affected by E2 (Figures 3.5D and E). 
Therefore, neither proliferative responses nor transcriptional activation account for the 
DNA damage observed in BALB/cJ mice though the presence of R loops induced by E2 
continued to be observed (Figure 3.4G). These data suggest that E2 stimulates continual 
DNA damage in BALB/cJ mice which can contribute to their susceptibility to mammary 
tumors.  
 The critical role of DNA damage and repair pathways has become increasingly 
important in determining breast cancer risk and guides the selection of therapies. High 
penetrance risk alleles affecting the functions of BRCA1, BRCA2, PALB2 emphasize the 
importance of canonical homologous recombination in assuring genomic stability. While 
this mechanism is present in all cells, the fact that breast cancer is the most common tumor 
type in carriers of pathogenic mutations suggests that breast tissue is keenly sensitive to 
disruptions in the repair of DNA double-strand breaks through homologous recombination. 
Deficiencies in canonical homologous recombination can lead to a greater reliance on the 
repair of DNA double-strand breaks using the lower fidelity single-strand annealing 
pathway and ALT-end joining pathways. Increased reliance on these lower fidelity 




of breast cancer (Keimling et al., 2012). Utilization of single-strand annealing (SSA) and 
ALT-EJ to repair DNA double-strand breaks is 3-fold greater in BALB/c compared to 
C57BL/6 mice (Böhringer et al., 2013). The differences in DNA repair between these 
strains are genetically linked to the Suprmam1 locus on mouse chromosome 7 (Blackburn 
et al., 2007). Therefore, susceptibility to mammary tumors in BALB/c mice may be due to 
combined effects of low levels of DNA double-strand breaks caused by E2 and their repair 
by error-prone SSA mechanisms. The levels of γH2AX induced by E2 treatment were also 
greater in breast tissues from women with strong familial risk associated with defects in 
DNA double strand break repair (Figure 3.7A) compared to tissues from average risk 
women. These data offer a common theme among rodents and humans where the 
prevalence of γH2AX foci induced by estrogen interacts with the proficiency of DNA 
double-strand repair mechanisms to determine the risk of developing breast cancer. Levels 
of γH2AX have been considered as a biomarker of prognosis in breast cancers. Here we 
have used quantification of nuclear foci to provide a refined quantification of DNA damage 
in normal breast epithelium that can be applied to analyses of breast tumors as well.  
 Our results support a mechanism in which estrogen exposure preferentially causes 
DNA double-strand breaks mediated by ERα. However, the extent of the damage appears 
to be augmented when DNA double-strand break repair pathways are defective. BALB/c 
mice are more sensitive to DNA damage which appears to be associated with genetic 
polymorphisms that affect non-homologous end-joining (Yu et al., 2001) as well as 
increased homology-directed repair through error-prone pathways (Böhringer et al., 2013). 
The results are consistent with data showing that E2 stimulated hyperplastic lesions in 




due to mutations in Prkdc. DNA damage in these mice was blocked by treatment with 
Fulvestrant, and therefore, is dependent on ERα. We also found increased E2-induced 
DNA damage in human breast tissues from women with inherited breast cancer risk alleles 
affecting DNA double-strand break repair. In contrast to average-risk women where ERα-
positive breast cancers have a good prognosis, ERα-positive breast cancers among women 
with pathogenic mutations in BRCA1 or BRCA2 have a 3-fold higher recurrence rate and 
risk of death (Metcalfe et al., 2019; Vocka et al., 2019). It appears that DNA double-strand 
breaks are necessary to facilitate transcription of ERα target genes which, in repair-
proficient individuals, is promptly repaired using high fidelity pathways. However, in 
individuals with impairments of DNA double-strand break repair, the DNA damage in 















Table 3.1.  Sequence of primers 














F:  AGTGTCTGTGATCTTGTCCAG 
R:  TGTGTGCCTCAAATCCATCA 
 
F:  GACCACATCAGGCTCAATGCT 












Table 3.2.  Details of patient derived breast explant donors: 
Patient ID Age Type of Surgery Risk Category 
184 27 Reduction mammoplasty Average 
237 18 Reduction mammoplasty Average 
243 45 Reduction mammoplasty Average 
814 23 Reduction mammoplasty Average 
772 44 Reduction mammoplasty Average 
833 42 Prophylactic mastectomy High 













Figure 3.1. Effect of acute (4 days) 1x E2 treatment on mammary gland in 
ovariectomized BALB/c and C57BL/6 mice.   
(A) Workflow of experimental design and animal treatment. (B) Proliferation marker: Ki-
67 staining of mouse mammary epithelial cells. Scale bar = 50µM (C) Percentage of Ki-
67-stained cells were counted (n=5 for BALB/c control and C57BL/6 control, n=8 for 
BALB/c E2, n= 6 for C57BL/6 E2). (D) Immunostaining of mouse mammary epithelium 
with γH2AX antibody harvested from BALB/c and C57BL/6 mice treated with control 
(n=3) or E2 (n=5). Each image shows a ductal structure with a nucleus stained with DAPI 
(blue) and γH2AX (green). Scale bar = 20µM. (E) Quantification of immunostaining data 
of γH2AX foci inside the nucleus. (F) Immunostaining of mouse mammary epithelium 
with S9.6 antibody for R loops in BALB/c and C57BL/6 mice treated with control (n=3) 
or E2 (n=5). Scale bar = 20µM. (G) Quantification of immunostaining data of S9.6 foci 
inside the nucleus. Gene Expression of (H) Pgr (I) Areg in mammary gland tissues from 
ovariectomized mice treated with control or E2 (0.25mg/kg/d) for 4 days (n=5) or E2 (n=5).  
***p > 0.0001 compared to control with treatments using one-way analysis of variance 
(ANOVA) followed by Tukey's honestly significant difference (HSD) multiple-range test. 
All graphs show mean ± SEM. Data collection in collaboration with Prabin. D. Majhi and 


































Figure 3.2. Localization of DNA damage in mammary gland epithelium of 4 days 
treated BALB/c and C57BL/6 ovariectomized mice.  
(A) Dual immunostaining on mouse mammary epithelium with γH2AX antibody and ER-
alpha harvested from BALB/c and C57BL/6 mice treated with control (n=5) or E2 (n=5). 
Each image shows a ductal structure with a nucleus stained with DAPI (blue), ER-alpha 
(Red), and γH2AX (green). Scale bar = 20µM. (B) Quantification of total ER-alpha 
positivity (%) in the dual immunostaining. (C) Quantification and comparison of γH2AX 
foci inside the nucleus of ER-alpha positive versus ER-alpha negative cells. (D) 
Distribution of the number of γH2AX foci per nucleus in each ERα positive cell from 
BALB/c and C57BL/6 mice treated with control or E2 (0.25mg/kg/d) for 4 days (control 
n=5, E2 treated n=5). (E) Percentage of ERα positive cells with greater than equal to 10 
γH2AX foci per nucleus in the mammary epithelium of BALB/c and C57BL/6 mice treated 
with control or E2 (0.25mg/kg/d) for 4 days (control n=5, E2 treated n=5). ***p > 0.0001 
compared to control with treatments using one-way analysis of variance (ANOVA) 
followed by Tukey's honestly significant difference (HSD) multiple-range test. All graphs 













Figure 3.3. Effect of acute (4 days) 3xE2 treatment on mammary gland in ovary intact 
BALB/c and C57BL/6 mice. 
(A) Workflow of experimental design and animal treatment. (B) Proliferation marker: Ki-
67 staining of mouse mammary epithelial cells in BALB/c and C57BL/6 treated with 
control (n=5) or E2 (n=5). Scale bar = 50µM. (C) Percentage of Ki-67-stained cells were 
counted. (D) Immunostaining of mouse mammary epithelium with γH2AX antibody 
harvested from BALB/c and C57BL/6 mice treated with control (n=5) or E2 (n=5). Each 
image shows a ductal structure with a nucleus stained with DAPI (blue) and γH2AX 
(green). Scale bar = 20µM. (E) Quantification of immunostaining data of γH2AX foci 
inside the nucleus. (F) Immunostaining of mouse mammary epithelium with S9.6 antibody 
for R loops in BALB/c and C57BL/6 mice treated with control (n=5) or E2 (n=5). Scale 
bar = 20µM. (G) Quantification of immunostaining data of S9.6 foci inside the nucleus. 
***p > 0.0001 compared to control with treatments using one-way analysis of variance 
(ANOVA) followed by Tukey's honestly significant difference (HSD) multiple-range test. 









Figure 3.4. Effect of chronic (28 days) 3xE2 treatment on mammary gland in ovary 
intact BALB/c and C57BL/6 mice. 
(A) Workflow of experimental design and animal treatment. (B) Proliferation marker: Ki-
67 staining of mouse mammary epithelial cells in BALB/c and C57BL/6 treated with 
control (n=5) or E2 (n=10). Scale bar = 50µM. (C) Percentage of Ki-67-stained cells were 
counted. (D) Immunostaining of mouse mammary epithelium with γH2AX antibody 
harvested from BALB/c and C57BL/6 mice treated with control (n=5) or E2 (n=10). Each 
image shows a ductal structure with a nucleus stained with DAPI (blue) and γH2AX 
(green). Scale bar = 20µM. (E) Quantification of immunostaining data of relative γH2AX 
foci inside the nucleus. (F) Immunostaining of mouse mammary epithelium with S9.6 
antibody for R loops in BALB/c and C57BL/6 mice treated with control (n=5) or E2 
(n=10). Scale bar = 20µM. (G) Quantification of immunostaining data of relative S9.6 foci 
inside the nucleus. ***p > 0.0001 compared to control with treatments using one-way 
analysis of variance (ANOVA) followed by Tukey's honestly significant difference (HSD) 
multiple-range test. All graphs show mean ± SEM. Data collection in collaboration with 








































Figure 3.5. Estrogen target genes expression on acute (4 days) and chronic (28 days) 
treatment with 3xE2 on mammary gland in ovary intact BALB/c and C57BL/6 mice. 
Left panel – Gene Expression of (A), Pgr (C) Areg (E) Esr1 (G) Krt18 (I) Apobec3 from 
mammary gland tissues in ovary-intact mice treated with control or E2 (0.75mg/kg/d) for 
4 days (n=5) or E2 (n=5). Right panel - Gene Expression of (B), Pgr (D), and Areg (F) 
Esr1 (H) Krt18 (I) Apobec3 from mammary gland tissue of 28 days treated ovary intact 
mice with control (n=5) or E2 (n=10). Gene expression was normalized with the gene Krt18 
expression – luminal epithelium marker. All graphs show mean ± SEM. Data collection in 








































Figure 3.6: E2 induced DNA damage in mammary gland epithelium of 7 days treated 
ACI and BN rat strain.  
(A) Immunostaining of mammary epithelium with γH2AX antibody, harvested from ACI 
and BN rat strain treated with control (n=5) or E2 (n=5). Each image shows a ductal 
structure with nucleus stained with DAPI (blue) and γH2AX (green). Scale bar = 20µM. 
(B) Quantification of immunostaining data of γH2AX foci inside the nucleus. ***p > 
0.0001 compared to control with treatments using one-way analysis of variance (ANOVA) 
followed by Tukey's honestly significant difference (HSD) multiple-range test. All graphs 









Figure 3.7. E2 induced DNA damage in a subset of human breast tissue explants. 
(A) Quantification of γH2AX foci per nucleus in the breast epithelium of average risk 
patients (normal) undergoing reduction mammoplasty and high-risk patients undergoing 
prophylactic mastectomy (n=2 in each group). (B) The frequency distribution graph was 
generated using the number of γH2AX foci/nucleus in the breast epithelial cells (%) from 
E2 treated average risk and high-risk patients. (C) Representative images of γH2AX 
immunostaining in human breast explants. Scale bar = 20µM. (D) Quantification of 
γH2AX foci per nucleus in the breast epithelium of 3 average risk patients treated with 
basal media or E2 (10nM). (E) The frequency distribution graph was generated using the 
number of γH2AX foci/nucleus in the breast epithelial cells (%) from E2 treated average 
risk patients. ****p<0.0001 compared control with treatments using one-way analysis of 
variance (ANOVA) followed by Tukey's honestly significant difference (HSD) multiple-




































Estrogen induces DNA damage and R-loop stabilization mediated by  







DNA can adopt multiple alternative conformations which differ from canonical B-
DNA structure. Non-B DNA structures, such as co-transcriptional DNA: RNA hybrids also 
known as R-loops, are three-stranded nucleic acid structures.  R-loops are formed when the 
nascent RNA hybridizes with the template DNA strand causing transient displacement of 
the non-template strand. R-loops are a normal consequence of transcription, however 
unscheduled or persistent R loops may form due to a lack of resolvases. The persistence of 
R loops can induce DNA damage responses that result in DNA double-strand breaks 
(Aguilera and García-Muse, 2012a; Skourti-Stathaki and Proudfoot, 2014; Sollier and 
Cimprich, 2015). Reactive oxygen species (ROS) have been shown to also play a role in 
R-loop formation at actively transcribed regions (Teng et al., 2018).  Recently, the hormone 
estrogens (E2, 17β-estradiol) and endocrine-disrupting chemicals (Benzophenone-3, BP-
3) were shown to induce DNA damage in breast epithelial cells by promoting R loops 
mediated by estrogen receptor -mediated (ER) (Majhi et al., 2020; Stork et al., 2016). BP-
3 induces DNA damage independent of proliferation (Majhi and Sharma et al., 2020). In 




and DNA damage to promote breast cancer (Felty et al., 2005; Mobley and Brueggemeier, 
2004; Okoh et al., 2011; Roy et al., 2007; Tian et al., 2016).  
Similarly, another non-canonical DNA secondary structure known as G 
quadruplexes (G4s) is formed at single-stranded guanine-rich DNA sequences. DNA G4s 
arise from Hoogsteen hydrogen bonding of four guanine residues arranged within a planar 
G-quartet. Self-stacking of two or more G-quartets generates a G4 structure that is 
stabilized by monovalent cations such as K+ and Na+ (Kwok and Merrick, 2017). DNA G4s 
play a crucial role in several biological functions such as transcription, replication, and 
telomere maintenance but also promotes genomic instability (Rhodes and Lipps, 2015; T. 
Tian et al., 2018). With the advancement of Next Generation Sequencing (NGS) 
technologies, G4s have been mapped to critical regions such as promoters, replication 
origins, and telomeres (Hänsel-Hertsch et al., 2016; Langley et al., 2016; Maizels, 2006; 
Zahler et al., 1991).  
Previous literature has shown the cooperative relationship between G4s and R loops 
to form a stable structure called G-loops. G-loops are the co-existence of G4 and R-loop, 
where R loops are formed on the template DNA and G4 on the displaced non-template 
DNA strand (Duquette et al., 2004; Magis et al., 2018; Tan et al., 2020; Tan and Lan, 2020). 
For instance, G4 ligands such as Pyridostatin (PDS) were shown to stabilize G4 structures 
in cancer cells and increased levels of G4s and R loops were colocalized (G-loops) as well 
as DNA damage (Magis et. al. 2018). Another study showed the co-existence of G4, and 
R-loop (G-loop) mediated by ROS at transcriptionally active sites and that, if such stable 




The formation of transient R-loops is a general indicator of transcription activation 
in response to E2. Therefore, we investigated the role of ER-mediated secondary DNA 
structures and their role in DNA damage in breast cells. Here, we show that treatment with 
E2 and BP-3 promotes DNA G4 formation in the ER+ breast cancer cells.  Approximately, 
half of the G4 foci induced by E2 and BP-3 treatment in the cells colocalize with R-loops 
indicating G-loop formation, but these structures were blocked by treatment with ROS 
scavenger. These data suggest a mechanism in which E2, and BP-3 bind to ER to induce 
ROS-mediated G4 formation promoting stabilization of G-loops and leading to increased 


















Materials and Methods 
 
Cell culture and treatments:  
T47D (ATCC #HTB-1330), and MCF-7(ATCC #HTB 22) cells were passaged in 
growth media containing phenol-red free (PRF) DMEM-F12 (Sigma #D6434) or MEM 1x 
(Gibco #51200-038) with 10% heat inactivated FBS (Omega Scientific # FB-02) and 10 
μg/ml insulin (Sigma #9278), 2 mM L-glutamine (Hyclone # SH30034.01), gentamycin 15 
μg/ml (Gibco #15750-060) and 1X antibiotics/antimycotics (AB/AM, Gibco #15240-062) 
and incubated at 37oC with 5% CO2. For experiments, cells were grown in clearing media 
with charcoal-stripped serum (CSS) (MEM 1x with 10% charcoal-dextran treated FBS 
(Omega Scientific #FB-04), and 2 mM L-glutamine) for 48 h before being plated for 
experiments. T47D and MCF7 cells were grown in clearing media for 48 h and plated on 
20 mm glass uncoated coverslips in 12 well plates with a density of 2 x 105 cells/well. Cells 
were treated with 10nM or 100nM E2, 5 µM BP3, 10uM PDS (G4 stabilizer) with or 
without 10 mM N-acetyl cysteine (NAC) for 16-18 hrs. 
 
Immunostaining 
 Cells were fixed in 4% PFA for 20 mins at RT and quenched with 0.1 M Glycine 
for 15 mins. Cells were permeabilized with 0.5% Triton-X 100. Cells were washed with 
two times with PBS. Cells were incubated with 20ug of RNase A at 37C for 30 mins to 
eliminate RNA G4s and then washed 3 times with PBS. Cells were blocked in 10% goat 
serum with 0.1% Tween20 for 1hr at room temperature (RT), incubated overnight with 




followed by 1 hour with anti-rabbit Alexa Fluor Plus-488-conjugated secondary antibody 
(ThermoFisher) or anti-mouse Alexa Fluor Plus-488-conjugated (ThermoFisher) at RT. 
Cells were mounted with Vectashield mounting medium containing DAPI (Vector 
Laboratories # H-1200). For BG4, Cells were incubated with 1:800 of DYKDDDDK Tag 
antibody (Cell Signaling ref #2368) in 5% goat serum for 1 hour at RT before the secondary 
incubation. Slides were imaged at 60X (immersion oil) with Nikon A1 Spectral Confocal 
microscope. Analysis of γH2AX, BG4 and 1H6 foci per nucleus was calculated using 
Nikon analysis software, where DAPI was used as a mask for the nucleus.  
 
Co-staining of cells with BG4 and S9.6 antibodies.  
Cell were fixed with ice-cold methanol at room temperature (RT) for 10 minutes. 
After a brief wash with PBS, cells were permeabilized with 0.5% Triton™ X-100 in PBS 
at RT for 15 minutes. Cells were blocked with 8% BSA/PBS and then incubated with 2 μg 
per slide each of BG4 and S9.6 antibodies diluted in 2% BSA/PBS for 2 hours. Cells were 
then incubated with 1:800 of DYKDDDDK Tag antibody (Cell Signaling ref #2368) in 2% 
BSA/PBS for 1 hour. Next, cells were incubated at RT with 1:1000 Alexa Fluor 594 goat 
Anti-Mouse IgG and Alexa Fluor 488 goat anti-rabbit IgG in 2% BSA/PBS for 1 hour. 
After each step, cells were washed with PBS. Cells were mounted with Vectashield 
mounting medium containing DAPI (Vector Laboratories # H-1200). Slides were imaged 
at 60X (immersion oil) with Nikon A1 Spectral Confocal microscope. Analysis of BG4 
and S9.6 foci per nucleus was calculated using Nikon analysis software, where DAPI was 






Unless specified, data were analyzed by one-way or two-way analysis of variance 
(ANOVA) followed by Tukey's honestly significant difference (HSD) multiple-range test 
using GraphPad Prism 9 statistical analysis software. Results are presented as mean ± 
























E2 and BP-3 induce G4 formation.  
Activation of ER by E2 stimulates both transcription of target genes within minutes 
and proliferation becomes evident after about 24 h when foci of H2AX become prevalent 
indicating the presence of DNA double strand breaks. BP-3 was used in these studies as it 
also induces H2AX foci but without significant transcription of target genes or 
proliferation. Therefore, the effects of transcription and proliferation can be discriminated 
by comparing responses to E2 and BP-3. The concentration of E2 (10 and 100nM) was 
selected to approximate the range found during pregnancy in women. The median urinary 
concentration of BP-3 in pregnant women is ~0.5M and greater than 30M in the 95th 
percentile. Therefore, 5M BP-3 was used to reflect levels of exposure that are common 
in US women.  
We first sought to characterize the G4 formation in response to E2 and BP-3 in ER-
positive breast epithelial cancer cell lines – T47D and MCF7 cells. Cells were hormone 
starved for 48 hours and then treated with the compounds for 16-18 hrs. After treatment, 
we performed immunofluorescence with G4 specific antibody – BG4 in the breast cancer 
cells and measured the amount of G4 foci present inside the nucleus (Figure 4.1A). We 
observed that basal levels of G4 foci are present in the untreated (control) T47D and MCF7 
cells. Cells treated with E2 causes a significant increase in the number of G4 foci when 
compared with control treatment in both cell lines with no differences between the 10 and 




both MCF7 and T47D cells (Figure 4.1 A, B, and C). Taken together, these results 
demonstrate that E2 and BP-3 induce G4 formation in the ER+ breast cancer cells.  
 
E2 and BP-3 induce colocalization of G4s and R loops.  
Recently, we have shown that E2 and BP3 cause R-loop formation in T47D and 
MCF7 cells (Majhi et al., 2020). G4 formation has been shown to co-exist with R-loop 
structures, forming a stable structure called G-loops (Magis et al., 2018; Tan et al., 2020). 
Next, we wanted to investigate whether G4, and R loop structures induced by E2, and BP-
3 are formed in a similar vicinity. Therefore, we colocalized BG4 (G4 antibody) and S9.6 
(R-loop antibody) immunofluorescence and measured the % of overlapping BG4 and S9.6 
signals in both T47D and MCF7 cells (Figure 4.2 A).  
Untreated T47D cells showed low levels of colocalization (median=20%) of G4 
and R loop foci. In MCF7 cells, there was very little colocalization (median=0%) (Figure 
4.2 B and C). However, cells treated with E2 (10nM and 100nM) showed a significant 
increase in colocalization of G4 and R-loop signals as seen by yellow foci in the merged 
images of green and red foci (Figure 4.2 A, lower panel). Treatment with 10nM E2 
showed 40% colocalization and 50 – 59% colocalization was observed in 100nM E2 
treatment of T47D and MCF7 cells (Figure 4.2 B and C). Treatment with 5uM BP-3 
treatment resulted in 40% and 57% colocalization of G4 and R-loop signals in T47D and 
MCF7 cells (Figure 4.2 B and C).  Almost half of the G4 foci induced by E2 and BP3 are 






E2 and BP-3 induced G4s, and DNA damage is ROS dependent.  
Previous studies have shown that ROS plays a role in the induction of G4 formation 
in cancer cells (Tan et al., 2020; Tan and Lan, 2020) and that E2 causes induction of ROS 
via estrogen receptor-dependent or independent mechanism (Maleki et al., 2015; Okoh et 
al., 2011; Roy et al., 2007; Tian et al., 2016). We hypothesized that in ER+ breast cancer 
cells, E2 and BP-3 could induce G4 formation mediated by the ROS mechanism. To 
determine the ROS-mediated G4 formation, we treated the cells with or without ROS 
inhibitor/scavenger - N-acetyl cysteine (NAC) along with 10nM E2, 5uM BP-3. The G4 
ligand Pyridostatin (PDS) was included as a positive control to directly stabilize G4 
structures. For these experiments, we performed immunostaining with another G4 specific 
antibody – 1H6 in an effort to confirm the results obtained with BG4 and measured the 
number of 1H6 foci present inside the nucleus (Figure 4.3A).  
In control cells, treatment with the ROS scavenger (NAC) did not significantly 
affect basal levels of nuclear G4 foci. This indicates that a subset of G4s is present and are 
independent of ROS (Figure 4.3A and B).  Cells treated with 10nM E2, 5uM BP-3, and 
10uM PDS showed a significant increase in the number of G4 foci inside the nucleus. 
However, the presence of NAC blocked the formation of G4 foci in E2 and BP-3 treated 
cells resulting in levels similar to that in control cells (Figure 4.3A and B). Cells treated 
with 10uM PDS (G4 stabilizer) showed no change in the number of G4 foci with or without 
the presence of ROS scavenger, which is expected to observe because PDS directly 
stabilizes G4 structures.  
 We also examined the DNA damage response by immunostaining with DNA 




induction of DNA damage (Majhi and Sharma et. al., 2020). Here, we observed similar 
findings that E2 and BP-3 treatments showed significant increases in γΗ2AX foci when 
compared with the control-treated T47D and MCF7 cells (Figure 4.4A, B and C). As 
expected, treatment with G4 stabilizer – PDS causes significant induction of DNA damage 
in both cell lines. Interestingly, cells treated with E2 and BP-3 in the presence of NAC 
showed a significant reduction of γΗ2AX foci which suggests that DNA damage induced 
by E2 and BP3 is dependent on ROS (Figure 4.4A, B and C). On the other hand, PDS 
treatment in the presence or absence of NAC showed no significant changes in the number 
of γΗ2AX foci. Overall, our results demonstrate that E2 and BP3 induce ROS-mediated 



















Since the discovery of canonical right-handed DNA double-helical structure (B-
DNA) in 1953, many non-B DNA conformations have been reported to form at repetitive 
sequences (Ghosh and Bansal, 2003; Sharma, 2011). The non-canonical secondary 
structures, such as DNA: RNA hybrids (R-loops) and G-quadruplexes (G4), act as a 
double-edged sword that is involved in both biological and pathological functions such as 
transcriptional regulation, telomere maintenance, and genomic instability. Physiological 
R-loops and G4s are programmed processes and form transiently for their biological 
functions (Ohle et al., 2016; Pavri, 2017; Qiao et al., 2017). On the other side, stabilized or 
pathological R-loops and G4s that occur in an unscheduled manner can cause genomic 
instability. These non-canonical secondary structures forming during gene transcription 
and DNA replication can result in DNA double-strand breaks (Aguilera and García-Muse, 
2012b; García-Muse and Aguilera, 2019; Rhodes and Lipps, 2015). The DNA damage and 
genomic instability arises from these structures due to transcriptional pausing, replication 
stress or transcription-replication conflicts. Multiple RNA processing factors and helicases 
have been shown to be involved in the resolution of R-loops and G4 structures. Failure to 
resolve R-loops and G4s can allow these structures to accumulate to pathological levels 
and cause genomic instability. Disruption of genes involved in resolution of R-loops and 
G4s have been linked to human diseases such as neurological disorders and cancers (Groh 
and Gromak, 2014; Maizels, 2015; Richard and Manley, 2017).  In the context of breast 
cancer, the tumor suppressor proteins BRCA1 and BRCA2 have been shown to resolve 




double strand breaks (Chiang et al., 2019; D’Alessandro et al., 2018; Hatchi et al., 2015; 
Shivji et al., 2018).  
 Multiple studies have shown that R-loops are more prevalent in genomic regions 
that are G-rich. During transcription, the non-template DNA strand is displaced allowing 
G4 structures to form in the single-stranded DNA strand (Ginno et al., 2013, 2012; Reaban 
et al., 1994; Skourti-Stathaki and Proudfoot, 2014). Recent studies have shown the co-
existence of the R-loop and G4 to form a unique stable structure called as “G-loop”, where 
those G-rich sequences on the non-template strand fold into a G4 structure and R-loops on 
the template DNA strand (Lee et al., 2020). Using electron microscopy, (Duquette et al., 
2004), showed the first evidence of the existence of G-loop structure in vitro and in 
Escherichia coli. Another study used G4 ligands, such as Pyridostatin (PDS), to stabilize 
G4 structures in human cancer cells and observed that G4 ligands induce DNA damage by 
R-loops stabilization (Magis et al., 2018). In these studies, 50 - 60% of stabilized G4s 
colocalized with R-loops. Importantly, R-loops allow G4 formation and those G4s 
reversibly stabilize the R-loop structure as a feedback loop indicating the interrelationship 
of G4 and R-loop (Tan et al., 2020). The kinetics of R-loop and G4 formation was found 
to be similar in the cells at different timepoints and failure to resolve these structures 
promotes DNA damage and delays the repair process.   
Here we show that E2 and BP-3 induce G4 formation in the estrogen receptor-
positive MCF7 and T47D breast cancer cells using two G4 specific antibodies – BG4 and 
1H6 (Figure 4.1 and Figure 4.3). Almost 50% of the G4 foci induced by E2 and BP3 were 
observed in a similar vicinity with the R-loops as performed by colocalization of S9.6 and 




formation in breast cancer cells. The extent of G4 and R loop colocalization by E2 and BP-
3 treatment was found to be similar to the G4 ligands used in Magis et. al., 2018. Therefore, 
ER ligands have the potential to stimulate ongoing mutagenesis in ER+ breast cancer cells. 
 Previous literature has demonstrated the mechanistic connection between Reactive 
Oxygen Species (ROS) and G4 formation (Fleming et al., 2017; Fleming and Burrows, 
2019; Roychoudhury et al., 2020). Recently, it was shown that ROS induces G4 formation 
at actively transcribed regions (Tan et al., 2020). Besides, it is already known E2 induces 
ROS, which causes oxidative stress and DNA damage (Felty et al., 2005; Mobley and 
Brueggemeier, 2004; Okoh et al., 2011; Roy et al., 2007; Tian et al., 2016). In the present 
study, our findings demonstrate that the levels of E2 and BP-3 induced G4 foci in the cells 
were significantly reduced with the presence of ROS scavenger (Figure 4.3). Similarly, 
we observed that the DNA damage marker – γH2AX foci were also significantly reduced 
in E2 and BP-3 treated cells when ROS was inhibited (Figure 4.4). This indicates that ROS 
plays an important role to induce G4 formation and DNA damage. We proposed a 
mechanistic model of E2, and BP-3 induced DNA damage (Figure 4.5). According to the 
model, E2 and BP-3 bind with the estrogen receptor to trigger R-loop formation, and the 
R-loops are stabilized by G4 formation mediated by the ROS mechanism. This promotes 
G-loop formation and is associated with DNA damage. Therefore, we have uncovered a 









Figure 4.1. Evaluation of G4 formation in cells treated with 17β-Estradiol (E2), 
Benzophenone-3 (BP3).   
(A) Immunofluorescence of BG4 foci in T47D and MCF7 cells treated with 10 or 100nM 
E2 and 5μM BP3. (B and C) Quantification of nuclear BG4 foci in T47D and MCF-7 cells 
treated with control, E2 and BP-3.   ****p < 0.0001 compared control with treatments 
using one-way analysis of variance (ANOVA) followed by Tukey's honestly significant 
difference (HSD) multiple-range test. Scale bar = 10 µM. All graphs show box plots with 

































































Figure 4.2 Evaluation of G4 and R loop colocalization in cells treated with E2 and BP-
3. (A) Co-staining of BG4 and S9.6 foci in T47D and MCF7 cells treated with 10 or 100nM 
E2 and 5μM BP3. (Upper panel) - BG4 and S9.6 colocalization confocal images with DAPI 
(blue) masked as a nucleus. (Lower panel) – Only BG4 and S9.6 channel to show clear 
yellow foci indicating G-loops. (B and C) Quantification of nuclear BG4 foci in T47D and 
MCF-7 cells treated with control, E2 and BP-3.  **p=0.003 ***p=0.0003 ****p < 0.0001 
compared control with treatments using one-way analysis of variance (ANOVA) followed 
by Tukey's honestly significant difference (HSD) multiple-range test. Scale bar = 10 µM.  
All graphs show box plots with interquartile range and central line as median. 
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Figure 4.3 Evaluation of G4 formation in cells treated with E2, BP-3 and PDS with or 
without the presence of ROS scavenger (NAC).  
(A) Immunofluorescence of 1H6 foci in T47D cells treated with 10nM E2, 5μM BP3, 
10uM PDS, and 10mM NAC. (B) Quantification of nuclear 1H6 foci in T47D treated with 
control, E2, BP-3, PDS and NAC.  **p < 0.01   ****p < 0.0001 compared control with 
treatments using two-way analysis of variance (ANOVA) followed by Tukey's honestly 
significant difference (HSD) multiple-range test. Scale bar = 10 µM. All graphs show box 

















































































































































































Figure 4.4. Evaluation of γH2AX formation in cells treated with E2, BP-3 and PDS 
with or without the presence of ROS scavenger (NAC).  
(A) Immunofluorescence of γH2AX foci in MCF7 cells treated with 10nM E2, 5μM BP3, 
10uM PDS, and 10mM NAC. (B and C) Quantification of nuclear γH2AX foci in T47D 
and MCF7 cells treated with control, E2, BP-3, PDS and NAC.  **p < 0.01   ****p < 
0.0001 compared control with treatments using two-way analysis of variance (ANOVA) 
followed by Tukey's honestly significant difference (HSD) multiple-range test. Scale bar 























Figure 4.5. Mechanism of DNA damage induction by E2 and BP-3.  
E2 and BP-3 binds with the receptor and simulates G4 and R-loops formation 
simultaneously to form G-loops which is associated with DNA damage. E2 and BP-3 
induced G4 formation and DNA damage is mediated by ROS. PDS – a G4 ligand directly 















Adamovic, T., Roshani, L., Chen, L., Schaffer, B.S., Helou, K., Levan, G., Olsson, B., 
Shull, J.D., 2007. Nonrandom pattern of chromosome aberrations in 17β‐estradiol‐
induced rat mammary tumors: Indications of distinct pathways for tumor development. 
Genes Chromosomes Cancer 46, 459–469. https://doi.org/10.1002/gcc.20428 
Aguilera, A., García-Muse, T., 2012a. R Loops: From Transcription Byproducts to Threats 
to Genome Stability. Mol Cell 46, 115–124. 
https://doi.org/10.1016/j.molcel.2012.04.009 
Aguilera, A., García-Muse, T., 2012b. R Loops: From Transcription Byproducts to Threats 
to Genome Stability. Mol Cell 46, 115–124. 
https://doi.org/10.1016/j.molcel.2012.04.009 
Ahmed, S., Thomas, G., Ghoussaini, M., Healey, C.S., Humphreys, M.K., Platte, R., 
Morrison, J., Maranian, M., Pooley, K.A., Luben, R., Eccles, D., Evans, D.G., Fletcher, 
O., Johnson, N., Silva, I. dos S., Peto, J., Stratton, M.R., Rahman, N., Jacobs, K., 
Prentice, R., Anderson, G.L., Rajkovic, A., Curb, J.D., Ziegler, R.G., Berg, C.D., Buys, 
S.S., McCarty, C.A., Feigelson, H.S., Calle, E.E., Thun, M.J., Diver, W.R., Bojesen, S., 
Nordestgaard, B.G., Flyger, H., Dörk, T., Schürmann, P., Hillemanns, P., Karstens, J.H., 
Bogdanova, N.V., Antonenkova, N.N., Zalutsky, I.V., Bermisheva, M., Fedorova, S., 
Khusnutdinova, E., SEARCH, Kang, D., Yoo, K.-Y., Noh, D.Y., Ahn, S.-H., Devilee, 
P., Asperen, C.J. van, Tollenaar, R.A.E.M., Seynaeve, C., Garcia-Closas, M., 
Lissowska, J., Brinton, L., Peplonska, B., Nevanlinna, H., Heikkinen, T., Aittomäki, K., 
Blomqvist, C., Hopper, J.L., Southey, M.C., Smith, L., Spurdle, A.B., Schmidt, M.K., 
Broeks, A., Hien, R.R. van, Cornelissen, S., Milne, R.L., Ribas, G., González-Neira, 
A., Benitez, J., Schmutzler, R.K., Burwinkel, B., Bartram, C.R., Meindl, A., Brauch, 
H., Justenhoven, C., Hamann, U., Consortium, G., Chang-Claude, J., Hein, R., Wang-
Gohrke, S., Lindblom, A., Margolin, S., Mannermaa, A., Kosma, V.-M., Kataja, V., 
Olson, J.E., Wang, X., Fredericksen, Z., Giles, G.G., Severi, G., Baglietto, L., English, 
D.R., Hankinson, S.E., Cox, D.G., Kraft, P., Vatten, L.J., Hveem, K., Kumle, M., 
Sigurdson, A., Doody, M., Bhatti, P., Alexander, B.H., Hooning, M.J., Ouweland, 
A.M.W. van den, Oldenburg, R.A., Schutte, M., Hall, P., Czene, K., Liu, J., Li, Y., Cox, 
A., Elliott, G., Brock, I., Reed, M.W.R., Shen, C.-Y., Yu, J.-C., Hsu, G.-C., Chen, S.-
T., Anton-Culver, H., Ziogas, A., Andrulis, I.L., Knight, J.A., kConFab, Group, 
A.O.C.S., Beesley, J., Goode, E.L., Couch, F., Chenevix-Trench, G., Hoover, R.N., 
Ponder, B.A.J., Hunter, D.J., Pharoah, P.D.P., Dunning, A.M., Chanock, S.J., Easton, 
D.F., 2009. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. 




Albrektsen, G., Heuch, I., Hansen, S., Kvåle, G., 2005. Breast cancer risk by age at birth, 
time since birth and time intervals between births: exploring interaction effects. Brit J 
Cancer 92, 167–175. https://doi.org/10.1038/sj.bjc.6602302 
Anderson, E., Clarke, R.B., 2004. Steroid Receptors and Cell Cycle in Normal Mammary 
Epithelium. J Mammary Gland Biol 9, 3–13. 
https://doi.org/10.1023/b:jomg.0000023584.01750.16 
Aupperlee, M.D., Drolet, A.A., Durairaj, S., Wang, W., Schwartz, R.C., Haslam, S.Z., 
2008. Strain-Specific Differences in the Mechanisms of Progesterone Regulation of 
Murine Mammary Gland Development. Endocrinology 150, 1485–1494. 
https://doi.org/10.1210/en.2008-1459 
Azvolinsky, A., Giresi, P.G., Lieb, J.D., Zakian, V.A., 2009. Highly Transcribed RNA 
Polymerase II Genes Are Impediments to Replication Fork Progression in 
Saccharomyces cerevisiae. Mol Cell 34, 722–734. 
https://doi.org/10.1016/j.molcel.2009.05.022 
Bacolla, A., Tainer, J.A., Vasquez, K.M., Cooper, D.N., 2016. Translocation and deletion 
breakpoints in cancer genomes are associated with potential non-B DNA-forming 
sequences. Nucleic Acids Res 44, 5673–5688. https://doi.org/10.1093/nar/gkw261 
Bacolla, A., Ye, Z., Ahmed, Z., Tainer, J.A., 2019. Cancer mutational burden is shaped by 
G4 DNA, replication stress and mitochondrial dysfunction. Prog Biophysics Mol 
Biology 147, 47–61. https://doi.org/10.1016/j.pbiomolbio.2019.03.004 
Baldacci, G., Chérif-Zahar, B., Bernardi, G., 1984. The initiation of DNA replication in 
the mitochondrial genome of yeast. Embo J 3, 2115–2120. 
https://doi.org/10.1002/j.1460-2075.1984.tb02099.x 
Barroso, S., Herrera‐Moyano, E., Muñoz, S., García‐Rubio, M., Gómez‐González, B., 
Aguilera, A., 2019. The DNA damage response acts as a safeguard against harmful 
DNA–RNA hybrids of different origins. Embo Rep 20. 
https://doi.org/10.15252/embr.201847250 
Besnard, E., Babled, A., Lapasset, L., Milhavet, O., Parrinello, H., Dantec, C., Marin, J.-
M., Lemaitre, J.-M., 2012. Unraveling cell type–specific and reprogrammable human 
replication origin signatures associated with G-quadruplex consensus motifs. Nat Struct 
Mol Biol 19, 837–844. https://doi.org/10.1038/nsmb.2339 
Bhatia, V., Barroso, S.I., García-Rubio, M.L., Tumini, E., Herrera-Moyano, E., Aguilera, 
A., 2014. BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA 




Blackburn, A.C., Hill, L.Z., Roberts, A.L., Wang, J., Aud, D., Jung, J., Nikolcheva, T., 
Allard, J., Peltz, G., Otis, C.N., Cao, Q.J., Ricketts, R.St.J., Naber, S.P., Mollenhauer, 
J., Poustka, A., Malamud, D., Jerry, D.J., 2007. Genetic Mapping in Mice Identifies 
DMBT1 as a Candidate Modifier of Mammary Tumors and Breast Cancer Risk. Am J 
Pathology 170, 2030–2041. https://doi.org/10.2353/ajpath.2007.060512 
Blance, R.N., Sims, A.H., Anderson, E., Howell, A., Clarke, R.B., 2009. Normal Breast 
Tissue Implanted into Athymic Nude Mice Identifies Biomarkers of the Effects of 
Human Pregnancy Levels of Estrogen. Cancer Prev Res 2, 257–264. 
https://doi.org/10.1158/1940-6207.capr-08-0161 
Bocchinfuso, W.P., Korach, K.S., 1997. Mammary Gland Development and 
Tumorigenesis in Estrogen Receptor Knockout Mice. J Mammary Gland Biol 2, 323–
334. https://doi.org/10.1023/a:1026339111278 
Böhringer, M., Obermeier, K., Griner, N., Waldraff, D., Dickinson, E., Eirich, K., 
Schindler, D., Hagen, M., Jerry, D.J., Wiesmüller, L., 2013. siRNA screening identifies 
differences in the Fanconi anemia pathway in BALB/c-Trp53+/− with susceptibility 
versus C57BL/6-Trp53+/− mice with resistance to mammary tumors. Oncogene 32, 
5458–5470. https://doi.org/10.1038/onc.2013.38 
Boubakri, H., Septenville, A.L. de, Viguera, E., Michel, B., 2010. The helicases DinG, Rep 
and UvrD cooperate to promote replication across transcription units in vivo. Embo J 
29, 145–157. https://doi.org/10.1038/emboj.2009.308 
Brinton, L.A., Hoover, R., Fraumeni, J.F., 1983. Reproductive factors in the aetiology of 
breast cancer. Brit J Cancer 47, 757–762. https://doi.org/10.1038/bjc.1983.128 
Brinton, L.A., Schairer, C., Hoover, R.N., Fraumeni, J.F., 2009. Menstrual Factors and 
Risk of Breast Cancer. Cancer Invest 6, 245–254. 
https://doi.org/10.3109/07357908809080645 
Brooks, J.D., Sung, J.S., Pike, M.C., Orlow, I., Stanczyk, F.Z., Bernstein, J.L., Morris, 
E.A., 2018. MRI background parenchymal enhancement, breast density and serum 
hormones in postmenopausal women. Int J Cancer 143, 823–830. 
https://doi.org/10.1002/ijc.31370 
Burns, M.B., Lackey, L., Carpenter, M.A., Rathore, A., Land, A.M., Leonard, B., Refsland, 
E.W., Kotandeniya, D., Tretyakova, N., Nikas, J.B., Yee, D., Temiz, N.A., Donohue, 
D.E., McDougle, R.M., Brown, W.L., Law, E.K., Harris, R.S., 2013. APOBEC3B is an 
enzymatic source of mutation in breast cancer. Nature 494, 366–370. 
https://doi.org/10.1038/nature11881 
Buteau-Lozano, H., Ancelin, M., Lardeux, B., Milanini, J., Perrot-Applanat, M., 2002. 




tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha 
and beta. Cancer Res 62, 4977–84. 
Byford, J.R., Shaw, L.E., Drew, M.G.B., Pope, G.S., Sauer, M.J., Darbre, P.D., 2002. 
Oestrogenic activity of parabens in MCF7 human breast cancer cells. J Steroid Biochem 
Mol Biology 80, 49–60. https://doi.org/10.1016/s0960-0760(01)00174-1 
Calafat, A.M., Wong, L.-Y., Ye, X., Reidy, J.A., Needham, L.L., 2008. Concentrations of 
the Sunscreen Agent Benzophenone-3 in Residents of the United States: National 
Health and Nutrition Examination Survey 2003–2004. Environ Health Persp 116, 893–
897. https://doi.org/10.1289/ehp.11269 
Cavalieri, E.L., Rogan, E.G., 2016. Depurinating estrogen‐DNA adducts, generators of 
cancer initiation: their minimization leads to cancer prevention. Clin Transl Medicine 
5, 12. https://doi.org/10.1186/s40169-016-0088-3 
Cavalieri, E.L., Stack, D.E., Devanesan, P.D., Todorovic, R., Dwivedy, I., Higginbotham, 
S., Johansson, S.L., Patil, K.D., Gross, M.L., Gooden, J.K., Ramanathan, R., Cerny, 
R.L., Rogan, E.G., 1997. Molecular origin of cancer: Catechol estrogen-3,4-quinones 
as endogenous tumor initiators. Proc National Acad Sci 94, 10937–10942. 
https://doi.org/10.1073/pnas.94.20.10937 
Chambers, V.S., Marsico, G., Boutell, J.M., Antonio, M.D., Smith, G.P., Balasubramanian, 
S., 2015. High-throughput sequencing of DNA G-quadruplex structures in the human 
genome. Nat Biotechnol 33, 877–881. https://doi.org/10.1038/nbt.3295 
Chiang, H.-C., Zhang, X., Li, J., Zhao, X., Chen, J., Wang, H.T.-H., Jatoi, I., Brenner, A., 
Hu, Y., Li, R., 2019. BRCA1-associated R-loop affects transcription and differentiation 
in breast luminal epithelial cells. Nucleic Acids Res 47, 5086–5099. 
https://doi.org/10.1093/nar/gkz262 
Chiarle, R., Zhang, Y., Frock, R.L., Lewis, S.M., Molinie, B., Ho, Y.-J., Myers, D.R., Choi, 
V.W., Compagno, M., Malkin, D.J., Neuberg, D., Monti, S., Giallourakis, C.C., 
Gostissa, M., Alt, F.W., 2011. Genome-wide Translocation Sequencing Reveals 
Mechanisms of Chromosome Breaks and Rearrangements in B Cells. Cell 147, 107–
119. https://doi.org/10.1016/j.cell.2011.07.049 
Chie, W.-C., Hsieh, C., Newcomb, P.A., Longnecker, M.P., Mittendorf, R., Greenberg, 
E.R., Clapp, R.W., Burke, K.P., Titus-Ernstoff, L., Trentham-Dietz, A., MacMahon, B., 
2000. Age at Any Full-term Pregnancy and Breast Cancer Risk. Am J Epidemiol 151, 
715–722. https://doi.org/10.1093/oxfordjournals.aje.a010266 
Ciarloni, L., Mallepell, S., Brisken, C., 2007. Amphiregulin is an essential mediator of 
estrogen receptor α function in mammary gland development. Proc National Acad Sci 




Clarke, R.B., 2004. Complementary yet distinct roles for oestrogen receptor-α and 
oestrogen receptor-β in mouse mammary epithelial proliferation. Breast Cancer Res 6, 
135. https://doi.org/10.1186/bcr795 
Clarke, R.B., Howell, A., Potten, C.S., Anderson, E., 1997. Dissociation between steroid 
receptor expression and cell proliferation in the human breast. Cancer Res 57, 4987–91. 
Clemons, M., Goss, P., 2001. Estrogen and the Risk of Breast Cancer. New Engl J Med 
344, 276–285. https://doi.org/10.1056/nejm200101253440407 
Cogoi, S., Paramasivam, M., Membrino, A., Yokoyama, K.K., Xodo, L.E., 2010. The 
KRAS Promoter Responds to Myc-associated Zinc Finger and Poly(ADP-ribose) 
Polymerase 1 Proteins, Which Recognize a Critical Quadruplex-forming GA-element. 
J Biol Chem 285, 22003–22016. https://doi.org/10.1074/jbc.m110.101923 
Coutts, A.S., Murphy, L.C., 1998. Elevated mitogen-activated protein kinase activity in 
estrogen-nonresponsive human breast cancer cells. Cancer Res 58, 4071–4. 
Cummings, S.R., Eckert, S., Krueger, K.A., Grady, D., Powles, T.J., Cauley, J.A., Norton, 
L., Nickelsen, T., Bjarnason, N.H., Morrow, M., Lippman, M.E., Black, D., Glusman, 
J.E., Costa, A., Jordan, V.C., 1999. The Effect of Raloxifene on Risk of Breast Cancer 
in Postmenopausal Women. Jama 281, 2189. https://doi.org/10.1001/jama.281.23.2189 
Cuzick, J., Sestak, I., Bonanni, B., Costantino, J.P., Cummings, S., DeCensi, A., Dowsett, 
M., Forbes, J.F., Ford, L., LaCroix, A.Z., Mershon, J., Mitlak, B.H., Powles, T., 
Veronesi, U., Vogel, V., Wickerham, D.L., Group, for the S.C. of B.C.O., 2013. 
Selective oestrogen receptor modulators in prevention of breast cancer: an updated 
meta-analysis of individual participant data. Lancet 381, 1827–1834. 
https://doi.org/10.1016/s0140-6736(13)60140-3 
D’Alessandro, G., Whelan, D.R., Howard, S.M., Vitelli, V., Renaudin, X., Adamowicz, 
M., Iannelli, F., Jones-Weinert, C.W., Lee, M., Matti, V., Lee, W.T.C., Morten, M.J., 
Venkitaraman, A.R., Cejka, P., Rothenberg, E., Fagagna, F. d’Adda di, 2018. BRCA2 
controls DNA:RNA hybrid level at DSBs by mediating RNase H2 recruitment. Nat 
Commun 9, 5376. https://doi.org/10.1038/s41467-018-07799-2 
Dall, G.V., Britt, K.L., 2017. Estrogen Effects on the Mammary Gland in Early and Late 
Life and Breast Cancer Risk. Frontiers Oncol 7, 110. 
https://doi.org/10.3389/fonc.2017.00110 
Dennison, K.L., Samanas, N.B., Harenda, Q.E., Hickman, M.P., Seiler, N.L., Ding, L., 
Shull, J.D., 2015. Development and characterization of a novel rat model of estrogen-





Ding, L., Zhao, Y., Warren, C.L., Sullivan, R., Eliceiri, K.W., Shull, J.D., 2013. 
Association of cellular and molecular responses in the rat mammary gland to 17β-
estradiol with susceptibility to mammary cancer. Bmc Cancer 13, 573. 
https://doi.org/10.1186/1471-2407-13-573 
Dunphy, K.A., Black, A.L., Roberts, A.L., Sharma, A., Li, Z., Suresh, S., Browne, E.P., 
Arcaro, K.F., Ser-Dolansky, J., Bigelow, C., Troester, M.A., Schneider, S.S., Makari-
Judson, G., Crisi, G.M., Jerry, D.J., 2020. Inter-Individual Variation in Response to 
Estrogen in Human Breast Explants. J Mammary Gland Biol 1–18. 
https://doi.org/10.1007/s10911-020-09446-3 
Duquette, M.L., Handa, P., Vincent, J.A., Taylor, A.F., Maizels, N., 2004. Intracellular 
transcription of G-rich DNAs induces formation of G-loops, novel structures containing 
G4 DNA. Gene Dev 18, 1618–1629. https://doi.org/10.1101/gad.1200804 
Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D.P., Thompson, D., Ballinger, 
D.G., Struewing, J.P., Morrison, J., Field, H., Luben, R., Wareham, N., Ahmed, S., 
Healey, C.S., Bowman, R., Luccarini, C., Conroy, D., Shah, M., Munday, H., Jordan, 
C., Perkins, B., West, J., Redman, K., Driver, K., Meyer, K.B., Haiman, C.A., Kolonel, 
L.K., Henderson, B.E., Marchand, L.L., Brennan, P., Sangrajrang, S., Gaborieau, V., 
Odefrey, F., Shen, C.-Y., Wu, P.-E., Wang, H.-C., Eccles, D., Evans, D.G., Peto, J., 
Fletcher, O., Johnson, N., Seal, S., Stratton, M.R., Rahman, N., Chenevix-Trench, G., 
Bojesen, S.E., Nordestgaard, B.G., Axelsson, C.K., Garcia-Closas, M., Brinton, L., 
Chanock, S., Lissowska, J., Peplonska, B., Nevanlinna, H., Fagerholm, R., Eerola, H., 
Kang, D., Yoo, K.-Y., Noh, D.-Y., Ahn, S.-H., Hunter, D.J., Hankinson, S.E., Cox, 
D.G., Hall, P., Wedren, S., Liu, J., Low, Y.-L., Bogdanova, N., Schürmann, P., Dörk, 
T., Tollenaar, R.A.E.M., Jacobi, C.E., Devilee, P., Klijn, J.G.M., Sigurdson, A.J., 
Doody, M.M., Alexander, B.H., Zhang, J., Cox, A., Brock, I.W., MacPherson, G., Reed, 
M.W.R., Couch, F.J., Goode, E.L., Olson, J.E., Meijers-Heijboer, H., Ouweland, A. van 
den, Uitterlinden, A., Rivadeneira, F., Milne, R.L., Ribas, G., Gonzalez-Neira, A., 
Benitez, J., Hopper, J.L., McCredie, M., Southey, M., Giles, G.G., Schroen, C., 
Justenhoven, C., Brauch, H., Hamann, U., Ko, Y.-D., Spurdle, A.B., Beesley, J., Chen, 
X., Aghmesheh, M., Amor, D., Andrews, L., Antill, Y., Armes, J., Armitage, S., Arnold, 
L., Balleine, R., Begley, G., Beilby, J., Bennett, I., Bennett, B., Berry, G., Blackburn, 
A., Brennan, M., Brown, M., Buckley, M., Burke, J., Butow, P., Byron, K., Callen, D., 
Campbell, I., Chenevix-Trench, G., Clarke, C., Colley, A., Cotton, D., Cui, J., Culling, 
B., Cummings, M., Dawson, S.-J., Dixon, J., Dobrovic, A., Dudding, T., Edkins, T., 
Eisenbruch, M., Farshid, G., Fawcett, S., Field, M., Firgaira, F., Fleming, J., Forbes, J., 
Friedlander, M., Gaff, C., Gardner, M., Gattas, M., George, P., Giles, G., Gill, G., 
Goldblatt, J., Greening, S., Grist, S., Haan, E., Harris, M., Hart, S., Hayward, N., 
Hopper, J., Humphrey, E., Jenkins, M., Jones, A., Kefford, R., Kirk, J., Kollias, J., 
Kovalenko, S., Lakhani, S., Leary, J., Lim, J., Lindeman, G., Lipton, L., Lobb, L., 
Maclurcan, M., Mann, G., Marsh, D., McCredie, M., McKay, M., McLachlan, S.A., 
Meiser, B., Milne, R., Mitchell, G., Newman, B., O’Loughlin, I., Osborne, R., Peters, 




B., Rudzki, B., Salisbury, E., Sambrook, J., Saunders, C., Scott, C., Scott, E., Scott, R., 
Seshadri, R., Shelling, A., Southey, M., Spurdle, A., Suthers, G., Taylor, D., Tennant, 
C., Thorne, H., Townshend, S., Tucker, K., Tyler, J., Venter, D., Visvader, J., Walpole, 
I., Ward, R., Waring, P., Warner, B., Warren, G., Watson, E., Williams, R., Wilson, J., 
Winship, I., Young, M.A., Bowtell, D., Green, A., deFazio, A., Chenevix-Trench, G., 
Gertig, D., Webb, P., Mannermaa, A., Kosma, V.-M., Kataja, V., Hartikainen, J., Day, 
N.E., Cox, D.R., Ponder, B.A.J., 2007. Genome-wide association study identifies novel 
breast cancer susceptibility loci. Nature 447, 1087–1093. 
https://doi.org/10.1038/nature05887 
Eliassen, A.H., Missmer, S.A., Tworoger, S.S., Spiegelman, D., Barbieri, R.L., Dowsett, 
M., Hankinson, S.E., 2006. Endogenous Steroid Hormone Concentrations and Risk of 
Breast Cancer Among Premenopausal Women. Jnci J National Cancer Inst 98, 1406–
1415. https://doi.org/10.1093/jnci/djj376 
Felty, Q., Singh, K.P., Roy, D., 2005. Estrogen-induced G1/S transition of G0-arrested 
estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling. 
Oncogene 24, 4883–4893. https://doi.org/10.1038/sj.onc.1208667 
Fernandez, S.V., Russo, J., 2010. Estrogen and Xenoestrogens in Breast Cancer. Toxicol 
Pathol 38, 110–122. https://doi.org/10.1177/0192623309354108 
Fleming, A.M., Burrows, C.J., 2019. Interplay of Guanine Oxidation and G-Quadruplex 
Folding in Gene Promoters. J Am Chem Soc 142, 1115–1136. 
https://doi.org/10.1021/jacs.9b11050 
Fleming, A.M., Ding, Y., Burrows, C.J., 2017. Oxidative DNA damage is epigenetic by 
regulating gene transcription via base excision repair. Proc National Acad Sci 114, 
2604–2609. https://doi.org/10.1073/pnas.1619809114 
Fullwood, M.J., Liu, M.H., Pan, Y.F., Liu, J., Xu, H., Mohamed, Y.B., Orlov, Y.L., 
Velkov, S., Ho, A., Mei, P.H., Chew, E.G.Y., Huang, P.Y.H., Welboren, W.-J., Han, 
Y., Ooi, H.S., Ariyaratne, P.N., Vega, V.B., Luo, Y., Tan, P.Y., Choy, P.Y., Wansa, 
K.D.S.A., Zhao, B., Lim, K.S., Leow, S.C., Yow, J.S., Joseph, R., Li, H., Desai, K.V., 
Thomsen, J.S., Lee, Y.K., Karuturi, R.K.M., Herve, T., Bourque, G., Stunnenberg, 
H.G., Ruan, X., Cacheux-Rataboul, V., Sung, W.-K., Liu, E.T., Wei, C.-L., Cheung, E., 
Ruan, Y., 2009. An oestrogen-receptor-α-bound human chromatin interactome. Nature 
462, 58–64. https://doi.org/10.1038/nature08497 
Fussell, K.C., Udasin, R.G., Smith, P.J.S., Gallo, M.A., Laskin, J.D., 2011. Catechol 
metabolites of endogenous estrogens induce redox cycling and generate reactive oxygen 





García-Muse, T., Aguilera, A., 2019. R Loops: From Physiological to Pathological Roles. 
Cell 179, 604–618. https://doi.org/10.1016/j.cell.2019.08.055 
Gaub, M.-P., Bellard, M., Scheuer, I., Chambon, P., Sassone-Corsi, P., 1990. Activation of 
the ovalbumin gene by the estrogen receptor involves the Fos-Jun complex. Cell 63, 
1267–1276. https://doi.org/10.1016/0092-8674(90)90422-b 
Ghosh, A., Bansal, M., 2003. A glossary of DNA structures from A to Z. Acta Crystallogr 
Sect D Biological Crystallogr 59, 620–626. 
https://doi.org/10.1107/s0907444903003251 
Ginno, P.A., Lim, Y.W., Lott, P.L., Korf, I., Chédin, F., 2013. GC skew at the 5′ and 3′ 
ends of human genes links R-loop formation to epigenetic regulation and transcription 
termination. Genome Res 23, 1590–1600. https://doi.org/10.1101/gr.158436.113 
Ginno, P.A., Lott, P.L., Christensen, H.C., Korf, I., Chédin, F., 2012. R-Loop Formation 
Is a Distinctive Characteristic of Unmethylated Human CpG Island Promoters. Mol Cell 
45, 814–825. https://doi.org/10.1016/j.molcel.2012.01.017 
Girard, G.M., Vanzulli, S.I., Cerliani, J.P., Bottino, M.C., Bolado, J., Vela, J., Becu-
Villalobos, D., Benavides, F., Gutkind, S., Patel, V., Molinolo, A., Lanari, C., 2007. 
Association of estrogen receptor-α and progesterone receptor A expression with 
hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer 
Res 9, R22. https://doi.org/10.1186/bcr1660 
Gómez-González, B., Aguilera, A., 2007. Activation-induced cytidine deaminase action is 
strongly stimulated by mutations of the THO complex. Proc National Acad Sci 104, 
8409–8414. https://doi.org/10.1073/pnas.0702836104 
Gostissa, M., Alt, F.W., Chiarle, R., 2011. Mechanisms that Promote and Suppress 
Chromosomal Translocations in Lymphocytes. Immunology 29, 319–350. 
https://doi.org/10.1146/annurev-immunol-031210-101329 
Gottipati, P., Cassel, T.N., Savolainen, L., Helleday, T., 2008. Transcription-Associated 
Recombination Is Dependent on Replication in Mammalian Cells▿ †. Mol Cell Biol 
28, 154–164. https://doi.org/10.1128/mcb.00816-07 
Gould, K.A., Tochacek, M., Schaffer, B.S., Reindl, T.M., Murrin, C.R., Lachel, C.M., 
VanderWoude, E.A., Pennington, K.L., Flood, L.A., Bynote, K.K., Meza, J.L., Newton, 
M.A., Shull, J.D., 2004. Genetic Determination of Susceptibility to Estrogen-Induced 
Mammary Cancer in the ACI Rat Mapping of Emca1 and Emca2 to Chromosomes 5 
and 18. Genetics 168, 2113–2125. https://doi.org/10.1534/genetics.104.033878 
Gould, M.N., 1986. Inheritance and site of expression of genes controlling susceptibility 




Groh, M., Gromak, N., 2014. Out of Balance: R-loops in Human Disease. Plos Genet 10, 
e1004630. https://doi.org/10.1371/journal.pgen.1004630 
Haag, J.D., Shepel, L.A., Kolman, B.D., Monson, D.M., Benton, M.E., Watts, K.T., 
Waller, J.L., Lopez-Guajardo, C.C., Samuelson, D.J., Gould, M.N., 2003. Congenic rats 
reveal three independent Copenhagen alleles within the Mcs1 quantitative trait locus 
that confer resistance to mammary cancer. Cancer Res 63, 5808–12. 
Hänsel-Hertsch, R., Beraldi, D., Lensing, S.V., Marsico, G., Zyner, K., Parry, A., Antonio, 
M.D., Pike, J., Kimura, H., Narita, M., Tannahill, D., Balasubramanian, S., 2016. G-
quadruplex structures mark human regulatory chromatin. Nat Genet 48, 1267–1272. 
https://doi.org/10.1038/ng.3662 
Hänsel-Hertsch, R., Simeone, A., Shea, A., Hui, W.W.I., Zyner, K.G., Marsico, G., Rueda, 
O.M., Bruna, A., Martin, A., Zhang, X., Adhikari, S., Tannahill, D., Caldas, C., 
Balasubramanian, S., 2020. Landscape of G-quadruplex DNA structural regions in 
breast cancer. Nat Genet 52, 878–883. https://doi.org/10.1038/s41588-020-0672-8 
Harvell, D.M.E., Strecker, T.E., Tochacek, M., Xie, B., Pennington, K.L., McComb, R.D., 
Roy, S.K., Shull, J.D., 2000. Rat strain-specific actions of 17β-estradiol in the mammary 
gland: Correlation between estrogen-induced lobuloalveolar hyperplasia and 
susceptibility to estrogen-induced mammary cancers. Proc National Acad Sci 97, 2779–
2784. https://doi.org/10.1073/pnas.050569097 
Hatchi, E., Skourti-Stathaki, K., Ventz, S., Pinello, L., Yen, A., Kamieniarz-Gdula, K., 
Dimitrov, S., Pathania, S., McKinney, K.M., Eaton, M.L., Kellis, M., Hill, S.J., 
Parmigiani, G., Proudfoot, N.J., Livingston, D.M., 2015. BRCA1 Recruitment to 
Transcriptional Pause Sites Is Required for R-Loop-Driven DNA Damage Repair. Mol 
Cell 57, 636–647. https://doi.org/10.1016/j.molcel.2015.01.011 
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., 
Ström, A., Treuter, E., Warner, M., Gustafsson, J.-Å., 2007. Estrogen Receptors: How 
Do They Signal and What Are Their Targets. Physiol Rev 87, 905–931. 
https://doi.org/10.1152/physrev.00026.2006 
Henderson, B.E., Feigelson, H.S., 2000. Hormonal carcinogenesis. Carcinogenesis 21, 
427–433. https://doi.org/10.1093/carcin/21.3.427 
Hoshina, S., Yura, K., Teranishi, H., Kiyasu, N., Tominaga, A., Kadoma, H., Nakatsuka, 
A., Kunichika, T., Obuse, C., Waga, S., 2013. Human Origin Recognition Complex 
Binds Preferentially to G-quadruplex-preferable RNA and Single-stranded DNA. J Biol 




Hu, X., Jiang, L., Tang, C., Ju, Y., Jiu, L., Wei, Y., Guo, L., Zhao, Y., 2017. Association 
of three single nucleotide polymorphisms of ESR1 with breast cancer susceptibility: a 
meta-analysis. J Biomed Res 31, 213–225. https://doi.org/10.7555/jbr.31.20160087 
Hunter, D.J., Kraft, P., Jacobs, K.B., Cox, D.G., Yeager, M., Hankinson, S.E., Wacholder, 
S., Wang, Z., Welch, R., Hutchinson, A., Wang, J., Yu, K., Chatterjee, N., Orr, N., 
Willett, W.C., Colditz, G.A., Ziegler, R.G., Berg, C.D., Buys, S.S., McCarty, C.A., 
Feigelson, H.S., Calle, E.E., Thun, M.J., Hayes, R.B., Tucker, M., Gerhard, D.S., 
Fraumeni, J.F., Hoover, R.N., Thomas, G., Chanock, S.J., 2007. A genome-wide 
association study identifies alleles in FGFR2 associated with risk of sporadic 
postmenopausal breast cancer. Nat Genet 39, 870–874. https://doi.org/10.1038/ng2075 
Huppert, J.L., Balasubramanian, S., 2005. Prevalence of quadruplexes in the human 
genome. Nucleic Acids Res 33, 2908–2916. https://doi.org/10.1093/nar/gki609 
Itoh, T., Tomizawa, J., 1980. Formation of an RNA primer for initiation of replication of 
ColE1 DNA by ribonuclease H. Proc National Acad Sci 77, 2450–2454. 
https://doi.org/10.1073/pnas.77.5.2450 
Itou, J., Takahashi, R., Sasanuma, H., Tsuda, M., Morimoto, S., Matsumoto, Y., Ishii, T., 
Sato, F., Takeda, S., Toi, M., 2020. Estrogen induces mammary ductal dysplasia via the 
upregulation of Myc expression in a DNA-repair deficient condition. Iscience 23, 
100821. https://doi.org/10.1016/j.isci.2020.100821 
Jerry, D.J., Shull, J.D., Hadsell, D.L., Rijnkels, M., Dunphy, K.A., Schneider, S.S., 
Vandenberg, L.N., Majhi, P.D., Byrne, C., Trentham-Dietz, A., 2018. Genetic variation 
in sensitivity to estrogens and breast cancer risk. Mamm Genome 29, 24–37. 
https://doi.org/10.1007/s00335-018-9741-z 
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., Charpentier, E., 2012. A 
Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial 
Immunity. Science 337, 816–821. https://doi.org/10.1126/science.1225829 
Ju, B.-G., Lunyak, V.V., Perissi, V., Garcia-Bassets, I., Rose, D.W., Glass, C.K., 
Rosenfeld, M.G., 2006. A Topoisomerase IIß-Mediated dsDNA Break Required for 
Regulated Transcription. Science 312, 1798–1802. 
https://doi.org/10.1126/science.1127196 
Kanoh, Y., Matsumoto, S., Fukatsu, R., Kakusho, N., Kono, N., Renard-Guillet, C., 
Masuda, K., Iida, K., Nagasawa, K., Shirahige, K., Masai, H., 2015. Rif1 binds to G 
quadruplexes and suppresses replication over long distances. Nat Struct Mol Biol 22, 
889–897. https://doi.org/10.1038/nsmb.3102 
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., 




the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase. 
Science 270, 1491–1494. https://doi.org/10.1126/science.270.5241.1491 
Keimling, M., Deniz, M., Varga, D., Stahl, A., Schrezenmeier, H., Kreienberg, R., 
Hoffmann, I., König, J., Wiesmüller, L., 2012. The power of DNA double‐strand break 
(DSB) repair testing to predict breast cancer susceptibility. Faseb J 26, 2094–2104. 
https://doi.org/10.1096/fj.11-200790 
Kerdivel, G., Guevel, R.L., Habauzit, D., Brion, F., Ait-Aissa, S., Pakdel, F., 2013. 
Estrogenic Potency of Benzophenone UV Filters in Breast Cancer Cells: Proliferative 
and Transcriptional Activity Substantiated by Docking Analysis. Plos One 8, e60567. 
https://doi.org/10.1371/journal.pone.0060567 
Kordon, E.C., Molinolo, A.A., Pasqualini, C.D., Charreau, E.H., Pazos, P., Dran, G., 
Lanari, C., 1993. Progesterone induction of mammary carcinomas in BALB/c female 
mice. Breast Cancer Res Tr 28, 29–39. https://doi.org/10.1007/bf00666353 
Kotsantis, P., Segura-Bayona, S., Margalef, P., Marzec, P., Ruis, P., Hewitt, G., Bellelli, 
R., Patel, H., Goldstone, R., Poetsch, A.R., Boulton, S.J., 2020. RTEL1 Regulates 
G4/R-Loops to Avert Replication-Transcription Collisions. Cell Reports 33, 108546. 
https://doi.org/10.1016/j.celrep.2020.108546 
Krege, J.H., Hodgin, J.B., Couse, J.F., Enmark, E., Warner, M., Mahler, J.F., Sar, M., 
Korach, K.S., Gustafsson, J.-Å., Smithies, O., 1998. Generation and reproductive 
phenotypes of mice lacking estrogen receptor β. Proc National Acad Sci 95, 15677–
15682. https://doi.org/10.1073/pnas.95.26.15677 
Kreuzer, K.N., Brister, J.R., 2010. Initiation of bacteriophage T4 DNA replication and 
replication fork dynamics: a review in the Virology Journal series on bacteriophage T4 
and its relatives. Virol J 7, 358. https://doi.org/10.1186/1743-422x-7-358 
Kuperwasser, C., Hurlbut, G.D., Kittrell, F.S., Dickinson, E.S., Laucirica, R., Medina, D., 
Naber, S.P., Jerry, D.J., 2000. Development of Spontaneous Mammary Tumors in 
BALB/c p53 Heterozygous Mice. Am J Pathology 157, 2151–2159. 
https://doi.org/10.1016/s0002-9440(10)64853-5 
Kwok, C.K., Merrick, C.J., 2017. G-Quadruplexes: Prediction, Characterization, and 
Biological Application. Trends Biotechnol 35, 997–1013. 
https://doi.org/10.1016/j.tibtech.2017.06.012 
Lago, S., Nadai, M., Cernilogar, F.M., Kazerani, M., Moreno, H.D., Schotta, G., Richter, 
S.N., 2021. Promoter G-quadruplexes and transcription factors cooperate to shape the 





Lan, H., Kendziorski, C.M., Haag, J.D., Shepel, L.A., Gould, M.A.N. and M.N., 2001. 
Genetic Loci Controlling Breast Cancer Susceptibility in the Wistar-Kyoto Rat. 
Lanari, C., Molinolo, A.A., Pasqualini, C.D., 1986. Induction of mammary 
adenocarcinomas by medroxyprogesterone acetate in BALBc female mice. Cancer Lett 
33, 215–223. https://doi.org/10.1016/0304-3835(86)90027-3 
Langley, A.R., Gräf, S., Smith, J.C., Krude, T., 2016. Genome-wide identification and 
characterisation of human DNA replication origins by initiation site sequencing (ini-
seq). Nucleic Acids Res 44, 10230–10247. https://doi.org/10.1093/nar/gkw760 
LaPlante, C.D., Bansal, R., Dunphy, K.A., Jerry, D.J., Vandenberg, L.N., 2018. 
Oxybenzone alters mammary gland morphology in mice exposed during pregnancy and 
lactation. J Endocr Soc 2, js.2018-00024-. https://doi.org/10.1210/js.2018-00024 
Lee, C.-Y., McNerney, C., Ma, K., Zhao, W., Wang, A., Myong, S., 2020. R-loop induced 
G-quadruplex in non-template promotes transcription by successive R-loop formation. 
Nat Commun 11, 3392. https://doi.org/10.1038/s41467-020-17176-7 
Lejault, P., Mitteaux, J., Sperti, F.R., Monchaud, D., 2021. How to untie G-quadruplex 
knots and why? Cell Chem Biol. https://doi.org/10.1016/j.chembiol.2021.01.015 
Levin, E.R., 2009. Plasma membrane estrogen receptors. Trends Endocrinol Metabolism 
20, 477–482. https://doi.org/10.1016/j.tem.2009.06.009 
Li, S., Weroha, S., Tawfik, O., Li, J., 2002. Prevention of solely estrogen-induced 
mammary tumors in female aci rats by tamoxifen: evidence for estrogen receptor 
mediation. J Endocrinol 175, 297–305. https://doi.org/10.1677/joe.0.1750297 
Lin, C.-Y., Vega, V.B., Thomsen, J.S., Zhang, T., Kong, S.L., Xie, M., Chiu, K.P., 
Lipovich, L., Barnett, D.H., Stossi, F., Yeo, A., George, J., Kuznetsov, V.A., Lee, Y.K., 
Charn, T.H., Palanisamy, N., Miller, L.D., Cheung, E., Katzenellenbogen, B.S., Ruan, 
Y., Bourque, G., Wei, C.-L., Liu, E.T., 2007. Whole-Genome Cartography of Estrogen 
Receptor α Binding Sites. Plos Genet 3, e87. 
https://doi.org/10.1371/journal.pgen.0030087 
Lipphardt, M.F., Deryal, M., Ong, M.F., Schmidt, W., Mahlknecht, U., 2013. ESR1 single 
nucleotide polymorphisms predict breast cancer susceptibility in the central European 
Caucasian population. Int J Clin Exp Med 6, 282–8. 
MacMahon, B., Cole, P., Lin, T.M., Lowe, C.R., Mirra, A.P., Ravnihar, B., Salber, E.J., 
Valaoras, V.G., Yuasa, S., 1970. Age at first birth and breast cancer risk. B World 




MacMillan, A.L., Kohli, R.M., Ross, S.R., 2013. APOBEC3 Inhibition of Mouse 
Mammary Tumor Virus Infection: the Role of Cytidine Deamination versus Inhibition 
of Reverse Transcription. J Virol 87, 4808–4817. https://doi.org/10.1128/jvi.00112-13 
Madireddy, A., Kosiyatrakul, S.T., Boisvert, R.A., Herrera-Moyano, E., García-Rubio, 
M.L., Gerhardt, J., Vuono, E.A., Owen, N., Yan, Z., Olson, S., Aguilera, A., Howlett, 
N.G., Schildkraut, C.L., 2016. FANCD2 Facilitates Replication through Common 
Fragile Sites. Mol Cell 64, 388–404. https://doi.org/10.1016/j.molcel.2016.09.017 
Magis, A.D., Manzo, S.G., Russo, M., Marinello, J., Morigi, R., Sordet, O., Capranico, G., 
2018. DNA damage and genome instability by G-quadruplex ligands are mediated by 
R loops in human cancer cells. Proc National Acad Sci 116, 201810409. 
https://doi.org/10.1073/pnas.1810409116 
Maizels, N., 2015. G4‐associated human diseases. Embo Rep 16, 910–922. 
https://doi.org/10.15252/embr.201540607 
Maizels, N., 2006. Dynamic roles for G4 DNA in the biology of eukaryotic cells. Nat Struct 
Mol Biol 13, 1055–1059. https://doi.org/10.1038/nsmb1171 
Maizels, N., Gray, L.T., 2013. The G4 Genome. Plos Genet 9, e1003468. 
https://doi.org/10.1371/journal.pgen.1003468 
Majewski, A.R., Chuong, L.M., Neill, H.M., Roberts, A.L., Jerry, D.J., Dunphy, K.A., 
2018. Sterilization of Silastic Capsules Containing 17β-Estradiol for Effective Hormone 
Delivery in Mus musculus. J Am Assoc Lab Anim. https://doi.org/10.30802/aalas-
jaalas-18-000030 
Majhi, P.D., Sharma, A., Roberts, A.L., Daniele, E., Majewski, A.R., Chuong, L.M., Black, 
A.L., Vandenberg, L.N., Schneider, S.S., Dunphy, K.A., Jerry, D.J., 2020. Effects of 
Benzophenone-3 and Propylparaben on Estrogen Receptor–Dependent R-Loops and 
DNA Damage in Breast Epithelial Cells and Mice. Environ Health Persp 128, 017002. 
https://doi.org/10.1289/ehp5221 
Maleki, J., Nourbakhsh, M., Shabani, M., Korani, M., Nourazarian, S.M., Dahaghi, 
M.R.O., Moghadasi, M.H., 2015. 17β-Estradiol Stimulates Generation of Reactive 
Species Oxygen and Nitric Oxide in Ovarian Adenocarcinoma Cells (OVCAR 3). 
Iranian J Cancer Prev 8, e2332. https://doi.org/10.17795/ijcp2332 
Manavathi, B., Dey, O., Gajulapalli, V.N.R., Bhatia, R.S., Bugide, S., Kumar, R., 2013. 
Derailed Estrogen Signaling and Breast Cancer: An Authentic Couple. Endocr Rev 34, 
1–32. https://doi.org/10.1210/er.2011-1057 
Mao, S.-Q., Ghanbarian, A.T., Spiegel, J., Cuesta, S.M., Beraldi, D., Antonio, M.D., 




quadruplex structures mold the DNA methylome. Nat Struct Mol Biol 25, 951–957. 
https://doi.org/10.1038/s41594-018-0131-8 
Marino, M., Galluzzo, P., Ascenzi, P., 2006. Estrogen signaling multiple pathways to 
impact gene transcription. Curr Genomics 7, 497–508. 
https://doi.org/10.2174/138920206779315737 
Martino, S., Cauley, J.A., Barrett-Connor, E., Powles, T.J., Mershon, J., Disch, D., Secrest, 
R.J., Cummings, S.R., Investigators, F. the C., 2004. Continuing Outcomes Relevant to 
Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a 
Randomized Trial of Raloxifene. Jnci J National Cancer Inst 96, 1751–1761. 
https://doi.org/10.1093/jnci/djh319 
Metcalfe, K., Lynch, H.T., Foulkes, W.D., Tung, N., Olopade, O.I., Eisen, A., Lerner-Ellis, 
J., Snyder, C., Kim, S.J., Sun, P., Narod, S.A., 2019. Oestrogen receptor status and 
survival in women with BRCA2-associated breast cancer. Brit J Cancer 120, 398–403. 
https://doi.org/10.1038/s41416-019-0376-y 
Mobley, J.A., Brueggemeier, R.W., 2004. Estrogen receptor-mediated regulation of 
oxidative stress and DNA damage in breast cancer. Carcinogenesis 25, 3–9. 
https://doi.org/10.1093/carcin/bgg175 
Molinolo, A.A., Lanari, C., Charreau, E.H., Sanjuan, N., Pasqualini, C.D., 1987. Mouse 
mammary tumors induced by medroxyprogesterone acetate: immunohistochemistry and 
hormonal receptors. J Natl Cancer I 79, 1341–50. 
Möller, S., Mucci, L.A., Harris, J.R., Scheike, T., Holst, K., Halekoh, U., Adami, H.-O., 
Czene, K., Christensen, K., Holm, N.V., Pukkala, E., Skytthe, A., Kaprio, J., Hjelmborg, 
J.B., 2016. The Heritability of Breast Cancer among Women in the Nordic Twin Study 
of Cancer. Cancer Epidemiology Prev Biomarkers 25, 145–150. 
https://doi.org/10.1158/1055-9965.epi-15-0913 
Mucci, L.A., Hjelmborg, J.B., Harris, J.R., Czene, K., Havelick, D.J., Scheike, T., Graff, 
R.E., Holst, K., Möller, S., Unger, R.H., McIntosh, C., Nuttall, E., Brandt, I., Penney, 
K.L., Hartman, M., Kraft, P., Parmigiani, G., Christensen, K., Koskenvuo, M., Holm, 
N.V., Heikkilä, K., Pukkala, E., Skytthe, A., Adami, H.-O., Kaprio, J., Collaboration, 
N.T.S. of C. (NorTwinCan), 2016. Familial Risk and Heritability of Cancer Among 
Twins in Nordic Countries. Jama 315, 68–76. https://doi.org/10.1001/jama.2015.17703 
Ohle, C., Tesorero, R., Schermann, G., Dobrev, N., Sinning, I., Fischer, T., 2016. Transient 
RNA-DNA Hybrids Are Required for Efficient Double-Strand Break Repair. Cell 167, 
1001-1013.e7. https://doi.org/10.1016/j.cell.2016.10.001 
Okamoto, Y., Abe, M., Itaya, A., Tomida, J., Ishiai, M., Takaori‐Kondo, A., Taoka, M., 




processing enzymes to resolve R‐loops during mild replication stress. Febs J 286, 139–
150. https://doi.org/10.1111/febs.14700 
Okeoma, C.M., Petersen, J., Ross, S.R., 2009. Expression of Murine APOBEC3 Alleles in 
Different Mouse Strains and Their Effect on Mouse Mammary Tumor Virus Infection▿ 
†. J Virol 83, 3029–3038. https://doi.org/10.1128/jvi.02536-08 
Okoh, V., Deoraj, A., Roy, D., 2011. Estrogen-induced reactive oxygen species-mediated 
signalings contribute to breast cancer. Biochimica Et Biophysica Acta Bba - Rev Cancer 
1815, 115–133. https://doi.org/10.1016/j.bbcan.2010.10.005 
Paeschke, K., Bochman, M.L., Garcia, P.D., Cejka, P., Friedman, K.L., Kowalczykowski, 
S.C., Zakian, V.A., 2013. Pif1 family helicases suppress genome instability at G-
quadruplex motifs. Nature 497, 458–462. https://doi.org/10.1038/nature12149 
Palaniappan, M., Nguyen, L., Grimm, S.L., Xi, Y., Xia, Z., Li, W., Coarfa, C., 2019. The 
genomic landscape of estrogen receptor α binding sites in mouse mammary gland. Plos 
One 14, e0220311. https://doi.org/10.1371/journal.pone.0220311 
Pavri, R., 2017. R Loops in the Regulation of Antibody Gene Diversification. Genes-basel 
8, 154. https://doi.org/10.3390/genes8060154 
Pedram, A., Razandi, M., Kim, J.K., O’Mahony, F., Lee, E.Y., Luderer, U., Levin, E.R., 
2009. Developmental Phenotype of a Membrane Only Estrogen Receptor α (MOER) 
Mouse*. J Biol Chem 284, 3488–3495. https://doi.org/10.1074/jbc.m806249200 
Periyasamy, M., Patel, H., Lai, C.-F., Nguyen, V.T.M., Nevedomskaya, E., Harrod, A., 
Russell, R., Remenyi, J., Ochocka, A.M., Thomas, R.S., Fuller-Pace, F., Győrffy, B., 
Caldas, C., Navaratnam, N., Carroll, J.S., Zwart, W., Coombes, R.C., Magnani, L., 
Buluwela, L., Ali, S., 2015. APOBEC3B-Mediated Cytidine Deamination Is Required 
for Estrogen Receptor Action in Breast Cancer. Cell Reports 13, 108–121. 
https://doi.org/10.1016/j.celrep.2015.08.066 
Pohjoismäki, J.L.O., Holmes, J.B., Wood, S.R., Yang, M.-Y., Yasukawa, T., Reyes, A., 
Bailey, L.J., Cluett, T.J., Goffart, S., Willcox, S., Rigby, R.E., Jackson, A.P., Spelbrink, 
J.N., Griffith, J.D., Crouch, R.J., Jacobs, H.T., Holt, I.J., 2010. Mammalian 
Mitochondrial DNA Replication Intermediates Are Essentially Duplex but Contain 
Extensive Tracts of RNA/DNA Hybrid. J Mol Biol 397, 1144–1155. 
https://doi.org/10.1016/j.jmb.2010.02.029 
Ponnaiya, B., Cornforth, M.N., Ullrich, R.L., 1997. Radiation-induced chromosomal 
instability in BALB/c and C57BL/6 mice: the difference is as clear as black and white. 




Prado, F., Aguilera, A., 2005. Impairment of replication fork progression mediates RNA 
polII transcription‐associated recombination. Embo J 24, 1267–1276. 
https://doi.org/10.1038/sj.emboj.7600602 
Preston-Martin, S., Pike, M.C., Ross, R.K., Jones, P.A., Henderson, B.E., 1990. Increased 
cell division as a cause of human cancer. Cancer Res 50, 7415–21. 
Puget, N., Miller, K., Legube, G., 2019. Non-canonical DNA/RNA structures during 
Transcription-Coupled Double-Strand Break Repair: Roadblocks or Bona fide repair 
intermediates? Dna Repair 81, 102661. https://doi.org/10.1016/j.dnarep.2019.102661 
Qiao, Q., Wang, L., Meng, F.-L., Hwang, J.K., Alt, F.W., Wu, H., 2017. AID Recognizes 
Structured DNA for Class Switch Recombination. Mol Cell 67, 361-373.e4. 
https://doi.org/10.1016/j.molcel.2017.06.034 
Reaban, M.E., Lebowitz, J., Griffin, J.A., 1994. Transcription induces the formation of a 
stable RNA.DNA hybrid in the immunoglobulin alpha switch region. J Biological Chem 
269, 21850–7. 
Rhodes, D., Lipps, H.J., 2015. G-quadruplexes and their regulatory roles in biology. 
Nucleic Acids Res 43, 8627–8637. https://doi.org/10.1093/nar/gkv862 
Ribeyre, C., Lopes, J., Boulé, J.-B., Piazza, A., Guédin, A., Zakian, V.A., Mergny, J.-L., 
Nicolas, A., 2009. The Yeast Pif1 Helicase Prevents Genomic Instability Caused by G-
Quadruplex-Forming CEB1 Sequences In Vivo. Plos Genet 5, e1000475. 
https://doi.org/10.1371/journal.pgen.1000475 
Richard, P., Manley, J.L., 2017. R Loops and Links to Human Disease. J Mol Biol 429, 
3168–3180. https://doi.org/10.1016/j.jmb.2016.08.031 
Rossouw, J.E., Anderson, G.L., Prentice, R.L., LaCroix, A.Z., Kooperberg, C., Stefanick, 
M.L., Jackson, R.D., Beresford, S.A., Howard, B.V., Johnson, K.C., al., et, 2002. Risks 
and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal 
Results From the Women’s Health Initiative Randomized Controlled Trial. Jama 288, 
321–333. https://doi.org/10.1001/jama.288.3.321 
Roy, D., Cai, Q., Felty, Q., Narayan, S., 2007. Estrogen-Induced Generation of Reactive 
Oxygen and Nitrogen Species, Gene Damage, and Estrogen-Dependent Cancers. J 
Toxicol Environ Heal Part B 10, 235–257. 
https://doi.org/10.1080/15287390600974924 
Roy, D., Liehr, J.G., 1999. Estrogen, DNA damage and mutations. Mutat Res Fundam Mol 




Roychoudhury, S., Pramanik, S., Harris, H.L., Tarpley, M., Sarkar, A., Spagnol, G., 
Sorgen, P.L., Chowdhury, D., Band, V., Klinkebiel, D., Bhakat, K.K., 2020. 
Endogenous oxidized DNA bases and APE1 regulate the formation of G-quadruplex 
structures in the genome. Proc National Acad Sci 201912355. 
https://doi.org/10.1073/pnas.1912355117 
Rudolph, A., Chang-Claude, J., Schmidt, M.K., 2016. Gene–environment interaction and 
risk of breast cancer. Brit J Cancer 114, 125–133. https://doi.org/10.1038/bjc.2015.439 
Russo, J., Ao, X., Grill, C., Russo, I.H., 1999. Pattern of distribution of cells positive for 
estrogen receptor α and progesterone receptor in relation to proliferating cells in the 
mammary gland. Breast Cancer Res Tr 53, 217–227. 
https://doi.org/10.1023/a:1006186719322 
Russo, J., Russo, I.H., 2006. The role of estrogen in the initiation of breast cancer. J Steroid 
Biochem Mol Biology 102, 89–96. https://doi.org/10.1016/j.jsbmb.2006.09.004 
Samavat, H., Kurzer, M.S., 2015. Estrogen metabolism and breast cancer. Cancer Lett 356, 
231–243. https://doi.org/10.1016/j.canlet.2014.04.018 
Santen, R., Cavalieri, E., Rogan, E., Russo, J., Guttenplan, J., Ingle, J., Yue, W., 2009. 
Estrogen Mediation of Breast Tumor Formation Involves Estrogen Receptor‐
Dependent, as Well as Independent, Genotoxic Effects. Ann Ny Acad Sci 1155, 132–
140. https://doi.org/10.1111/j.1749-6632.2008.03685.x 
Sasanuma, H., Tsuda, M., Morimoto, S., Saha, L.K., Rahman, M.M., Kiyooka, Y., Fujiike, 
H., Cherniack, A.D., Itou, J., Moreu, E.C., Toi, M., Nakada, S., Tanaka, H., Tsutsui, K., 
Yamada, S., Nussenzweig, A., Takeda, S., 2018. BRCA1 ensures genome integrity by 
eliminating estrogen-induced pathological topoisomerase II–DNA complexes. Proc 
National Acad Sci 115, 201803177. https://doi.org/10.1073/pnas.1803177115 
Sauer, M., Paeschke, K., 2017. G-quadruplex unwinding helicases and their function in 
vivo. Biochem Soc T 45, 1173–1182. https://doi.org/10.1042/bst20170097 
Saville, B., Wormke, M., Wang, F., Nguyen, T., Enmark, E., Kuiper, G., Gustafsson, J.A., 
Safe, S., 2000. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent 
activation at GC-rich (Sp1) promoter elements. J Biological Chem 275, 5379–87. 
https://doi.org/10.1074/jbc.275.8.5379 
Schaffer, B.S., Lachel, C.M., Pennington, K.L., Murrin, C.R., Strecker, T.E., Tochacek, 
M., Gould, K.A., Meza, J.L., McComb, R.D., Shull, J.D., 2006. Genetic Bases of 
Estrogen-Induced Tumorigenesis in the Rat: Mapping of Loci Controlling 
Susceptibility to Mammary Cancer in a Brown Norway × ACI Intercross. Cancer Res 




Schlotz, N., Kim, G.-J., Jäger, S., Günther, S., Lamy, E., 2017. In vitro observations and 
in silico predictions of xenoestrogen mixture effects in T47D-based receptor 
transactivation and proliferation assays. Toxicol In Vitro 45, 146–157. 
https://doi.org/10.1016/j.tiv.2017.08.017 
Schlumpf, M., Kypke, K., Wittassek, M., Angerer, J., Mascher, H., Mascher, D., Vökt, C., 
Birchler, M., Lichtensteiger, W., 2010. Exposure patterns of UV filters, fragrances, 
parabens, phthalates, organochlor pesticides, PBDEs, and PCBs in human milk: 
Correlation of UV filters with use of cosmetics. Chemosphere 81, 1171–1183. 
https://doi.org/10.1016/j.chemosphere.2010.09.079 
Schwab, R.A., Nieminuszczy, J., Shah, F., Langton, J., Lopez Martinez, D., Liang, C.-C., 
Cohn, M.A., Gibbons, R.J., Deans, A.J., Niedzwiedz, W., 2015. The Fanconi Anemia 
Pathway Maintains Genome Stability by Coordinating Replication and Transcription. 
Mol Cell 60, 351–361. https://doi.org/10.1016/j.molcel.2015.09.012 
Sessa, G., Gómez‐González, B., Silva, S., Pérez‐Calero, C., Beaurepere, R., Barroso, S., 
Martineau, S., Martin, C., Ehlén, Å., Martínez, J.S., Lombard, B., Loew, D., Vagner, 
S., Aguilera, A., Carreira, A., 2021. BRCA2 promotes R‐loop resolution by DDX5 
helicase at DNA breaks to facilitate their repair by homologous recombination. Embo J 
e106018. https://doi.org/10.15252/embj.2020106018 
Sharma, S., 2011. Non-B DNA Secondary Structures and Their Resolution by RecQ 
Helicases. J Nucleic Acids 2011, 724215. https://doi.org/10.4061/2011/724215 
Shim, W.-S., Conaway, M., Masamura, S., Yue, W., Wang, J.-P., Kumar, R., Santen, R.J., 
2000. Estradiol Hypersensitivity and Mitogen-Activated Protein Kinase Expression in 
Long-Term Estrogen Deprived Human Breast Cancer Cells in Vivo 1. Endocrinology 
141, 396–405. https://doi.org/10.1210/endo.141.1.7270 
Shivji, M.K.K., Renaudin, X., Williams, Ç.H., Venkitaraman, A.R., 2018. BRCA2 
Regulates Transcription Elongation by RNA Polymerase II to Prevent R-Loop 
Accumulation. Cell Reports 22, 1031–1039. 
https://doi.org/10.1016/j.celrep.2017.12.086 
Shull, J.D., Dennison, K.L., Chack, A.C., Trentham-Dietz, A., 2018. Rat models of 17β-
estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and 
prevention. Physiol Genomics 50, 215–234. 
https://doi.org/10.1152/physiolgenomics.00105.2017 
Shull, J.D., Spady, T.J., Snyder, M.C., Johansson, S.L., Pennington, K.L., 1997. Ovary-
intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly 





Siegel, R.L., Miller, K.D., Fuchs, H.E., Jemal, A., 2021. Cancer Statistics, 2021. Ca Cancer 
J Clin 71, 7–33. https://doi.org/10.3322/caac.21654 
Silva, B., Pentz, R., Figueira, A.M., Arora, R., Lee, Y.W., Hodson, C., Wischnewski, H., 
Deans, A.J., Azzalin, C.M., 2019. FANCM limits ALT activity by restricting telomeric 
replication stress induced by deregulated BLM and R-loops. Nat Commun 10, 2253. 
https://doi.org/10.1038/s41467-019-10179-z 
Singh, B., Bhat, N.K., Bhat, H.K., 2011. Partial Inhibition of Estrogen-Induced Mammary 
Carcinogenesis in Rats by Tamoxifen: Balance between Oxidant Stress and Estrogen 
Responsiveness. Plos One 6, e25125. https://doi.org/10.1371/journal.pone.0025125 
Singleton, D.W., Khan, S.A., 2003. Xenoestrogen exposure and mechanisms of endocrine 
disruption. Front Biosci 8, s110-118. https://doi.org/10.2741/1010 
Skourti-Stathaki, K., Proudfoot, N.J., 2014. A double-edged sword: R loops as threats to 
genome integrity and powerful regulators of gene expression. Gene Dev 28, 1384–1396. 
https://doi.org/10.1101/gad.242990.114 
Smith, J.S., Chen, Q., Yatsunyk, L.A., Nicoludis, J.M., Garcia, M.S., Kranaster, R., 
Balasubramanian, S., Monchaud, D., Teulade-Fichou, M.-P., Abramowitz, L., Schultz, 
D.C., Johnson, F.B., 2011. Rudimentary G-quadruplex–based telomere capping in 
Saccharomyces cerevisiae. Nat Struct Mol Biol 18, 478–485. 
https://doi.org/10.1038/nsmb.2033 
Sollier, J., Cimprich, K.A., 2015. Breaking bad: R-loops and genome integrity. Trends Cell 
Biol 25, 514–522. https://doi.org/10.1016/j.tcb.2015.05.003 
Sollier, J., Stork, C.T., García-Rubio, M.L., Paulsen, R.D., Aguilera, A., Cimprich, K.A., 
2014. Transcription-Coupled Nucleotide Excision Repair Factors Promote R-Loop-
Induced Genome Instability. Mol Cell 56, 777–785. 
https://doi.org/10.1016/j.molcel.2014.10.020 
Sonnenschein, C., Soto, A.M., 1998. An updated review of environmental estrogen and 
androgen mimics and antagonists11Proceedings of the 13th International Symposium 
of the Journal of Steroid Biochemistry & Molecular Biology “Recent Advances in 
Steroid Biochemistry & Molecular Biology” Monaco 25–28 May 1997. J Steroid 
Biochem Mol Biology 65, 143–150. https://doi.org/10.1016/s0960-0760(98)00027-2 
Spady, T.J., Harvell, D.M.E., Snyder, M.C., Pennington, K.L., McComb, R.D., Shull, J.D., 
1998. Estrogen-induced tumorigenesis in the Copenhagen rat: disparate susceptibilities 
to development of prolactin-producing pituitary tumors and mammary carcinomas. 




Spiegel, J., Cuesta, S.M., Adhikari, S., Hänsel-Hertsch, R., Tannahill, D., 
Balasubramanian, S., 2021. G-quadruplexes are transcription factor binding hubs in 
human chromatin. Genome Biol 22, 117. https://doi.org/10.1186/s13059-021-02324-z 
Stacey, S.N., Manolescu, A., Sulem, P., Rafnar, T., Gudmundsson, J., Gudjonsson, S.A., 
Masson, G., Jakobsdottir, M., Thorlacius, S., Helgason, A., Aben, K.K., Strobbe, L.J., 
Albers-Akkers, M.T., Swinkels, D.W., Henderson, B.E., Kolonel, L.N., Marchand, 
L.L., Millastre, E., Andres, R., Godino, J., Garcia-Prats, M.D., Polo, E., Tres, A., Mouy, 
M., Saemundsdottir, J., Backman, V.M., Gudmundsson, L., Kristjansson, K., 
Bergthorsson, J.T., Kostic, J., Frigge, M.L., Geller, F., Gudbjartsson, D., Sigurdsson, 
H., Jonsdottir, T., Hrafnkelsson, J., Johannsson, J., Sveinsson, T., Myrdal, G., 
Grimsson, H.N., Jonsson, T., Holst, S. von, Werelius, B., Margolin, S., Lindblom, A., 
Mayordomo, J.I., Haiman, C.A., Kiemeney, L.A., Johannsson, O.T., Gulcher, J.R., 
Thorsteinsdottir, U., Kong, A., Stefansson, K., 2007. Common variants on 
chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast 
cancer. Nat Genet 39, 865–869. https://doi.org/10.1038/ng2064 
Stork, C.T., Bocek, M., Crossley, M.P., Sollier, J., Sanz, L.A., Chédin, F., Swigut, T., 
Cimprich, K.A., 2016. Co-transcriptional R-loops are the main cause of estrogen-
induced DNA damage. Elife 5, e17548. https://doi.org/10.7554/elife.17548 
Tamimi, R.M., Spiegelman, D., Smith-Warner, S.A., Wang, M., Pazaris, M., Willett, W.C., 
Eliassen, A.H., Hunter, D.J., 2016. Population Attributable Risk of Modifiable and 
Nonmodifiable Breast Cancer Risk Factors in Postmenopausal Breast Cancer. Am J 
Epidemiol 184, 884–893. https://doi.org/10.1093/aje/kww145 
Tan, J., Lan, L., 2020. The DNA secondary structures at telomeres and genome instability. 
Cell Biosci 10, 47. https://doi.org/10.1186/s13578-020-00409-z 
Tan, J., Wang, X., Phoon, L., Yang, H., Lan, L., 2020. Resolution of ROS‐induced G‐
quadruplexes and R‐loops at transcriptionally active sites is dependent on BLM 
helicase. Febs Lett 594, 1359–1367. https://doi.org/10.1002/1873-3468.13738 
Técher, H., Koundrioukoff, S., Nicolas, A., Debatisse, M., 2017. The impact of replication 
stress on replication dynamics and DNA damage in vertebrate cells. Nat Rev Genet 18, 
535–550. https://doi.org/10.1038/nrg.2017.46 
Teng, Y., Yadav, T., Duan, M., Tan, J., Xiang, Y., Gao, B., Xu, J., Liang, Z., Liu, Y., 
Nakajima, S., Shi, Y., Levine, A.S., Zou, L., Lan, L., 2018. ROS-induced R loops 
trigger a transcription-coupled but BRCA1/2-independent homologous recombination 





Tian, H., Gao, Z., Wang, G., Li, H., Zheng, J., 2016. Estrogen potentiates reactive oxygen 
species (ROS) tolerance to initiate carcinogenesis and promote cancer malignant 
transformation. Tumor Biol 37, 141–150. https://doi.org/10.1007/s13277-015-4370-6 
Tian, J.-M., Ran, B., Zhang, C.-L., Yan, D.-M., LI, X.-H., 2018. Estrogen and progesterone 
promote breast cancer cell proliferation by inducing cyclin G1 expression. Braz J Med 
Biol Res 51, 1–7. https://doi.org/10.1590/1414-431x20175612 
Tian, T., Chen, Y.-Q., Wang, S.-R., Zhou, X., 2018. G-Quadruplex: A Regulator of Gene 
Expression and Its Chemical Targeting. Chem 4, 1314–1344. 
https://doi.org/10.1016/j.chempr.2018.02.014 
Travis, R.C., Key, T.J., 2003. Oestrogen exposure and breast cancer risk. Breast Cancer 
Res 5, 239. https://doi.org/10.1186/bcr628 
Trichopoulos, D., MacMahon, B., Cole, P., 1972. Menopause and breast cancer risk. J Natl 
Cancer I 48, 605–13. 
Udquim, K.-I., Zettelmeyer, C., Banday, A.R., Lin, S.H.-Y., Prokunina-Olsson, L., 2020. 
APOBEC3B expression in breast cancer cell lines and tumors depends on the estrogen 
receptor status. Carcinogenesis. https://doi.org/10.1093/carcin/bgaa002 
Ullrich, R.L., Bowles, N.D., Satterfield, L.C., Davis, C.M., 1996. Strain-Dependent 
Susceptibility to Radiation-Induced Mammary Cancer Is a Result of Differences in 
Epithelial Cell Sensitivity to Transformation. Radiat Res 146, 353. 
https://doi.org/10.2307/3579468 
Varshney, D., Spiegel, J., Zyner, K., Tannahill, D., Balasubramanian, S., 2020. The 
regulation and functions of DNA and RNA G-quadruplexes. Nat Rev Mol Cell Bio 1–
16. https://doi.org/10.1038/s41580-020-0236-x 
Vladusic, E.A., Hornby, A.E., Guerra-Vladusic, F.K., Lakins, J., Lupu, R., 2000. 
Expression and regulation of estrogen receptor beta in human breast tumors and cell 
lines. Oncol Rep. https://doi.org/10.3892/or.7.1.157 
Vocka, M., Zimovjanova, M., Bielcikova, Z., Tesarova, P., Petruzelka, L., Mateju, M., 
Krizova, L., Kotlas, J., Soukupova, J., Janatova, M., Zemankova, P., Kleiblova, P., 
Novotny, J., Konopasek, B., Chodacka, M., Brychta, M., Sochor, M., Smejkalova-
Musilova, D., Cmejlova, V., Kozevnikovova, R., Miskarova, L., Argalacsova, S., 
Stolarova, L., Lhotova, K., Borecka, M., Kleibl, Z., 2019. Estrogen Receptor Status 
Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers 
Versus Non-Carriers. Cancers 11, 738. https://doi.org/10.3390/cancers11060738 
Vrtačnik, P., Ostanek, B., Mencej-Bedrač, S., Marc, J., 2014. The many faces of estrogen 




Waks, A.G., Winer, E.P., 2019. Breast Cancer Treatment. Jama 321, 288–300. 
https://doi.org/10.1001/jama.2018.19323 
Wang, Y., Yang, J., Wild, A.T., Wu, W.H., Shah, R., Danussi, C., Riggins, G.J., Kannan, 
K., Sulman, E.P., Chan, T.A., Huse, J.T., 2019. G-quadruplex DNA drives genomic 
instability and represents a targetable molecular abnormality in ATRX-deficient 
malignant glioma. Nat Commun 10, 943. https://doi.org/10.1038/s41467-019-08905-8 
Wang, Z., Chandrasena, E.R., Yuan, Y., Peng, K., Breemen, R.B. van, Thatcher, G.R.J., 
Bolton, J.L., 2010. Redox Cycling of Catechol Estrogens Generating 
Apurinic/Apyrimidinic Sites and 8-oxo-Deoxyguanosine via Reactive Oxygen Species 
Differentiates Equine and Human Estrogens. Chem Res Toxicol 23, 1365–1373. 
https://doi.org/10.1021/tx1001282 
Wendt, C., Margolin, S., 2019. Identifying breast cancer susceptibility genes – a review of 
the genetic background in familial breast cancer. Acta Oncol 58, 1–12. 
https://doi.org/10.1080/0284186x.2018.1529428 
Wietmarschen, N. van, Merzouk, S., Halsema, N., Spierings, D.C.J., Guryev, V., Lansdorp, 
P.M., 2018. BLM helicase suppresses recombination at G-quadruplex motifs in 
transcribed genes. Nat Commun 9, 271. https://doi.org/10.1038/s41467-017-02760-1 
Williamson, L.M., Lees-Miller, S.P., 2011. Estrogen receptor α-mediated transcription 
induces cell cycle-dependent DNA double-strand breaks. Carcinogenesis 32, 279–285. 
https://doi.org/10.1093/carcin/bgq255 
Wu, W., Bhowmick, R., Vogel, I., Özer, Ö., Ghisays, F., Thakur, R.S., Leon, E.S. de, 
Richter, P.H., Ren, L., Petrini, J.H., Hickson, I.D., Liu, Y., 2020. RTEL1 suppresses G-
quadruplex-associated R-loops at difficult-to-replicate loci in the human genome. Nat 
Struct Mol Biol 27, 424–437. https://doi.org/10.1038/s41594-020-0408-6 
Wu, W., Rokutanda, N., Takeuchi, J., Lai, Y., Maruyama, R., Togashi, Y., Nishikawa, H., 
Arai, N., Miyoshi, Y., Suzuki, N., Saeki, Y., Tanaka, K., Ohta, T., 2018. HERC2 
facilitates BLM and WRN helicase complex interaction with RPA to suppress G-
quadruplex DNA. Cancer Res 78, canres.1877.2018. https://doi.org/10.1158/0008-
5472.can-18-1877 
Wu, Y., Shin-ya, K., Brosh, R.M., 2008. FANCJ Helicase Defective in Fanconia Anemia 
and Breast Cancer Unwinds G-Quadruplex DNA To Defend Genomic Stability▿ †. 
Mol Cell Biol 28, 4116–4128. https://doi.org/10.1128/mcb.02210-07 
Xu, B., Clayton, D.A., 1996. RNA-DNA hybrid formation at the human mitochondrial 
heavy-strand origin ceases at replication start sites: an implication for RNA-DNA 




Xu, H., Antonio, M.D., McKinney, S., Mathew, V., Ho, B., O’Neil, N.J., Santos, N.D., 
Silvester, J., Wei, V., Garcia, J., Kabeer, F., Lai, D., Soriano, P., Banáth, J., Chiu, D.S., 
Yap, D., Le, D.D., Ye, F.B., Zhang, A., Thu, K., Soong, J., Lin, S., Tsai, A.H.C., Osako, 
T., Algara, T., Saunders, D.N., Wong, J., Xian, J., Bally, M.B., Brenton, J.D., Brown, 
G.W., Shah, S.P., Cescon, D., Mak, T.W., Caldas, C., Stirling, P.C., Hieter, P., 
Balasubramanian, S., Aparicio, S., 2017. CX-5461 is a DNA G-quadruplex stabilizer 
with selective lethality in BRCA1/2 deficient tumours. Nat Commun 8, 14432. 
https://doi.org/10.1038/ncomms14432 
Yager, J.D., Davidson, N.E., 2006. Estrogen Carcinogenesis in Breast Cancer. New Engl J 
Medicine 354, 270–282. https://doi.org/10.1056/nejmra050776 
Yang, Y., McBride, K.M., Hensley, S., Lu, Y., Chedin, F., Bedford, M.T., 2014. Arginine 
Methylation Facilitates the Recruitment of TOP3B to Chromatin to Prevent R Loop 
Accumulation. Mol Cell 53, 484–497. https://doi.org/10.1016/j.molcel.2014.01.011 
Yaşar, P., Ayaz, G., User, S.D., Güpür, G., Muyan, M., 2017. Molecular mechanism of 
estrogen–estrogen receptor signaling. Reproductive Medicine Biology 16, 4–20. 
https://doi.org/10.1002/rmb2.12006 
Ye, X., Bishop, A.M., Reidy, J.A., Needham, L.L., Calafat, A.M., 2006. Parabens as 
Urinary Biomarkers of Exposure in Humans. Environ Health Persp 114, 1843–1846. 
https://doi.org/10.1289/ehp.9413 
Yersal, O., Barutca, S., 2014. Biological subtypes of breast cancer: Prognostic and 
therapeutic implications. World J Clin Oncol 5, 412. 
https://doi.org/10.5306/wjco.v5.i3.412 
Yi, P., Wang, Z., Feng, Q., Chou, C.-K., Pintilie, G.D., Shen, H., Foulds, C.E., Fan, G., 
Serysheva, I., Ludtke, S.J., Schmid, M.F., Hung, M.-C., Chiu, W., O’Malley, B.W., 
2017. Structural and Functional Impacts of ER Coactivator Sequential Recruitment. 
Mol Cell 67, 733-743.e4. https://doi.org/10.1016/j.molcel.2017.07.026 
Yu, J.-C., Hsiung, C.-N., Hsu, H.-M., Bao, B.-Y., Chen, S.-T., Hsu, G.-C., Chou, W.-C., 
Hu, L.-Y., Ding, S.-L., Cheng, C.-W., Wu, P.-E., Shen, C.-Y., 2011. Genetic variation 
in the genome-wide predicted estrogen response element-related sequences is 
associated with breast cancer development. Breast Cancer Res 13, R13. 
https://doi.org/10.1186/bcr2821 
Yu, K., Chedin, F., Hsieh, C.-L., Wilson, T.E., Lieber, M.R., 2003. R-loops at 
immunoglobulin class switch regions in the chromosomes of stimulated B cells. Nat 
Immunol 4, 442–451. https://doi.org/10.1038/ni919 
Yu, Y., Okayasu, R., Weil, M.M., Silver, A., McCarthy, M., Zabriskie, R., Long, S., Cox, 




with unique functional polymorphism of the Prkdc (DNA-dependent protein kinase 
catalytic subunit) gene. Cancer Res 61, 1820–4. 
Zahid, M., Kohli, E., Saeed, M., Rogan, E., Cavalieri, E., 2006. The Greater Reactivity of 
Estradiol-3,4-quinone vs Estradiol-2,3-quinone with DNA in the Formation of 
Depurinating Adducts:  Implications for Tumor-Initiating Activity. Chem Res Toxicol 
19, 164–172. https://doi.org/10.1021/tx050229y 
Zahler, A.M., Williamson, J.R., Cech, T.R., Prescott, D.M., 1991. Inhibition of telomerase 
by G-quartet DMA structures. Nature 350, 718–720. https://doi.org/10.1038/350718a0 
Zhu, M., Wu, W., Togashi, Y., Liang, W., Miyoshi, Y., Ohta, T., 2021. HERC2 inactivation 
abrogates nucleolar localization of RecQ helicases BLM and WRN. Sci Rep-uk 11, 360. 
https://doi.org/10.1038/s41598-020-79715-y 
  
 
 
 
 
